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The major part of this thesis describes studies of human ubiquitin-specific protease 7 (USP7), a 
deubiquitinating enzyme that regulates cellular levels of key oncoproteins and tumor suppressors. 
Inactivation of USP7 has recently emerged as a new approach to treatment of malignancies. However, 
design of potent and specific small-molecule compounds requires detailed understanding of the molecular 
mechanisms of USP7 substrate recognition and regulation of its catalytic activity. The goal of this work 
was to explore these mechanisms using solution nuclear magnetic resonance spectroscopy in combination 
with other methods. In our studies of USP7 substrate recognition, we structurally characterized its 
interaction with ICP0 protein from Herpes Simplex virus 1 and identified a novel USP7 substrate-binding 
site harbored within its C-terminal region. To address the question of USP7 activity regulation, we 
investigated its interaction with ubiquitin, which was believed to cause structural rearrangement of USP7 
active site from an unproductive to a catalytically competent conformation. Surprisingly, we showed that 
in solution USP7 – ubiquitin interaction alone is not sufficient for activation of the enzyme as was 
previously postulated. Finally, we uncovered a previously unknown mechanism of USP7 inactivation by 
two of its known inhibitors. We found that these compounds bind to the active site of USP7 and inactivate 
the enzyme via covalent modification of a catalytic cysteine residue. The efficacy of the inhibitors was 
confirmed in cells. Altogether, these results advance our understanding of the mechanisms of substrate 
specificity, activation and inhibition of USP7 and open new strategies for rational structure-based drug 
design. 
Chapter 4 describes another example of using NMR spectroscopy in studies of complex biological 
systems. REV1 is a translesion synthesis (TLS) DNA polymerase that plays a key role in replication  
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across the sites of DNA damage. Beyond its catalytic activity, its major role is to recruit other TLS 
polymerases to DNA lesions. The goal of this work was to structurally characterize protein – protein 
interactions mediated by the C-terminal region of REV1 (REV1-CT). We determined a solution NMR 
structure of REV1-CT alone and in complex with TLS polymerase η, and unraveled the molecular 
mechanism by which REV1 recognizes other Y-family TLS polymerases. 
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1.1. USP7 – a complex, pharmaceutically relevant biological system 
1.1.1. Overview of ubiquitin – proteasome system 
As a part of their metabolism cells constantly synthetize new proteins and, at the same time, 
break down proteins that are misfolded, aggregated or no longer needed. Eukaryotic cells 
developed two major systems responsible for protein degradation: lysosomal proteolysis and the 
ubiquitin – proteasome system (UPS). While the first system is specialized in degradation of 
membrane and endocytosed proteins, UPS is versatile and accomplishes degradation of the 
majority of cellular proteins (1). In this pathway a polyubiquitin chain is conjugated to a protein 
substrate. This chain serves as a signal for the substrate recognition and degradation by the 26S 
proteasome. Protein ubiquitination is a multi-step process, involving consecutive action of three 
enzymes: ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2 and E3 ligase 
(Figure 1.1). First, E1 uses ATP to form a thioester bond between a cysteine residue in its active 
site and the C-terminal glycine of ubiquitin. Activated ubiquitin is then transferred to E2 with the 
formation of second thioester intermediate. In the final step, ubiquitin is transferred to a protein 
substrate with help of E3 ligase (2). There are two families of E3 ligases that act through 
different mechanisms. RING E3 ligases bind both the E2 – ubiquitin complex and a substrate 
bringing them together and, thereby, promoting the attack of the substrate lysine residue on E2 – 
ubiquitin thioester (3). E3 ligases of the HECT family receive ubiquitin from E2 with formation 
of the third thioester intermediate and then transfer it to the substrate (4). The process described 
above can be repeated several times to generate a polyubiquitin chain that consists of ubiquitin 
monomers attached to each other through a linkage between one of seven lysine residues (Lys6, 
Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63) of one monomer and the C-terminal glycine of 
another. Chains linked through N-terminal methionine can also be formed (5). Interestingly, only 
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Lys48- and Lys11-linked chains are known to target proteins to proteasome (6) while other 
linkage types are involved in signaling pathways distinct from protein degradation. Specifically, 
K63-linked chains play a role in regulating signal transduction, DNA repair and endocytosis 
(7,8), and linear polyubiquitin (Met1-linked) is important in inflammatory cytokine signaling (9). 
In addition to polyubiquitination, protein monoubiquitination often takes place in various cellular 
pathways such as intracellular and membrane trafficking, DNA transcription and DNA repair 
(10). Overall, the functions of protein ubiquitination are not limited to mediating proteasome-
dependent degradation. The ability of ubiquitin to form various polymers adds a complexity to 
UPS in which mono- and polyubiquitination as well as diverse chain linkage types determine 
different functional outcomes for protein substrates. 
1.1.2. Deubiquitinating enzymes and their role in the ubiquitin – proteasome system 
Protein ubiquitination can be reversed by action of deubiquitinating enzymes (DUBs) that 
cleave ubiquitin moieties from their substrates. Nearly 100 DUBs identified in human genome 
can be classified into two mechanistically distinct classes: metalloproteases and cysteine 
proteases (11). Metalloproteases coordinate a zinc ion and a water molecule in the active site. 
During catalysis, a hydrogen atom from the water molecule is abstracted by a neighboring 
glutamate residue and the resulting hydroxyl ion attacks the carbonyl carbon of the isopeptide 
bond. In humans, metalloproteases are represented by a family of JAB1/MPN/MOV34 domain 
containing proteases (JAMM) that consists of 12 members (12). The catalytic mechanism of 
cysteine proteases is analogous to that of well-studied plant enzymes papains (13). All cysteine 
peptidases share a catalytic triad consisting of cysteine, histidine and aspartate/asparagine 
residues. The role of the histidine is to deprotonate the thiol group of the cysteine and initiate its 
nucleophilic attack on the isopeptide bond, while the aspartate restricts side-chain rotation of the 
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histidine and polarizes it. Based on the architecture of the catalytic core, cysteine proteases can 
be subdivided into five families (Figure 1.2). Four families including ubiquitin-specific proteases 
(USPs) ubiquitin carboxyl-terminal hydrolases (UCHs), ovarian tumor proteases (OTUs) and 
Machado-Joseph (Josephin) domain containing (MJD) proteases have been extensively studied 
(14). The fifth family of MINDY proteases (motif interacting with ubiquitin-containing novel 
DUB family) was recently discovered and, to date, contains only one characterized protein 
MINDY-1 (15). Structurally, proteins of UCH family are relatively small and do not have 
domains other than the catalytic core while DUBs from other families often have varying 
numbers of additional domains with distinct structures and functions. These domains often 
participate in protein – protein interactions such as assembly in macromolecular complexes or 
DUB binding to substrates and substrate adaptors (16). 
DUBs perform a variety of functions in the UPS (Figure 1.1). They remove polyubiquitin 
chains from their substrates thus preventing their proteasomal degradation. Furthermore, DUBs 
recycle ubiquitin by disassembling the chains. These enzymes are also involved in maturation of 
ubiquitin, which is synthetized as a linear fusion protein. DUBs cleave the precursor and 
generate a pool of ubiquitin monomers. Finally, DUBs can redirect the fate of a substrate by 
editing the conjugated ubiquitin chains. For example, they can transform polyubiquitinated 
protein into monoubiquitinated and vice versa. In some instances, they disassemble a chain of 
one linkage type so a chain of a different linkage could be formed (17). Interestingly, some 
DUBs, including many USPs, recognize ubiquitin chains of several linkage types while others 
demonstrate linkage specificity (16). For example, proteases of the JAMM family cleave K63-
linked chains only (18,19). In contrast, OTU family members vary in their linkage preferences. 
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Thus, OTUD4 and OTUB1 are specific to Lys48, Cezanne and Cezanne2 – to Lys11, OTUD1 – 
to Lys63 and OTULIN – to Met1 (14). 
Given the number of cellular pathways involving protein deubiquitination, it is not surprising 
that DUBs activity is tightly regulated. To date, a few mechanisms of DUBs regulation have 
been discovered that function independently or in combination, depending on the particular 
enzyme. These mechanisms include post-translational modifications, recruitment to substrates 
and/or proteasome, inner structural rearrangements upon substrate binding and, finally, 
interactions with other proteins that can either activate or inhibit the enzyme (20). In turn, 
dysregulation of DUBs activity was linked to prostate, colon, ovary and other cancers as well as 
to neurodegenerative diseases such as Parkinson disease and ataxia (21,22). 
Overall, protein ubiquitination and deubiquitination are two highly dynamic processes that 
maintain a delicate balance between protein stabilization and degradation, and mediate numerous 
signaling pathways in the cell. Interest in studying DUBs rapidly developed in recent years due 
to their contribution to almost every cellular process and their role in human pathologies. Despite 
some progress made in elucidation of DUBs activity and regulation, only a small fraction of 
these enzymes has been well characterized. The substrates, mechanisms of regulation as well as 
three-dimensional structures of many DUBs are still not known and many questions remain 
unanswered even for those enzymes that have been extensively studied. How do DUBs 
distinguish between ubiquitin chains of different linkage types? What are the general 
mechanisms of controlling DUBs activity that are applied within and across the families? 
Multiple layers of regulation were described for several enzymes but in order to generalize these 
mechanisms we need further studies of many other DUBs. The same is true for defining the 
determinants of DUBs substrate specificity. The lack of information about protein targets for 
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many enzymes prevents determination of common substrate features. Finally, we do not know 
how DUBs are regulated in the context of macromolecular complexes since such studies are 
complex and limited by modern technology. 
1.1.3. Introducing USP7: functions, substrates and regulation 
Human ubiquitin-specific protease 7 (USP7) also known as Herpes virus associated protease 
(HAUSP) belongs to the largest DUB family of USPs. Located in the nucleus, it regulates the 
stability of many proteins involved in multiple cellular processes (Table 1.1) (23). One such 
process is the DNA damage response where USP7 performs several functions. First, it 
deubiquitinates both transcription factor p53 and E3 ligase HDM2 responsible for 
polyubiquitination of p53 and targeting it to the proteasome (24-26). Interestingly, USP7 
preferably binds HDM2 preventing its degradation (27). In turn, HDM2 ubiquitinates p53 and 
maintains low cellular levels of this tumor suppressor during normal homeostasis. DNA damage 
causes ATM-dependent dephosphorylation of USP7 by PPM1G that decreases the affinity of the 
enzyme towards HDM2 (28). Consequently, USP7 associates with p53 and protects it from 
ubiquitination. This interaction results in p53 stabilization and initiation of the p53-dependent 
DNA damage response. Second, USP7 is involved in regulation of nucleotide excision repair. 
Specifically, it prevents degradation of the XPC protein that recognizes helix-distorting DNA 
lesions and initiates the repair (29). Furthermore, USP7 plays a significant role in the ATR-Chk1 
branch of the DNA damage response pathway where it deubiquitinates and stabilizes Chk1, an 
important checkpoint kinase (30), and clapsin, an adapter protein (31). Another interesting 
substrate of USP7 is UVSSA, one of the initiating factors of UV-induced transcription-coupled 
DNA repair (32). Finally, in response to genotoxic stress, USP7 stabilizes HLTF that regulates 
error-free replication through DNA lesions (33). 
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On the other hand, USP7 is also involved in DNA damage tolerance pathways. It controls the 
stability of E3 ligase Rad18 that monoubiquitinates a proliferating-cell nuclear antigen (PCNA) 
in response to the presence of DNA lesions stalling the replication fork (34). PCNA 
monoubiquitination facilitates recruitment of specialized translesion synthesis (TLS) DNA 
polymerases, which can efficiently bypass DNA lesions, thereby allowing replication to proceed 
(35). The stability of at least one TLS polymerase, polymerase η, is also controlled by USP7 
(36). In addition, USP7 plays a role in conventional DNA replication. First, its complex with 
MCM-BP unloads the minichromosome maintenance protein complex from chromatin at the end 
of S-phase (37). Second, it was recently suggested that USP7 might regulate replication fork 
progression through creating SUMO-rich environment at sites of DNA replication (38). Finally, 
USP7 controls protein levels of replisome components UHRF1 and methyltransferase DNMT1 
that function together in maintaining tissue-specific DNA methylation patterns (39,40). 
There are many other cellular pathways that require the deubiquitinase activity of USP7. For 
instance, this enzyme associates with chromatin and participates in epigenetic control of gene 
expression. Specifically, USP7 interacts with BMI1, MEL18, SCML2 and E3 ligase RING1B – 
components of the PRC1 complex responsible for monoubiquitination of histone H2A, which 
results in gene repression (41-43). It also stabilizes several other histone-associated proteins such 
as acetyltransferase TIP60 (44), demethylase PHF8 (45), methyltransferase MLL5 (46) and E3 
ligase RNF168 (47). Furthermore, USP7 functions in the immune response where it regulates the 
transcription activity of master transcription factor NF-kB via stabilization of its subunit p65 
(48). 
Although USP7 is mostly known for removing polyubiquitin chains from its substrates, it is 
also capable of deubiquitinating monoubiquitinated proteins. Thus, USP7 forms a complex with 
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GMPS in Drosophila and removes monoubiquitin from histone H2B thereby contributing to 
gene silencing (49). In humans, USP7 deubiquitinates monoubiquitinated transcription factors 
PTEN and FOX(O)4 (50,51). In this case, the activity of USP7 is a part of a mechanism 
negatively regulating the transcription activity of these proteins since deubiquitination of both 
PTEN and FOX(O)4 causes their translocation from the nucleus to cytoplasm and, therefore, 
their inactivation. As a side note, some functions of USP7 do not require its deubiquitinase 
activity at all. In particular, the enzyme negatively regulates PML nuclear bodies and the 
mechanism relies only on USP7 interactions with other proteins (52).  
In addition to numerous cellular processes, USP7 is known to play a role in viral infection. 
Originally, it was discovered as an enzyme associated with ICP0, an immediate-early protein 
from Herpes Simplex Virus-1 (53). ICP0 is the E3 ligase required for efficient lytic infection 
(54). Its binding to USP7 prevents its auto-ubiquitination and proteasomal degradation (55). 
Later studies revealed that USP7 interacts with proteins from three other viruses of the 
Herpesviridae family. Thus, binding of USP7 to LANA from Kaposi’s sarcoma-associated 
herpes virus (KSHV) and its functional homologue EBNA-1 from Epstein-Barr virus (EBV) has 
a regulatory effect on latent viral replication (56,57). Furthermore, EBNA-1 – USP7 interaction 
blocks the interaction of the latter to p53 and, therefore, diminishes p53 stabilization (58). The 
similar viral mechanism that disrupts the p53-mediated antiviral response was proposed for 
another USP7 substrate, the vIRF4 protein from KSHV (59), while the significance of interaction 
between USP7 and UL35 from human cytomegalovirus (HCMV) remains elusive (60). Finally, 
besides the role in infections mediated by Herpesviruses, USP7 also promotes adenoviral 
replication via interaction with viral multifunctional protein E1B-55K (61). 
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USP7 is an important component of UPS and its activity in the cell is tightly regulated to 
avoid uncontrolled stabilization of its multiple substrates. There are several levels of USP7 
regulation including intermolecular mechanisms, post-transcriptional modifications and protein – 
protein interactions. Intramolecular mechanisms include the domain reorganization required for 
the enzyme activation and the active site rearrangement upon ubiquitin binding (described in 
chapter 1.1.4). Post-transcriptional modifications further tune USP7 activity. In particular, the 
enzyme was shown to be phosphorylated at Ser18 and Ser963, and ubiquitinated at Lys869 (62). 
Phosphorylation at Ser18 by protein kinase CK2 alters affinity of USP7 towards its substrates 
HDM2 and p53 in such a way that the phosphorylated enzyme preferably binds to HDM2 while 
its dephosphorylation results in higher affinity to p53 (28). USP7 ubiquitination at Lys869 by E3 
ligase TRIM27 promotes TNF-α-induced apoptosis through deubiquitination of RIPK1 (63) and 
the role of phosphorylation at Ser963 remains to be determined. In addition, USP7 is aberrantly 
phosphorylated at Tyr243 by chimeric protein p210 BCR-ABL in chronic myeloid leukemia 
(CML) cells. This post-translational modification enhances deubiquitinase activity of the enzyme 
towards tumor suppressor PTEN, whose dysregulation is critical for CML pathogenesis (64). The 
highest level of USP7 regulation is mediated by several proteins that interact with the enzyme 
and mediate its activity. Thus, Daxx binds to USP7 and HDM2 facilitating deubiquitination of 
the latter (65). Daxx – USP7 complex also regulates stability of E3 ligase CHFR and Aurora-A 
kinase involved in mitosis progression (66). In the Wnt/β-catenin signaling pathway USP7 
mediated stabilization of β-catenin depends on E3 ligase RNF220 that forms a tertiary complex 
with both USP7 and β-catenin and promotes deubiquitination of the latter (67). Another protein, 
MBD4, recruits USP7 to heterochromatin foci in order to co-localize it with UHRF1 and 
DNMT1 thus promoting their interaction (68). Finally, at least one protein, TRAF4 negatively 
10 
 
regulates USP7 activity. It binds to the same region of USP7 as p53 blocking p53 accesses to the 
enzyme. This inhibition mechanism was shown to play an important role in breast cancers where 
TRAF4 overexpression prevents USP7-mediated p53 stabilization and diminishes cytotoxic 
stress response (69). 
1.1.4. Structure of USP7 
Schematic representation of USP7 domain organization is shown in Figure 1.3A. USP is a 
large 1102 residue (135 kDa) protein that consists of seven domains including an N-terminal 
TRAF (tumor necrosis factor receptor – associated factor)-like domain, a central catalytic core 
and five C-terminal ubiquitin-like domains (UBLs) (70,71). The N-terminal TRAF-like domain 
encompasses the protein residues 53-205 and has a characteristic for all TRAF domains fold 
(58). Specifically, it adopts a conformation of an eight-stranded, antiparallel β-sandwich (Figure 
1.3B). The function of the USP7 TRAF-like domain is to bind USP7 substrates. Transcription 
factor p53 was the first protein shown to be recognized by this region of USP7 (72) and later 
studies revealed many others such as HDM2, UbE2E1 and MCM-BP. Interestingly all these 
interactions occur through the same molecular mechanism. Briefly, all the substrates contain a 
Pro/Ala-X-X-Ser motif in their protein sequences that binds to a shallow grove on the surface of 
the TRAF-like domain (Figure 1.3C) (27,37,73,74). The almost identical manner of the binding 
in all cases allows some substrates to compete for interaction with USP7 as was shown, for 
example, for p53 and HDM2 (27). 
The function of the DUB catalytic core is to bind ubiquitin and to cleave the isopeptide bond 
between ubiquitin and a modified protein substrate. The catalytic core of USP7 is the largest 
domain within the protein (residues 208-560) and is centrally located between the TRAF-like 
and UBL domains (Figure 1.3A). It has characteristic for all USP enzymes fold that resembles a 
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right hand (Figure 1.3D). Residues Cys223, His464 and Asp481 form the catalytic site of the 
enzyme that is located in a cleft between the two protein regions referred to as Thumb and Palm. 
The third region, Fingers, is responsible for binding to ubiquitin (72,75). Remarkably, the 
structure of isolated USP7 catalytic domain differs from available structures of other USPs in the 
conformation of its active site. While the catalytic residues are properly positioned for catalysis 
in USP4, USP8, USP14 and CYLD (76-79), the USP7 catalytic triad is found in an unproductive 
conformation. The catalytically competent conformation of the active site is formed only upon 
binding to ubiquitin as was shown in the crystal structure of USP7 in complex with ubiquitin 
aldehyde (72) (Figure 1.3E). These intramolecular rearrangements represent a hypothetical 
mechanism of USP7 autoregulation, which ensures the inactive state of the enzyme in the 
absence of a substrate. 
The C-terminal region of USP7 (C-USP7) encompasses residues 564-1102 and consists of 
five ubiquitin-like domains (UBLs 1-5) that are arranged in the following manner: UBL1 closely 
interacts with UBL2 (UBL12 tandem), UBL4 – with UBL5 (UBL45 tandem) and UBL3 is 
separated from UBL2 and UBL4 by linkers (Figure 1.4A) (71). These domains adopt a 
characteristic β-grasp ubiquitin fold consisting of β-β-α-β-β-α-β secondary structure elements 
(Figure 1.4B). Besides USP7, UBL domains are found in many cellular proteins and play roles in 
diverse biological processes (80). Within the USP family, 19 enzymes are predicted to have 
UBLs (16). Interestingly, the numbers of the domains varies from one in USP9X/Y, USP19, 
USP31 and several others to five in USP7, USP40 and USP47 (Figure 1.5). A position of the 
UBLs can also be different within a protein with some domains located either N- or C-terminally 
and others embedded in the catalytic core. The reason for such divergence within one protein 
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family is unclear since functions of the UBLs have been elucidated for only a couple of USPs 
(76,81,82). 
The functions of USP7 UBL domains remained unknown until recently. The new findings 
indicate that C-USP7 constitutes an additional substrate-binding region along with the N-
terminal TRAF-like domain. Interestingly, despite overall structural similarity, the protein 
sequences of USP7 UBLs significantly vary from ubiquitin and from each other resulting in 
surface charge distributions unique for each domain. The presence of these differently charged 
surfaces implies that in contrast to the TRAF-like domain that contains a single substrate-binding 
site, several distinct sites might be harbored within the C-USP7. Indeed, mounting evidence 
suggests that different USP7 substrates are recognized by its C-terminal region that bind 
different UBL domains. Thus, ICP0 from HSV-1 interacts with the first three UBL domains and 
human XPC, and RNF168 bind to UBL12 tandem (29,47,70). UBL3 and UBL45 were recently 
shown to contain second binding sites for HDM2 and p53 respectively (83), and UBL45 was also 
reported to recognize FOX(O)4 (50). However, the mechanism of substrate binding to C-USP7 
remains to be defined since no structural information is available for any of these complexes. 
In addition to five UBL domains, C-USP7 contains a conserved 23 amino residue peptide 
located at the extreme C-terminus (residues 1080-1102). Intriguingly, this non-structured peptide 
is required for activation of USP7 as its deletion significantly decreases the deubiquitinase 
activity of the enzyme (71,83). The molecular mechanism of activation, however, raised 
controversy in the literature. First, according to the crystal structure, five UBLs are in the 
extended conformation (Figure 1.4A), which positions the extreme C-terminus ~80 Å away from 
the active site. Next, as reported in the same study, the isolated USP7 C-terminal peptide does 
not directly interact with the catalytic core and only slightly restores its enzymatic activity in 
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trans (71). In contrast, another study found that a USP7 construct containing the C-terminal 
peptide attached to the catalytic domain through a 10 amino residue linker has almost full 
deubiquitinase activity, compared to the full-length protein (84). Furthermore, according to the 
crystal structure of this USP7 construct in complex with ubiquitin aldehyde, USP7 C-terminal 
peptide binds to a cleft on the surface of its catalytic core formed after active site rearrangement 
upon ubiquitin binding. Nevertheless, both groups highlighted the significance of UBL domains 
in activation of the enzyme. They proposed a model of the full-length protein where UBLs 
rearrange from an extended conformation into a more compact structure upon activation of USP7 
in order to bring the C-terminal peptide towards the catalytic domain (Figure 1.4C). In support of 
this hypothesis, it was recently shown that UBLs 1-3 can adopt a conformation that is more 
compact than previously reported in the structure of C-USP7 (85). 
1.1.5. USP7 in human disease 
USP7 expression is often dysregulated in human malignancies. Its overexpression contributes 
to tumor progression through aberrant changes in cancer related signaling pathways such as the 
DNA damage response, apoptosis and cell cycle control. In particular, overexpression of USP7 
in human prostate cancer correlates with tumor aggressiveness. This correlation is at least 
partially explained by USP7-dependent deactivation of tumor suppressor PTEN (51). USP7 is 
also overexpressed in breast carcinomas (45) as well as in lung squamous cell carcinoma and 
large cell carcinoma (86). Its dysregulation in non-small cell lung cancers leads to disruption of 
the HDM2 – p53 axis and is associated with induced cell epithelial mesenchymal transition, 
metastasis and overall poor prognosis (86). Similarly, high USP7 expression in patients with 
epithelial ovarian cancer was found to induce cell invasion ability and correlate with poor 
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survival (87,88). Finally, USP7 expression was shown to gradually increase with tumor 
progression form grade I to grade IV in glioma patients (89). 
Because of USP7 aberrant expression in many human cancers and its role in important 
signaling pathways, this enzyme recently emerged as a promising pharmaceutical target. 
1.1.6. Pharmaceutical potential of USP7 
Manipulating the stability of proteins that are mutated, overexpressed or downregulated in 
human malignancies represents a promising therapeutic strategy for cancer treatment. Between 
the two protein degradation pathways, lysosomal proteolysis and UPS, the latter is highly 
selective and, therefore, its inhibition has a potential for development of highly specific targeted 
therapies. E3 ligases and DUBs are of special interest since they determine the selectivity of 
UPS, although other components of UPS such as E2s and proteasome have also emerged as 
pharmaceutical targets (90). 
USP7 pharmaceutical potential emerged in recent years because of its role in cellular 
pathways involving oncogenes and tumor suppressors as well as evidence of its aberrant 
expression in various cancer cell lines. Early studies searching for small-molecule inhibitors of 
USP7 led to discovery of compound HBX 41,108, a cyano-indenopyrazine derivative, that 
inhibits USP7 in an uncompetitive and reversible manner and induces p53-dependent apoptosis 
in HCT116 colon cancer cells. However, HBX 41,108 activity against USP7 is relatively low 
(high nM range) and its specificity is modest (91). More recently, specific USP7 compounds 
HBX 19,818 and HBX 28,258 were reported. Treatment with HBX 19,818 leads to p53 
stabilization and G1 cell cycle arrest in HCT116 colon cancer cells (92). Finally, a family of dual 
USP7/USP47 inhibitors (compounds 1 - 14) was recently discovered (93). The lead compound 1 
(P5091) was shown to induce apoptosis in multiple myeloma cells resistant to bortezamib and to 
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prolong survival in mouse xenograft models (94). The mechanism of P5091 cytotoxic activity is 
p53-independent and at least partially relies on endoplasmic reticulum stress caused by 
accumulation of polyubiquitinated proteins (95). In contrast, compound 4 (DUB inhibitor VI, 
P22077) induces p53 stabilization and inhibits cell growth in neuroblastoma cell lines with 
intact, but not with the mutant p53 (96). Overall, all the reported USP7 inhibitors exhibit 
cytotoxic activity in several cancer models but their further optimization is needed in order to 
create highly specific and more potent compounds. 
It is worth mentioning that to date, over 30 proteins have been described as substrates of 
USP7 (Table 1.1) but, given the fact that only ~100 DUBs in humans deubiquitinate thousands 
of different proteins, it is likely that new USP7 substrates will be discovered in the near future. 
Importantly, all the above compounds target the catalytic core of USP7 and, therefore, affect 
ubiquitination status of its numerous binding partners. Such full inhibition of the enzyme might 
result in severe side effects due to changes in stability of multiple cellular proteins. Another 
potential way to manipulate USP7 activity is to block its interactions with a particular substrate 
such as oncogene HDM2 or viral protein ICP0. The discovery of such compounds would allow 
controlling deubiquitinase activity of the enzyme towards a specific protein without affecting 
others. 
In conclusion, although the design of compounds capable of breaking protein-protein 
interactions was considered to be challenging for a long time, recent advances in technology 
have allowed the pharmaceutical industry to successfully pursue this goal (97). However, the 
development of substrate-specific therapeutics for USP7, first, requires deep understanding of 
the molecular mechanisms of its activity and regulation as well as structural characterization of 
USP7/substrate binding interfaces. In this light, solution nuclear magnetic resonance 
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spectroscopy (NMR) might be a useful tool for studying this enzyme. NMR is the state-of-the-art 
structural biology method that might provide valuable information about USP7 itself and its 
interactions with either substrates or small-molecule compounds. Furthermore, only NMR may 
provide insight into USP7 dynamic behavior such as conformational changes upon enzyme 
activation or binding to a substrate. 
 
1.2. NMR spectroscopy as a powerful method for studies of proteins and protein-protein 
interactions 
1.2.1. Basics of NMR 
Several methods including NMR spectroscopy, X-ray crystallography, electron microscopy 
and small-angle X-ray scattering are widely used to gain structural information about 
macromolecules. However, only two of these methods, X-ray crystallography and NMR 
spectroscopy, provide information about the three-dimensional structure of proteins at the atomic 
level. Among those, only NMR spectroscopy can be used to determine protein structure in 
solution, which closer resembles physiological conditions. Moreover, NMR spectroscopy is the 
only method sensitive to very weak and transient intermolecular interactions invisible to other 
techniques. Finally, in contrast to X-ray crystallography, NMR can provide information about 
protein dynamics and folding. 
 The method of NMR relies on interaction of the magnetic moment of a nucleus (µ) with an 
external magnetic field. The nuclear magnetic moment is an intrinsic property of a nucleus such 
as charge and mass and is proportional to the spin angular momentum: 
?⃗? =  𝛾ħ𝐼 
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where γ is gyromagnetic ratio, a fundamental property of a given isotope, ħ = h/2π (h is Plank 
constant) and I is spin angular momentum quantum number. The nuclei with I = ½ (such as 
1
H, 
15
N, 
13
C, 
19
F and 
31
P) have the most favorable for NMR magnetic properties and are commonly 
observed in studies of biomolecules. 
When placed in a magnetic field (B0), nuclear spins precess about the direction of B0 with a 
characteristic frequency:  
ω0 = -γB0, 
which is called the Larmor frequency. As it follows from the above equation, ω0 is different for 
different nuclei and is proportional to the applied magnetic field. The orientation of the magnetic 
moments of a spin ½ nucleus may be either parallel or antiparallel to the field. The parallel 
orientation is characterized by a magnetic quantum number m = +½ (referred to as α-spin state) 
and antiparallel orientation is characterized by m = -½ (referred to as β-spin state). Importantly, 
while the energies of α- and β-spin states are the same in the absence of an external magnetic 
field, in the presence of the magnetic field they are slightly different (effect called Zeeman 
splitting): 
𝐸𝛼 =  −
1
2
ħ𝛾𝐵0 𝐸𝛽 =  
1
2
ħ𝛾𝐵0. 
The energy difference ∆E is given by 
𝐸𝛽 − 𝐸𝛼 = ħ𝛾𝐵0 = ħ𝜔0 
and is proportional to the resonance frequency of a nucleus ω0 = γB0. In NMR spectroscopy, 
radio-frequency pulses (rf-pulses) and/or irradiation are applied to a nucleus placed in a static 
magnetic field B0 at a carrier frequency ω matching ∆E. 
18 
 
 Notably, the low energy spin state is only slightly more populated in the magnetic field 
relative to the high energy state, with a ratio of spins in α- and β-spin states, Nα and Nβ, 
respectively, given by Boltzmann distribution: 
𝑁𝛽
𝑁𝛼
= 𝑒
−
𝛥𝐸
𝑘𝑏𝑇 
where kb is Boltzmann’s constant and T is the temperature. The modest excess of spins in the low 
energy state results in only a small fraction of spins excited during NMR experiments and 
contributing to the NMR signal, which explains the relatively low sensitivity of the NMR 
method (98). 
 Critical for structural biology, in context of biomolecules, Larmor frequency depends on the 
electronic environment of a nucleus. In proteins, adopting a three-dimensional structure 
electronic environment is unique for every nucleus. Elections induce currents and produce local 
magnetic fields that oppose B0 or, in other words, shield the nucleus from the field. Because of 
this chemical shielding, nuclei of the same type experience slightly different magnetic fields, 
which results in a range of resonance frequencies for each nucleus in an NMR spectrum. These 
frequency differences normalized to resonance frequency of the nucleus are referred as to 
chemical shifts. 
 The above description explains principles of NMR spectroscopy using an example of a single 
spin ½ system. Biological macromolecules contain complex multi-spin systems where spins of 
different nuclei are coupled through bonds (J-coupled spins) and through space (dipole-dipole 
coupled spins). Therefore, NMR experiments use various sequences of rf-pulses applied to nuclei 
of one or different types. Beyond recording one dimensional (1D) 
1
H, 
15
N or 
13
C NMR spectra, 
one can collect multi-dimensional (2D, 3D and 4D) NMR experiments to observe different types 
of correlations between coupled nuclei. 
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1.2.2. Protein structure determination using NMR spectroscopy 
NMR data does not immediately provide direct structural information about a protein unlike, 
for example, protein images obtained using electron microscopy. Instead, a set of structure 
related parameters including dihedral angles and distances between atoms within the molecule 
can be derived from analysis of NMR data and then this indirect experimental information can be 
used for protein structure calculation. In brief, the NMR structure determination process consists 
of the following steps: 1) sample preparation; 2) NMR data acquisition, illustrated in Figure 1.6A 
and described elsewhere (98); 3) NMR data analysis, including NMR resonance assignment and 
obtaining distance restraints based on NOEs (Nuclear Overhauser Effect) as well as dihedral 
angle restraints, and 4) calculation of the structure satisfying the restraints.  
Sample preparation is a first and important step. As mentioned above, only nuclei with spin 
½ are routinely observable in NMR spectroscopy meaning that a protein sample has to be 
produced using spin – ½ 15N, 13C and in some cases spin – 1 2H isotope labeled precursors as 
sources for nitrogen, carbon and hydrogen. The bacterium E. coli is the most suitable protein 
expression system for NMR purposes since it allows introducing isotopes and obtaining a protein 
of interest in high quantities in a relatively short time. Proteins overexpressed in E. coli must be 
purified prior NMR experiments, which sometimes can be difficult due to low expression levels 
or insolubility of certain proteins in solution. Another challenge is that not all proteins are stable 
at high concentration (e.g. ~ 1mM) and/or for the time necessary to perform NMR 
measurements. Overall, all the requirements can make protein sample preparation a time 
consuming and challenging task. 
NMR resonance assignment includes chemical shift assignments of backbone atoms, side-
chain carbons and all the hydrogens. 
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Assigning resonances for backbone 
15
N, 
1
H, 
13Cα, 13CO and, additionally, 13Cβ atoms is 
called the backbone chemical shift assignment. The first spectrum collected for the backbone 
assignment is usually 2D 
1
H-
15
N HSQC (Heteronuclear Single-Quantum Correlation) that 
correlates directly bonded N and H atoms (99). The majority of peaks in this spectrum 
correspond to the backbone amide groups. The number of amide peaks should be the same as the 
number of residues minus prolines and the first amino acid residue. Signals from the 
15Nε-1Hε 
pair of tryptophan indole groups and 
15
N
1
H2 groups of asparagine and arginine side-chains are 
also visible (Figure 1.6B). Importantly, the number of peaks and the range of resonance 
frequencies in the 
1
H-
15
N HSQC spectrum provides valuable information about whether the 
protein is folded or disordered (100). Also, the 
1
H-
15
N HSQC spectrum can be used to monitor 
protein – ligand interactions (described in subchapter 1.2.3). In addition to conventional 1H-15N 
HSQC, 
1
H-
15
N TROSY-HSQC spectrum (TROSY – transverse relaxation optimized 
spectroscopy) was designed for large macromolecules (101). 
The commonly used 3D triple-resonance spectra for backbone resonance assignment are: 
 HNCACO and HNCO that correlate amide Hi-Ni chemical shifts with COi and COi-1 
chemical shifts, and COi-1 chemical shifts, respectively; 
 HNCA and HNCOCA that correlate amide Hi-Ni chemical shifts with Cαi and Cαi-1 chemical 
shifts, and Cαi-1 chemical shifts, respectively; 
 HNCACB and HNCOCACB that correlate amide Hi-Ni chemical shifts with Cαi, Cβi, Cαi-1, 
and Cβi-1 chemical shifts, and Cαi-1 as well as Cβi-1 chemical shifts, respectively; 
where i is a residue in the protein sequence and i-1 is the preceding residue (102). During the 
process of backbone resonance assignment, first, sequential chains of strips (parts of the 
spectrum showing the particular frequencies in 
1
H and 
15
N dimensions but the whole range of 
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frequencies in 
13
C dimension) are build using information in 3D spectra (Figure 1.6C). Briefly, 
one looks for a strip with 
13
C resonances for residue i of the same frequency as 
13
C resonances 
for residue i-1 in the analyzed strip (Figure 1.6D). As a next step, assignment of resonances to 
specific amino-residues in the protein sequence is done based on the fact that 
13Cα and 13Cβ 
chemical shifts differ between various amino-acids (103). Finally, Hα and Hβ atoms are assigned 
using experiments HNCAHA and HN(CO)CAHA that correlate Hi-Ni pairs with Hαi and Hαi-1 
chemical shifts, and Hαi-1 chemical shifts, respectively; and experiments HBHA(CO)NH and 
HAHBNH that correlate Hi-Ni pairs with Hαi-1 and Hβi-1 chemical shifts, and Hαi, Hβi, Hαi-1 and 
Hβi-1, respectively (98). 
 Once the backbone resonance assignment is complete, side-chain assignment is performed 
using 3D double-resonance experiments H(C)CH-TOCSY and (H)CCH-TOCSY that provide 
correlations of 
1
H-
13
C pairs to all the 
1
H and 
13
C atoms in the same amino residue sidechain, 
respectively (104). 
 Importantly, chemical shifts contain information about secondary structure of a protein that 
can be derived using several available algorithms. 
13Cα, 13Cβ and 13CO chemical shifts can be 
used to predict secondary structure elements present in the protein fold using the Chemical shift 
index (CSI) method (105). This approach is based on the finding that the chemical shifts of Cα 
and CO nuclei located in α-helices and β-strands shift downfield and upfield, respectively 
(compared to the chemical shifts in random coil) and the resonances of Cβ nuclei shift in the 
opposite direction. Also, given the fact that secondary chemical shifts are dependent on local 
secondary structure, assigned backbone resonances can be used for prediction of dihedral angle 
restraints for angles φ and ψ (Figure 1.6E). The prediction is often made in program TALOS+ 
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(106) that compares chemical shifts of a given residue and its adjacent neighbors to a database of 
high resolution protein structures with known secondary chemical shifts and torsion angles.  
 Another set of restraints is obtained from the analysis of 3D
 15
N- and 
13
C-edited NOESY 
(Nuclear Overhauser Effect Spectroscopy) spectra that correlate protons from amide groups and 
C-H groups, respectively, with all nearby protons located within distance up to 5Å (102). Since 
inter-proton distances are limited by protein secondary and tertiary structure,
 1
H – 1H distance 
restraints obtained from NOEs are pivotal for structure calculation (Figure 1.6F). Briefly, NOE 
effect is a magnetization transfer between adjacent nuclei caused by cross relaxation in a dipolar 
coupled spin system. Important for structural biology, the cross relaxation rate is inversely 
proportional to the sixth power of the distance between the two interacting protons (98). Thus, 
the inter-proton distances in principle can be estimated from intensities of cross-peaks in 
NOESY spectra. However, because of the internal protein motions and complexity of the 
1
H-
1
H 
interaction network, it is impossible to measure the distances precisely, instead the peak 
intensities are clustered in three groups of strong, medium and weak. Each group is associated 
with upper distance limits: strong – 2.7 Å, medium – 3.3Å and weak – 5Å (103). 
Because of the complexity of the 
15
N- and 
13
C- edited 3D NOESY spectra, their assignment 
is done automatically in the beginning of the protein structure calculation process. Briefly, one of 
several available programs including CYANA, XPLOR-NIH, ARIA or UNIO (107-111) uses the 
resonance assignments to generate preliminary assignments for NOE peaks followed by their 
conversion into distance restraints. Then, a program generates an initial set of structures, which 
is used to confirm the NOE assignments that are satisfied in these structures and to discard ones 
that are violated. Once NOEs are unambiguously assigned and upper limits for inter-proton 
distances are defined, a program attempts to fold the protein structure in a way that every atom 
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will have space coordinates satisfying the given restraints. Fitness of the structure is 
characterized by its potential energy with lower energy indicating a smaller amount of the 
restraints violated. In practice, structure determination is an iterative process, in which one 
examines the distance (angle) restraints that have been violated during calculation, corrects the 
resonance and NOEs assignments and repeats the calculation. Importantly, NMR based restraints 
do not provide exact values but rather define the range of permitted distances and angle rotations. 
Thus, NMR structure calculation cannot result in the protein structure adopting a single 
conformation. Usually, 100 to 200 structures are calculated and 20 structures of the lowest 
energy are chosen for final water refinement (103).  
1.2.3. NMR studies of protein dynamics 
Knowing protein structure often helps one to elucidate functions. However, atomic 
coordinates do not provide insight into internal motions and conformational exchange inherent 
for all the proteins. Studying time-dependent changes in protein structure (referred to as protein 
dynamics) is important for understanding key biological processes including catalysis, ligand 
binding as well as protein folding/misfolding and aggregation. Solution NMR spectroscopy is a 
powerful tool for studying protein dynamics and to date many NMR experiments have been 
developed to probe protein motions on time scales ranging from femtoseconds to seconds (112). 
NMR spin relaxation, Carr-Purcell Meiboom-Gill relaxation dispersion (CPMG) and rotating 
frame relaxation (R1ρ) methods used in this work are briefly discussed below. 
Heteronuclear spin system excited by an rf-pulse will relax, e.g. return to equilibrium, with 
characteristic times T1 (recovery of M0) and T2 (loss of coherence between individual spins 
persessing perpendicular to the magnetic field). R1 = 1/T1, R2 = 1/T2 rate constants and the values 
of heteronuclear NOEs (hrNOEs) related to the rate of dipole-dipole cross-relaxation between 
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nuclei, are widely used to elucidate ps – ns protein dynamics. The reason is that the protein 
random tumbling occurring on ns time scale and internal motions such as rotation of torsion 
angles and loop motions occurring on ps – ns time scale cause fluctuations in local magnetic 
fields generated by spins that lead to relaxation of 
1
H-X pairs (X – 15N or 13C). Two major 
mechanisms relating these motions to time-dependent oscillating fields at MHz frequencies are 
dipolar coupling and chemical shift anisotropy, which is the dependency of chemical shift on 
orientation of the molecule relative to the applied magnetic field. R1, R2 rate constants and 
hrNOEs are given by: 
𝑅1 = (𝑑
2/4)[𝐽(𝜔𝐻 − 𝜔𝑋) + 3𝐽(𝜔𝑋) + 6𝐽(𝜔𝐻 + 𝜔𝑋)] + 𝑐
2𝐽(𝜔𝑥) 
𝑅2 = (𝑑
2/8)[4𝐽(0) + 𝐽(𝜔𝑋 − 𝜔𝐻) + 3𝐽(𝜔𝑋) + 6𝐽(𝜔𝐻) + 6𝐽(𝜔𝐻 + 𝜔𝑋)]
+ (𝑐2/6)[4𝐽(0) + 3𝐽(𝜔𝑋)] + 𝑅𝑒𝑥 
𝑁𝑂𝐸 = 1 + (𝑑2/4𝑅1)(𝛾𝑋/𝛾𝐻)[6𝐽(𝜔𝐻 + 𝜔𝑋) − 𝐽(𝜔𝐻 − 𝜔𝑋)] 
where d = μ0hγXγH〈𝑟𝑋𝐻
−3〉/(8π2); c = ωXΔσ/√3, µ0 is the magnetic permeability of free space; γH 
and γX are the gyromagnetic ratios of spins
 1
H and X, respectively; ωH and ωX are the Larmor 
frequencies of spins
 1
H and X, respectively; rXH is the X-
1
H bond length; ∆σ is the chemical shift 
anisotropy of spin X; Rex is conformational exchange term due to μs – ms time scale processes 
accompanied by changes in chemical shifts and J(ω) is spectral density function that quantifies 
the amplitude of local field fluctuations at frequency ω (113). J(ω) is obtained by a cosine 
Fourier transform of correlation function, C(t), which describes how rapidly bond vector 
“forgets” its prior orientation: 
𝐶(𝑡) = ⟨𝑃2(𝜇(0) ∙𝜇(𝑡))⟩ 
where μ(0) and μ(t) are orientations of a bond vector at time zero and t, respectively and P2 = 
(3x
2
 - 1)/2 is the Legendre polynomial of rank 2 (114). 
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Obtained backbone 
15
N NMR relaxation data are most commonly interpreted using model-
free data analysis originally introduced by Lipari and Szabo (115), and later extended by Clore et 
al. (116). This approach describes molecular motion using the correlation function, C(t), given 
by a product of two correlation functions Co(t) and CI(t) describing overall molecular tumbling 
and internal motions, respectively, that are assumed to be independent of each other: 
𝐶(𝑡) = 𝐶𝑜(𝑡)𝐶𝐼(𝑡). 
Co(t) for a spherical molecule is given by: 
𝐶(𝑡) = 𝑒−𝑡/𝜏𝑅 
where 𝜏𝑅is the effective overall rotational correlation time. CI(t) depends on the timescale of the 
internal motions. If the internal motions, 𝜏𝑒 , are much faster than the overall rotation of the 
molecule and are in the extreme narrowing limit (ωτe ≪ 1), CI(t) is given by: 
𝐶𝐼(𝑡) = 𝑆
2 + (1 − 𝑆2)𝑒−𝑡/𝜏𝑒 
where τe is effective correlation time and S
2
 is a generalized order parameter that describes a 
range of main chain motions and varies from 1 to 0 for completely restricted and unrestricted 
isotropic motion, respectively (115). The spectral density function J(ω) in this case is: 
𝐽(𝜔) =
𝑆2𝜏𝑅
1 + (𝜔𝜏𝑅)
+
(1 − 𝑆2)𝜏𝑒
′
1 + (𝜔𝜏𝑒′ )2
 
where 𝜏𝑒
′ = 𝜏𝑅𝜏𝑒/(𝜏𝑅 + 𝜏𝑒). If the internal motions are not in the extreme narrowing limit and 
fast, 𝜏𝑓, and slow, 𝜏𝑠, components significantly differ, CI(t) is given by: 
𝐶𝐼(𝑡) = 𝑆
2 + (1 − 𝑆𝑓
2)𝑒−𝑡/𝜏𝑓 + (𝑆𝑓
2 − 𝑆2)𝑒−𝜏/𝜏𝑠 
where 𝑆2 = 𝑆𝑓
2𝑆𝑠
2 (116). J(ω) in this case is: 
𝐽(𝜔) =
𝑆𝑓
2𝑆𝑠
2𝜏𝑅
1 + (𝜔𝜏𝑅)
+
(1 − 𝑆𝑓
2)𝜏𝑓
′
1 + (𝜔𝜏𝑓
′ )
2 +
𝑆𝑓
2(1 − 𝑆𝑠
2)𝜏𝑠
′
1 + (𝜔𝜏𝑠′ )2
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where 𝜏𝑓
′ = 𝜏𝑅𝜏𝑓/(𝜏𝑅 + 𝜏𝑓) and 𝜏𝑠
′ = 𝜏𝑅𝜏𝑠/(𝜏𝑅 + 𝜏𝑠) . Parameters of internal motions are 
obtained from least square fit of relaxation data to equations for R1, R2 rates and hrNOEs (113) 
constructed using spectral density functions appropriate for the particular case. For more detailed 
and comprehensive explanation of the model-free approach and the description of a case of 
anisotropic motion see (114). 
CPMG and R1ρ experiments are used to study relatively slow μs-ms protein dynamics (114). 
Conformational exchange in this time range accompanied by changes in chemical shifts is 
known to contribute to R2 rates: 
𝑅2 = 𝑅2
0 + 𝑅𝑒𝑥  
where 𝑅2
0 is the R2 rate in the absence of chemical exchange and Rex is the contribution from 
conformational exchange. A CPMG experiment exploits the dependence of Rex on repetition rate 
of series of refocusing 180° pulses. In the constant relaxation time CPMG experiment, a number 
of spin-echo refocusing elements (δ-180°-δ) are applied during a fixed relaxation period T with 
different values of delay δ (117). A R1ρ experiment measures longitudal relaxation in the doubly 
rotating frame as a function of the strength of the spin-locking field and the offset of nucleus 
resonance frequency from the carrier frequency of the rf-pulse, ω0 (118,119). In either case, 
exchange rates kex and/or populations of states A and B, pA and pB, respectively, are obtained by a 
least square fit of measured R2/R1ρ rates to theoretical two-state or more complex models of 
exchange process as described in (114,120). 
1.2.4. NMR titration experiments in studies of protein –ligand interactions 
 NMR spectroscopy is widely used for probing protein – ligand interactions with the ligand 
being another protein, DNA/RNA or a small-molecule compound. NMR titration experiments, 
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also called chemical shift perturbation experiments, are based on the fact that chemical shifts are 
extremely sensitive to the electronic environment of a nucleus. The most common NMR method 
for testing the binding includes gradual addition of an unlabeled ligand to a 
15
N-labeled protein 
and recording 
1
H-
15
N HSQC spectra of the protein at each point of titration. In the case of direct 
interaction, the proximity of the ligand and subtle conformational changes in the binding site 
lead to local changes in the electronic environment of the protein residues directly involved in 
binding. Therefore, corresponding peaks move in the NMR spectrum. In addition, if ligand 
binding induces a structural rearrangement in the protein, chemical shift perturbations for 
residues not involved in interaction but participating in conformational changes may also be 
observed. It is notable that strong dependence of chemical shifts on the electronic environment 
makes NMR spectroscopy sensitive to even very weak interactions with millimolar affinities that 
cannot be observed by other methods. 
 For a simple case of the ligand L reversibly binding to a single site within the protein P, 
interaction can be described by 𝑃 + 𝐿 ↔ 𝑃𝐿. Importantly, the exchange rate between free (P) 
and bound states (PL) of the protein kex = kon + koff (kon and koff are rates of the association and 
dissociation reactions, respectively) affects the observable chemical shift changes in 
1
H-
15
N 
HSQC spectra. If the binding process is fast on the NMR timescale (kex ≫ Δω) meaning that the 
complex association and dissociation occur rapidly during NMR signal detection, the resonances 
at each titration point will gradually move with increasing amount of the ligand. The frequency 
of each signal is the population weighted average of the chemical shifts for free and saturated 
protein states (Figure 1.6G, top). If the interaction is slow (kex ≪ Δω), the peaks corresponding to 
the free protein will gradually disappear and the peaks corresponding to the bound state will 
appear. Thus, in this case, two separate sets of the peaks are observed for the free protein and its 
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complex with the ligand, and the intensity of the signals reflects relative concentrations of the 
free and bound protein (Figure 1.6G, bottom). Finally, if exchange is in the intermediate regime 
(kex ~ Δω), the peaks will gradually move and broaden at the same time (Figure 1.6G, middle). 
 Notably, NMR spectroscopy is the only method that allows estimation of the dissociation 
constant KD and the mapping of the binding site from a single experiment, provided that the 
structure and the backbone resonance assignment of the protein are available. The binding site 
identification is straightforward. First, one maps residues exhibiting most significant chemical 
shift perturbations upon ligand binding on the protein structure. Next, considering the nature of 
interaction (hydrophobic or electrostatic) and the size of the ligand, one looks for a cluster of 
residues affected by binding, which is thought to form the binding site. The presence of more 
than one cluster may be indicative of two or more binding sites or allosteric conformational 
changes occurring upon interaction. The dissociation constant KD for a two-state binding process 
in thermodynamic equilibrium is equal to 
𝐾𝐷 =
[𝑃][𝐿]
[𝑃𝐿]
 
where [P], [L] and [PL] are concentrations of the protein, the ligand and the complex, 
respectively. KD can be estimated for protein – ligand interactions in the fast to intermediate 
regime on the NMR time scale by nonlinear least-square fitting of observed chemical shifts Δωobs 
as a function of ligand concentration to the following equation: 
∆ωobs = ∆ωmax
(𝐾D + [L]t + [P]t) − √([𝑃]t + [L]t + 𝐾D)2 − 4[P]t[L]t
2[P]t
 
where [P]t and [L]t are the total protein and ligand concentrations and Δωmax is the maximum 
chemical shift difference at saturation (121). 
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1.3. Thesis objectives 
USP7 is a deubiquitinating enzyme involved in regulation of several oncogenic pathways and 
its inhibition represents a promising pharmaceutical strategy for treatment of human 
malignancies. All existing USP7 inhibitors target its catalytic core and, therefore, may affect 
protein levels of its numerous substrates leading to unpredictable side effects. Blocking USP7 
interaction with a specific substrate may present a better strategy for manipulating the enzyme 
activity but given that USP7 deubiquitinates dozens of proteins, it is unclear how its substrate 
specificity is achieved. Several previously identified binding partners of USP7 share a Pro/Ala-
X-X-Ser motif recognized by its N-terminal TRAF-like domain, while others lack this sequence 
and are recognized by non-homologous C-terminal UBL domains. Interestingly, different UBL 
domains can recognize different substrates, suggesting that the C-USP7 may serve as a substrate-
specific binding platform. However, the precise location of the binding sites harbored within C-
USP7 is unknown. Furthermore, it is unclear whether the substrates recognized by C-USP7 share 
any common structural features or motifs recognized by USP7. In addition, USP7 is the only 
enzyme among USPs that has the catalytic triad in an unproductive conformation. The 
rearrangement into a catalytically competent conformation is thought to occur upon binding to 
ubiquitin as seen in the crystal structure of the USP7 catalytic core in a complex with ubiquitin 
aldehyde, but such an active site rearrangement has not been demonstrated for USP7 interacting 
with free ubiquitin and in solution. Answering the questions of “What determines USP7 substrate 
specificity?” and “How is USP7 activated?” will provide a structural basis for rational 
development of potent and highly targeted cancer therapeutics. 
Although all reported USP7 inhibitors are known to target its catalytic domain, no structural 
information characterizing their binding to the enzyme is currently available, which hinders 
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further optimization of the lead compounds. Thus, the third question we addressed here is: “What 
is the molecular mechanism of USP7 inhibition by small-molecule compounds that show anti-
tumor potential in cancer cell lines?” In order to answer these questions, we, for the first time, 
utilized NMR spectroscopy to study this fascinating and pharmaceutically relevant biological 
system. The overall goal of this thesis was to provide structural insights into the molecular 
mechanisms of USP7 substrate specificity, regulation and inhibition using solution NMR in 
combination with other biophysical and biological methods. The specific aims were the 
following
1
: 
Aim 1. Structurally characterize the C-USP7 interaction with viral ICP0 protein that is missing 
the conventional USP7 recognition motif in order to identify new determinants of USP7 
substrate specificity.  
a) Identify domains/regions of C-USP7 responsible for binding to ICP0. 
b) Map the binding site for ICP0 on the USP7 structure.  
c) Explore the significance of ICP0 interaction with USP7 during HSV-1 lytic infection in 
vivo. 
 
Aim 2. Identify the molecular mechanism of USP7 activation upon ubiquitin binding in order to 
provide new means for manipulating the enzyme. 
a) Test binding of ubiquitin to USP7 in solution. 
b) Track conformational changes occurring in the catalytic domain of USP7 upon 
interaction with ubiquitin. 
                                                          
1
 Note that in order to reflect the work described in the thesis, the overall goal and the specific aims were modified 
from those presented in the prospectus. 
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Aim 3. Identify the molecular and chemical mechanism of USP7 inhibition by small-molecule 
compounds to allow rational optimization of inhibitors targeting the enzyme. 
a) Map the binding site for USP7 inhibitors P22077 and P50429 on the structure of the 
USP7 catalytic core. 
b) Characterize the mode of action of USP7 inhibitors P22077 and P50429. 
 
 
In addition, chapter 4 of the thesis is not related to the USP7 project and represents another 
example of using solution NMR spectroscopy in studies of complex large biological systems. It 
describes structural studies of Y-family polymerase REV1 essential for DNA damage tolerance 
pathway translesion synthesis (TLS) and explores the mechanisms of REV1 interactions with 
other TLS polymerases. 
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Table 1.1. List of USP7 substrates. 
Substrate function  Substrate name Refs 
Transcription 
factors 
   
 p53  (24) 
 HDM2  (25) 
  Rb  (122) 
  FOX(O)4  
FOX(O)3 
(50) 
 PTEN  (51) 
 β-catenin (67) 
 PPARγ (123) 
 N-Myc (124) 
DNA replication/ 
Cell cycle 
   
 CHFR  (125) 
 Bub3  (126) 
 Sumo (38) 
DNA damage 
response/  
DNA repair 
   
 DAXX  (127) 
  Polymerase η  (36) 
 HLTF  (33) 
  Rad18  (34) 
  Clapsin  (31) 
  Chk1  (30) 
 UVSSA  (32) 
 Mule/ARF-BP1  (128) 
  XPC  (29) 
Epigenetic control 
of gene expression 
  
 MEL18 (42) 
 RING1B (41) 
 Bmi1 (42) 
 Histone H2B (49) 
 DNMT1 (129) 
 UHRF1 (39) 
 RNF168 (47) 
 MLL5 (46) 
 Tip60 (44) 
 UbE2E1 (74) 
 PHF8 (45) 
Telomere proteins   
 TPP1 (130) 
Immune response   
 NFκB  (48) 
 TRAF6  (131) 
 IKKγ (131) 
 TRIM27 (132) 
Viral proteins   
 EBNA1 from EBV (56) 
 ICP0 from HSV-1 (55) 
 vIRF4 from KSHV (59) 
 LANA from 
KSHV 
(57) 
 UL35 from HCMV (60) 
 E1B from 
Adenovirus 
(61) 
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Figure 1.1. Functions of DUBs in the ubiquitin-proteasome system. A protein substrate 
mono- and polyubiquitination is catalyzed by consecutive activity of E1, E2 and E3 enzymes. 
The polyubiquitination targets the substrate for proteasomal degradation while 
monoubiquitination results in a different functional outcome. DUBs deubiquitinate both poly- 
and monoubiquitinated proteins and redirect their fate. Also DUBs edit polyubiquitin chins and 
recycle them Finally, DUBs participate in maturation of free ubiquitin. Ub – ubiquitin; E1 – 
ubiquitin activating enzyme; E2 – ubiquitin conjugating enzyme; E3 – ubiquitin Ligase; DUB – 
deubiquitinating enzyme. 
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Figure 1.2. Human DUBs. DUBs are classified into two classes of cysteine proteases and 
metalloproteases. Cysteine proteases are further subdivided into five families of ubiquitin-
specific proteases (USPs) ubiquitin carboxyl-terminal hydrolases (UCHs), ovarian tumor 
proteases (OTUs), Machado-Joseph (Josephin) domain containing (MJD) proteases and MINDY 
(motif interacting with Ub-containing novel DUB family). Adapted from (133). The class of 
metalloproteases consists of the only family of JAB1/MPN/MOV34 domain containing proteases 
(JAMMs). 
35 
 
 
 
 
Figure 1.3. USP7 domain organization. A. Schematic representation of USP7 domains with 
borders specified. UBL – ubiquitin-like domain. B, C. Crystal structures of free USP7 TRAF-
like domain (PDB ID: 2F1W) and its complex with a p53364-367 peptide shown in yellow (PDB 
ID: 2FOJ) (27,73). D, E. Crystal structures of free USP7 catalytic core (PDB ID: 1NB8) and its 
complex with ubiquitin aldehyde (PDB ID: 1NBF) (72). The side-chains of the catalytic residues 
Cys223, His464 and Asp481 are shown in green. The distances between the Cγ atom in Cys223 
and the Nε2 atom in His464 are also shown. In E ubiquitin is shown in cyan. 
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Figure 1.4. C-terminal region of USP7. A. Crystal structure of the C-terminal region of USP7 
(PDB ID: 2YLM) consisting of five ubiquitin-like domains (UBL1 – 5) (71). Here and later, 
UBL1 is colored in blue, UBL2 – in green, UBL3 – in grey, UBL4 – in orange and UBL5 – in 
red. B. Overlay of the UBL1 NMR structure (PDB ID: 2KVR) (134) onto the structure of 
ubiquitin (PDB ID: 1UBQ) (135). C. Current model of USP7 activation by its C-terminal UBL 
domains. The model was adapted from (71,84). 
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Figure 1.5. Human USPs predicted to have at least one ubiquitin-like domain. The protein 
domains are drawn approximately to scale. The catalytic domain is colored in red, UBL – in 
green and DUSP (domain present in ubiquitin-specific protease) – in yellow. Other domains are 
also indicated. Adapted from (16). 
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Figure 1.6. NMR spectroscopy in structural biology. A. Schematic representation of a basic 
NMR experiment. d1 – relaxation delay, pw – pulse width, at – acquisition time and FID –free 
induction decay. B. Schematic representation of a 
1
H-
15
N HSQC spectrum. Amide peaks are 
shown in blue, side-chain NH2 groups of asparagines and glutamines are shown in green and Nε-
Hε pairs of tryptophans are shown in magenta. C. Schematic representation of 3D HNCA 
spectrum where CA peaks (colored in red) of a given and preceding residue are visible in every 
strip shown in orange. D. Representation of the sequential backbone assignment process. E. 
Backbone torsion angles. F. NMR Structure of UBL1 (PDB ID: 2KVR) with all inter-proton 
distances less than 5 Å shown. G. Examples of the chemical shift perturbations in 
1
H-
15
N 
TROSY-HSQC spectra caused by binding to a ligand. Three different experiments are shown 
with binding in fast (top), intermediate (middle) and slow (bottom) regimes on the NMR 
timescale. The direction of chemical shifts movement is indicated by arrows. 
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2.1. Abstract 
Human ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that prevents 
protein degradation by removing poly-ubiquitin chains from its substrates. It regulates stability 
of a number of human transcription factors and tumor suppressors and plays a critical role in the 
development of several types of cancer, including prostate and small cell lung cancer. In 
addition, human USP7 is targeted by several viruses of the Herpesviridae family and is required 
for effective Herpesvirus infection. The USP7 C-terminal region (C-USP7) contains five 
Ubiquitin-Like domains (UBL1-5) that interact with several USP7 substrates. Although 
structures of the USP7 C-terminus bound to its substrates could provide vital information for 
understanding USP7 substrate specificity, no such data has been available to date.  
In this work we have demonstrated that the USP7 UBL domains can be studied in isolation 
by solution NMR spectroscopy and have determined the structure of the UBL1 domain. 
Furthermore, we have employed NMR and viral plaque assays to probe the interaction between 
the C-USP7 and HSV-1 immediate-early protein ICP0 (infected cell protein 0), which is essential 
for efficient lytic infection and virus reactivation from latency. We have shown that depletion of 
the USP7 in HFF-1 cells negatively affects the efficiency of HSV-1 lytic infection. We have also 
found that USP7 directly binds ICP0 via its C-terminal UBL1-2 domains and mapped the USP7 
binding site for ICP0. This study, therefore, represents a first step toward understanding the 
molecular mechanism of C-USP7 specificity toward its substrates and may provide the basis for 
future development of novel anti-viral and anti-cancer therapies. 
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2.2. Introduction 
Conjugation of ubiquitin to target proteins is important in multiple cellular processes, 
including signaling cascades, proteasomal degradation and protein localization. Mono- and 
polyubiquitination can be reversed by deubiquitinating enzymes (DUBs), which cleave the 
isopeptide bond between ubiquitin and a substrate. Ubiquitin-specific protease 7 (USP7), also 
known as Herpes virus-associated ubiquitin-specific protease (HAUSP), is a 135 kDa cysteine 
isopeptidase (11). Misregulation of USP7 was linked to multiple human pathologies, including 
prostate and non-small cell lung cancers (51,136). 
A number of USP7 substrates have been identified, and USP7 knockdown was shown to 
affect cellular levels of at least 36 proteins in LS174T colon carcinoma cells (23). Among a 
variety of substrates, USP7 deubiquitinates both p53 tumor suppressor and its main regulator E3 
ligase Hdm2 (human double minute 2) and thus plays a central role in maintaining an appropriate 
p53 level in the cell (24-27). Other important targets of USP7 include several transcription 
factors such as FOX(O)4, PTEN, NF-kB and HLTF; DNA replication and repair proteins such as 
UbE2E1, claspin and MCM-BP; and proteins involved in epigenetic control of gene expression 
such as DNMT1 and PRC1 (33,37,39,41,48,50,51,74). 
In addition to cellular substrates, USP7 is known to interact with proteins from all three 
subfamilies of the Herpesviridae family of viruses. Specifically, it interacts with immediate early 
protein ICP0 from Herpes Simplex Virus-1 (HSV-1), which is required for efficient lytic 
infection and reactivation of latent and quiescent viral genomes (53). USP7 also binds two 
proteins from Kaposi’s sarcoma-associated herpes virus (KSHV) LANA and vIRF4 (57,59). 
LANA is the major viral protein expressed in all forms of KSHV-associated malignancies, and 
vlRF4 is the key player in the switch from latency to lytic reactivation. USP7 also interacts with 
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the EBNA1 protein from Epstein-Barr virus (EBV), which competes with the p53 transcription 
factor for USP7 binding (58,70). Thus, USP7 binding to EBNA1 results in p53 destabilization 
and blockage of the DNA damage response caused by EBV infection. Finally, USP7 binds the 
UL35 protein from cytomegalovirus essential for viral replication and particle formation (60). In 
addition to Herpesvirus targets, USP7 was recently shown to interact with at least one adenoviral 
protein, E1B-55K, a component of the E1B-55K/E4-orf6 E3 ligase complex that degrades a wide 
range of intracellular proteins. Downregulation or specific inhibition of USP7 destabilizes E1B-
55K and negatively affects viral replication (61,137). Due to the central role USP7 plays in viral 
infection and cancer development pathways, it represents an attractive target for the design of 
new anti-viral and anti-cancer therapies. Although knowledge of molecular mechanisms of USP7 
specificity towards its diverse substrates is essential for drug development, to date these 
mechanisms remain poorly understood. 
Structurally, USP7 consists of an N-terminal substrate-binding TRAF-like domain followed 
by a ubiquitin-binding catalytic domain and a large 64 kDa C-terminal region (C-USP7, residues 
557-1102) that contains five ubiquitin-like domains (UBL 1-5) shown in Figure 2.1A 
(70,71,138). USP7 complexes with several substrates have been previously characterized, 
including peptides derived from p53, Hdm2, HdmX, UbE2E1, MCM-BP, vlRF4 and EBNA1 
(27,37,58,59,73,74). Remarkably, all these substrates share a common USP7-binding Pro/Ala-X-
X-Ser motif and interact with the same site located in the TRAF-like domain. On the other hand, 
the function of the USP7 C-terminal UBL domains remains largely unknown. Interestingly, UBL 
domains were found in at least 16 members of the USP family. All of them share a characteristic 
β-grasp ubiquitin fold, although their sequence similarity to ubiquitin may be very limited. 
Although a few of these UBLs have been characterized, the functions of others, including UBLs 
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of the USP9, USP24, USP34, USP47 and USP48 remain elusive (139). The ICP0 E3 ligase from 
HSV-1 is the first USP7 substrate shown to interact with C-USP7, suggesting that the UBL 
domains may function as a platform for substrate binding. Recent studies revealed that the USP7 
C-terminal region contains additional binding sites for p53 and Hdm2, as well as for the 
transcription factor FOX(O)4, which interacts exclusively with the C-terminus (50,83). However, 
at this time no structural data is available for any of these C-USP7 complexes. 
Here, we report a structural study of the C-USP7 – substrate interaction. With the use of 
NMR spectroscopy we have shown that individual USP7 UBL domains and/or two-domain 
constructs are stable in isolation and can be studied independently in solution. Furthermore, we 
have determined solution NMR structure of the USP7 UBL1 domain and demonstrated that it is 
nearly identical to the crystal structure of the UBL1 in the context of the intact C-terminus (71). 
Finally, we have characterized the interaction between C-USP7 and the ICP0 protein from HSV-
1 virus and mapped the ICP0 binding interface on the surface of the UBL1-UBL2 domains. Our 
work represents the first structural study of the USP - substrate recognition mediated by its UBL 
domains. Since many of the USPs contain multiple UBLs (139), it is likely that substrate 
recognition by the UBL domains may prove to be a common feature shared among a class of 
UBL-containing USPs. 
 
2.3. Experimental procedures 
In vitro studies: 
Protein expression and purification. Sequences encoding UBL1 (residues 537-664), UBL12 
(residues 535-775), UBL3 (residues 775-888) and UBL45 (residues 884-1102) domains of the 
human USP7 were sub-cloned into pET28a-LIC Vector (Structural Genomics Consortium). All 
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proteins were purified following the same protocol. Plasmids containing recombinant proteins 
with the N-terminal His6-Tag were transformed into Escherichia coli BL21 (DE3). Proteins were 
expressed in M9 minimal medium containing 
15
NH4Cl (and 
13
C-glucose for production of the 
15
N/
13
C-labeled UBL1). 
15
N/
13
C-labeled deuterated UBL12 was expressed in 100% D2O-based 
M9 medium using uniformly 
13
C/
2
H-glucose as the sole carbon source. Transformed cells were 
grown at 37°C to an OD600 of 0.6-0.8. Protein expression was induced by adding 1mM IPTG 
followed by incubation overnight at 20°C. Cells were harvested, resuspended in buffer 
containing 20 mM NaH2PO4, 250 mM NaCl, 10 mM imidazole, 1 mM PMSF, pH 7.4, lysed by 
sonication and centrifuged at 15000 rpm for 45 min. The supernatant was applied to a Ni-NTA 
column and proteins were eluted with a buffer containing 20 mM NaH2PO4, 250 mM NaCl, 250 
mM imidazole, pH 7.4. Following thrombin or TEV digestion to remove the His6-tag, proteins 
were additionally purified using either HiLoad Superdex 75 (for UBL1, UBL3) or HiLoad 
Superdex 200 (for UBL12, UBL45) columns (GE Healthcare). Final samples used for NMR 
experiments contained 0.8-1.2 mM of purified protein, 20 mM NaH2PO4, 250 mM NaCl, 2 mM 
DTT, pH 7.0. The 
15
N/
13
C-labeled UBL1 sample additionally contained 0.5 mM PMSF, 1 mM 
benzamidine and 1 mM TCEP. 
NMR spectroscopy and structure calculation. 
1
H-
15
N HSQC spectra for all C-USP7 
constructs were recorded on 800 MHz (
1
H) Agilent VNMRS spectrometer at 25°C. All 
experiments for the UBL1 structure calculation were acquired on 600 MHz and 800 MHz (
1
H) 
Bruker Avance spectrometers at 25ºC. The data were processed with NMRPipe (140) and 
analyzed with Sparky (141) and CARA (142). The backbone and side-chain resonance 
assignments of the uniformly 
15
N/
13
C-labeled UBL1 domain were performed using standard 2D 
1
H-
15
N HSQC, 
1
H-
13
C HSQC and 3D HNCA, HNCO, HBHA(CO)NH, CBCA(CO)NH, 
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HC(C)H- and (H)CCH-TOCSY experiments (102). Sequence specific resonance assignment of 
the UBL1 was done using ABACUS software (143,144). Nearly complete UBL1 NMR 
resonance assignment was obtained with 93.3% of all expected chemical shifts assigned. NMR 
distance restraints were obtained from 3D 
15
N- and 
13
C-edited NOESY-HSQC experiments 
(102). H-bond restraints were added on the basis of NOE analysis. Backbone dihedral φ and ψ 
angle restraints were derived from the analysis of 
15
N, 
1
HN, 13C, 13C and 13CO 
chemical shifts using TALOS+ (106). Structures were calculated using CYANA (107). A total of 
200 structures of UBL1 were calculated and 20 structures with the lowest energy were selected 
and refined using CNS (145). 
The backbone resonance assignments of the 
15
N/
13
C-labeled deuterated UBL12 construct in 
its free and ICP0-bound forms were performed using 2D 
1
H-
15
N TROSY and TROSY-based 3D 
HNCA, HNCOCA, HNCO, HNCACO, HNCACB and 
15
N-edited NOESY-HSQC (102) 
recorded on 800 MHz (
1
H) Agilent VNMRS spectrometer at 25°C. The data were processed with 
NMRPipe (140) and analyzed with CcpNmr Analysis (146). 
NMR Studies of Protein Dynamics. The backbone
 15
N relaxation experiments for the 
15
N-
labeled UBL1 were performed at 25°C on 500 MHz (
1
H) Agilent VNMRS spectrometer as 
described elsewhere (118,147). All experiments were performed on a C576S UBL1 mutant 
generated using QuikChange Kit (Agilent) to avoid slow cysteine-induced dimerization. 15N R1 
and R1ρ relaxation rates were measured from a series of eight spectra recorded at different 
relaxation delays. Relaxation rates were extracted from exponential fits of peak intensities. 
15
N 
R2 were obtained from longitudinal R1 and rotating-frame R1ρ rates (119) measured at a spin-lock 
field strength of 1592.4 Hz. The 
15
N{
1
H} NOE experiment was carried out in an interleaved 
manner by recording 2D 
15
N-
1
H spectra with and without 
1
H saturation period of 2.5 s using an 
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inter-scan delay of 8 s. Heteronuclear NOE values were calculated as ratios of peak intensities in 
corresponding 2D 
1
H–15N correlation spectra. Errors in NOE values were calculated based on 
peak intensities and the measured spectral noise levels. 
NMR binding experiments. ICP0 binding to individual USP7 UBL domains was assessed by 
a series of titration experiments monitored by recording 800 MHz 
1
H-
15
N HSQC spectra of the 
domains. Peptide GPRKCARKTRH corresponding to the ICP0 residues 617-627 was custom 
synthesized (GenScript). The titrations were performed by gradual addition of the unlabeled 
peptide to ~0.5 mM 
15
N-labeled UBL domain samples (up to 1:10 protein to peptide ratio). Both 
the wild-type UBL1 and C576S mutant constructs were tested, and gave the identical results. 
Frequency (chemical shift) perturbations were calculated for each amino acid residue as 
i=(N
2
+H
2 
)
1/2
, where N and H are 
15
N and 
1
H frequency differences between ICP0-
bound and free states, respectively. The obtained i values were mapped onto the surface of the 
crystal structure of the UBL12 tandem (PDB ID: 2YLM) (71). 
Isothermal Titration Calorimetry (ITC). The affinity of USP7 UBL12 – ICP0 interaction was 
determined by ITC. Measurements were performed with a Nano ITC instrument (TA 
Instruments) in a buffer containing 20 mM NaH2PO, 100 mM NaCl, 2 mM β-mercaptoethanol, 
pH 7 at 25°C. ICP0 peptide at a concentration of 686 μM was titrated into 85 μM UBL12. A total 
of 20 injections were made with 300 second time intervals in between. ITC data were analyzed 
with NanoAnalyze software (TA Instruments). Data fitting was performed using an 
“independent” model after correcting for the heat produced by ICP0 dilution. 
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In vivo studies: 
Cell lines and Viruses. Vero and HFF-1 cells were purchased from the ATCC. HFF-1 cells 
were maintained in DMEM supplemented with 10% fetal bovine serum and used between 
passages 5 and 10. Vero cells were maintained in DMEM supplemented with 5% fetal bovine 
serum. Strain 17+ was used as wild type HSV-1. Virus in1863 is derived from strain 17+ and 
was obtained from Chris Preston (MRC Virology Unit, Glasgow, Scotland). This virus contains 
the lacZ gene under the control of the HCMV promoter/enhancer inserted in the tk gene. 
Growth yield of HSV-1 on shUSP7 cells. Lentivirus generation and virus infection were done 
as previously described (148). Briefly, the pLKO.1 system was used to package lentiviruses and 
deliver shRNA into target cells. HFF-1 cells were infected with lentiviruses expressing shRNA 
against GFP (GCAAGCUGACCCUGAAGUUCA) or USP7 targeting sequence 
(GGCAACCTTTCAGTTCACT) and selected with 2 g/mL puromycin. 72 hours post-lentiviral 
infection cells were infected with HSV-1 (in1863) at multiplicities of infection (MOI) of 0.1 
PFU/cell. Progeny virus was collected at 24 hours post infection and titers were determined on 
Vero cells by staining with crystal violet or X-gal for β-galactosidase-positive plaques as 
previously described (148). 
Western blot analysis was used to visualize USP7 and ICP0. Ku70 was used as a loading 
control. After lentiviral transfection cells were infected with HSV-1 at an MOI of 2 PFU/cell. 
Four hours post infection cells in 35mm dishes were lysed in 2X SDS sample buffer (4% SDS, 
20% glycerol, 100mM Tris pH 6.8, 100mM DTT, 10% β-mercaptoethanol, 1X protease inhibitor 
cocktail (Roche), and 0.1% bromophenol blue) and boiled for 5 minutes. Proteins were resolved 
by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked for 1 hour in 5% 
non-fat dry milk dissolved in TBST. Primary antibodies were diluted in blocking solution and 
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incubated overnight at 4°C. Primary antibodies used include monoclonal mouse ICP0 (5H7) 
(1:1,000; Abcam), polyclonal rabbit USP7 (H200) (1:1,000; Santa Cruz), and monoclonal mouse 
Ku70 (Ab-4) (1:5,000; NeoMarker). 
 
2.4. Results 
2.4.1. Isolated USP7 UBL domains can be studied independently in solution 
The full-length USP7 as well as the C-USP7 have long represented a challenge for structural 
studies because of their rapid degradation during recombinant expression in E. coli (149). As a 
consequence, difficulties in C-USP7 production hampered investigation of its structure and 
function. The recent crystal structure of the isolated C-USP7 produced in insect cells (71) 
revealed the domain organization of the C-USP7 and confirmed that it consists of five ubiquitin-
like domains. In order to produce stable constructs of the C-USP7 suitable for studies in solution 
we have tested bacterial expression of all individual UBL domains and their combinations in E. 
coli. We found that the isolated UBL1 and UBL3 express well and result in stable soluble 
proteins. In contrast, UBL2, UBL4 and UBL5 are unstable and degrade rapidly when expressed 
on their own. However, the two-domain combinations UBL12 and UBL45 express well and are 
stable and soluble. These results are in agreement with the C-USP7 crystal structure, which 
shows extensive interactions between UBL1 and UBL2 as well as between UBL4 and UBL5. 
1
H-
15
N HSQC NMR spectra of UBL1, UBL12, UBL3 and UBL45 are shown in Figure 2.1B. 
The high quality of spectra and good chemical shift dispersion suggest that isolated UBL 
domains and/or their combinations described above represent independently folding units that 
can be used for structural and functional studies. 
49 
 
2.4.2. Solution structure of the USP7 UBL1 domain 
Figure 2.2 shows the solution NMR structure of the USP7 UBL1 domain (residues 537-664). 
According to secondary structure prediction obtained from the backbone 1H, 15N and 13C NMR 
chemical shifts using TALOS+ program (106), UBL1 adopts a characteristic ubiquitin-like β-
grasp fold formed by β1-β2-α3-310-β3-β4-α4-α5-β5 elements (Figure 2.2A, top panel). The 
bottom panel on Figure 2.2A shows order parameters S
2
 for the backbone amide groups of the 
domain predicted from NMR chemical shifts using Random Coil Index (RCI) approach (150). 
High S
2
 values of 0.8 – 0.9, indicative of limited backbone flexibility, were obtained for a 
majority of the residues. The exceptions are a linker connecting the first two helices with the first 
β-strands of the β-grasp fold and two large loops: loop I and loop II. The final ensemble of the 20 
lowest energy structures (Figure 2.2B) displays root mean square deviation (rmsd) of 1.96 ± 0.44 
Å for the backbone and 2.70 ± 0.38 Å for all heavy atoms (see Table 2.1 for structural statistics). 
As expected, the overall structure of the domain is well defined in the NMR ensemble with the 
exception of the two loops. (Figure 2.2B). The structure consists of a long kinked N-terminal α-
helix (helices α1 and α2) followed by a β-grasp fold (Figures 2.2C and D). The α3-helix is 
packed against an anti-parallel β-sheet ( that forms a barrel-like structure 
(Figure 2.2D). In this barrel, the β4-strand is very short and is stabilized by a single hydrogen 
bond between the backbone amide group of Leu638 and carboxyl of Leu622 from the β3-strand. 
The N-terminal helix α1 does not belong to the ubiquitin-like fold and, in the context of the full-
length USP7, connects C-USP7 with the catalytic domain of the enzyme. Although the sequence 
similarity of the USP7 UBL1 to ubiquitin is only 21%, it closely resembles a ubiquitin fold (PDB 
ID: 1UBQ) with the backbone rmsd between the UBL1 and ubiquitin of 2.4 Å for regular 
secondary structure elements. Significant differences, however, are observed in the loop regions. 
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Thus, the UBL1 loop I that connects the β1- and β2-strands (residues 571-591) as well as loop II 
between the β3- and β4-strands (residues 625-637) are notably longer than those of ubiquitin. 
The hydrophobic patch equivalent to the ubiquitin Ile44 patch (151) is also present in UBL1 and 
is centered around Trp623 (Figure 2.2D). 
Figure 2.2E shows an overlay of the solution (red) and crystal (blue; PDB ID: 2YLM) 
structures of the UBL1 domain. The UBL1 NMR structure is in good agreement with the crystal 
structures of the entire C-USP7 (PDB ID: 2YLM) and the UBL12 tandem (PDB ID: 4PYZ) with 
the backbone rmsd between NMR and crystal structures of 2.40 Å and 2.35 Å, respectively. The 
most significant difference is in the loop conformations. The long loop II connecting the β3- and 
β4-strands is poorly defined in the solution structure with only short and medium-range (|i-j|<5) 
NOEs observed in this region (Figure 2.2F). This is in contrast to the crystal structure where 
residues 625-635 form type-I -hairpin. The position of the hairpin is stabilized by interaction 
with the UBL2 domain, including inter-domain salt bridges formed by residues Arg628 and 
Asp764, as well as Arg634 and Glu737. Similarly, the position of loop I connecting - and β2-
strands (residues 571-591) is poorly defined in our solution structure, while in the crystal 
structure it is stabilized by several inter-domain hydrogen bonds with the UBL2 residues. 
Additionally, in the crystal structure, the relative position of the two long loops is constrained by 
a hydrogen bond between the backbone HN group of Lys633 (loop II) and the OD2 group of 
Asp582 (loop I), while in the NMR ensemble the loops sample multiple conformations. Overall, 
the observed differences between the two structures may result from additional domains present 
in the X-ray structure and the fact that NMR is sensitive to protein dynamics in solution. 
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2.4.3. Backbone dynamics of the USP7 UBL1 domain 
To confirm flexible conformations of the loops we have investigated the extent of 
conformational dynamics of the UBL1 domain using backbone 
15
N NMR relaxation 
measurements, including 
15
N R1 and R2 rates and heteronuclear 
15
N{
1
H} NOE values 
(118,119,147). These data report on Brownian rotational diffusion of a protein and its 
conformational flexibility on the pico- to nanosecond time scales. 15N R1 and R2 relaxation rates 
and 15N{1H} NOEs suggest that UBL1 is a rigid molecule with increased sub-nanosecond time-
scale flexibility of the two long UBL1 loops, as evidenced by a decrease in 15N{1H} NOE values, 
lower R2 rate and elevated R1 rates for amino acid residues located in loops I and II (Figure 2.3). 
Additionally, relaxation rates and NOEs suggest that the N-terminal α-helix that does not belong 
to the β–grasp fold is also highly dynamic on the sub-nanosecond timescale. 
2.4.4. USP7 is required for the efficient HSV-1 infection in HFF-1 cells 
As a first step toward understanding the mechanism of substrate recognition by the C-USP7, 
we have characterized its interaction with the ICP0 E3 ligase from HSV-1. ICP0 was the first 
discovered and remains the best studied substrate of the USP7 that interacts exclusively with the 
enzyme's C-terminus (70). ICP0 is a 775 amino acid residue long immediate early protein that is 
expressed immediately after infection. Although ICP0 doesn’t interact with DNA directly, it acts 
as a promiscuous activator for all three temporally regulated kinetic classes of viral genes 
(reviewed in (54)). It was previously shown that ICP0 self-ubiquitination promotes its own 
degradation; however, the formation of a complex with cellular USP7 stabilizes ICP0 and 
rescues it from proteasomal degradation (55,152). Mutations that abolish the USP7 binding lead 
to ICP0 destabilization during HSV-1 infection in U2O2 cells (55). Moreover, treatment of HeLa 
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cells with siRNA against USP7 leads to a defect in ICP0 accumulation and reduced expression of 
many ICP0 target genes, including ICP4 and UL42 (153). Furthermore, ICP0 interaction with 
USP7 causes migration of the latter from the nucleus to the cytoplasm where it inhibits the NF-
kB dependent inflammatory cytokine response to protect HSV-1 from innate immunity (131). 
Altogether, these data suggest that USP7 not only plays an essential role in regulation of 
ICP0 levels in the infected cell, but also is required for establishment of successful HSV-1 
infection. This makes USP7/ICP0 binding interface an attractive target for the development of 
antiviral therapeutics. Therefore, we have explored the effect of a USP7 knockdown on the 
efficiency of HSV-1 infection. Although ICP0 is not essential for virus replication in cultured 
cells, ICP0-null mutant viruses grow poorly at low MOI. Because this effect is cell type 
dependent, we have utilized limited-passage human diploid fibroblasts since they are sensitive to 
the presence of ICP0 (reviewed in (54)). HFF-1 cells were infected with lentiviruses expressing 
shRNA against either USP7 or GFP (control) followed by HSV-1 infection at an MOI 2 
PFU/cell. The knockdown of USP7 was confirmed by a Western blot (Figure 2.4C). As 
expected, ICP0 levels were severely decreased in cells lacking USP7 compared to cells 
expressing shRNA against GFP. In addition, cells were infected with HSV-1 at a lower MOI of 
0.1 PFU/cell. Progeny virus was collected at 24 hours post infection and formation of plaques 
was monitored on Vero cells (Figures 2.4A and B). We observed that viral growth was reduced 
100-fold in cells expressing shRNA against USP7 compared to control cells treated with shRNA 
against GFP. These results suggest that the presence of USP7 in the cell and its interaction with 
ICP0 are essential for establishment of successful lytic infection at low MOI in HFF-1 cells. 
53 
 
2.4.5. The first two USP7 UBL domains (UBL12) are responsible for interaction with ICP0 
The minimal ICP0 region required for interaction with USP7 was previously defined by R. 
Everett et al. as residues 619-626 (152). This short peptide contains several Lysine and Arginine 
residues, which make it highly positively charged. On the other hand, the region of USP7 
responsible for interaction with ICP0 was roughly defined using limited proteolysis to reside 
within residues 599-801 (70). This region contains a part of UBL1, the entire UBL2 and a part of 
the UBL3 domains. To determine the domain(s) of C-USP7 responsible for interaction with ICP0 
we have performed a series of NMR binding experiments. Isolated 
15
N-labeled UBL1, UBL12 
and UBL3 domains of the USP7 were gradually titrated with the unlabeled ICP0 peptide 
(residues 617-GPRKCARKTRH-627) and binding-induced changes in peak positions in 
1
H-
15
N 
HSQC spectra of the domains were monitored. As seen in Figures 2.5B and C, no peak shifts 
were observed for the UBL1 and UBL3, indicating that these domains alone are not sufficient for 
interaction with the ICP0 peptide. In contrast, the addition of ICP0 peptide to the 
15
N UBL12 
caused progressive changes in the positions and intensities of a number of peaks in its 
1
H-
15
N 
HSQC spectrum indicative of specific ICP0 binding (Figure 2.5A). 
In the course of titration with ICP0, the peaks in the NMR spectrum of UBL12 do not move 
gradually, but rather disappear and then show up in new positions in the spectrum, indicative of a 
slow on the NMR time-scale binding process. Therefore, to measure UBL12 – ICP0 binding 
affinity and determine thermodynamic parameters for this interaction we have employed 
isothermal titration calorimetry (ITC) (Figure 2.5D). The results indicate that UBL12 binds ICP0 
in 1:1 stoichiometry. The best fit of the titration curve was obtained with an independent site 
model with a dissociation constant (KD) of 14.6 ± 1.3 μM and enthalpy (∆H) of -24.5 ± 0.7 
kcal/mol, resulting in entropy (ΔS) of -60.2 cal/(mol K) and Gibbs Free energy (ΔG) of -6.6 
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kcal/mol at 25°C. The high ΔH value suggests that the reaction is enthalpy-driven with primary 
contributions to the complex stabilization likely resulting from electrostatic interactions and/or 
hydrogen bonds. 
2.4.6. Mapping of the UBL12-ICP0 binding site 
As seen in Figure 2.5A, a large number of peaks have shifted in 
1
H-
15
N HSQC spectrum of the 
USP7 UBL12 as a result of ICP0 peptide binding. Due to slow on the NMR time scale binding, 
the backbone resonances of the UBL12 in complex with ICP0 cannot be assigned by tracing 
peak shifts in the UBL12 spectrum during the titration. Therefore, to quantify ICP0-induced 
changes in peak positions and thus identify the UBL12 amino acid residues responsible for ICP0 
recognition we have assigned the backbone resonances of the free and ICP0-bound forms of the 
UBL12. 
Figure 2.6A summarizes the extent of the UBL12 chemical shift assignment: circles below 
the amino acid sequence correspond to assigned peaks in the 
1
H-
15
N HSQC spectra of the free 
and ICP0-bound UBL12 constructs. UBL1 and UBL2 portions of UBL12 are colored in blue and 
green, respectively. A total of 74% of expected NMR resonances of free UBL12 and 82% 
resonances of ICP0-bound UBL12 have been assigned. The remaining peaks were broadened 
beyond detection. The residues with missing assignments in either free or ICP0-bound UBL12 
are marked by stars and arrows, respectively, above the amino acid sequence. Most of these 
residues are missing in the spectrum of free UBL12 and appear only after ICP0 binding. Such a 
behavior points to changes in the UBL12 conformation and dynamics as well as changes in 
chemical environment of the nuclei on the interaction interface associated with the substrate 
recognition. 
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ICP0 binding led to substantial frequency (chemical shift) changes for the vast majority of 
the UBL12 amide resonances (Figures 2.5A and 2.6F) with the largest perturbations (>150 Hz) 
observed for residues Gly631, Leu638, Val685, Leu699, Ile709, Ser710, Ser752, Leu757 and 
Asp758. The complex formation noticeably improved the quality of the spectrum, suggesting 
that ICP0 binding stabilizes the UBL12 tandem (Figure 2.5A, bottom panel). As a result, a 
number of intense peaks appeared in the UBL12 spectrum upon ICP0 binding. While the 
backbone amide resonances for 171 out of 230 non-proline residues were observed for the free 
protein, 25 additional peaks were assigned for the complex (Figure 2.6A). The vast majority of 
these new peaks correspond to residues located either on the UBL1/UBL2 interface or in its 
close proximity (Glu572, Phe575, His578, Gln579, Asn581, Asp582, Ile620, Gln626, Arg628, 
Asn630, Thr632, Glu663, Thr664, Val665, Met686, Asn700, Tyr701, Tyr706 and Val738) (Figure 
2.6D). In addition, 8 peaks in 1H-15N HSQC spectrum of the UBL12 disappeared upon ICP0 
binding, pointing to changes in the UBL12 conformation and/or dynamics caused by complex 
formation. These peaks correspond to residues Asp680, Lys681, Asp682, Gly763, Asp764 and 
Ile765 located on the UBL1/UBL2 interface and residues Glu759 and Leu760 located in the loop 
between the β4- and β5-strands of the UBL2. 
Overall, mapping binding-induced frequency (chemical shift) changes onto the UBL12 
structure (71) identified residues sensitive to ICP0 binding in both UBL1 and UBL2 domains. 
The regions of the UBL1 and UBL2 with NMR peaks affected by ICP0 addition are shown on 
the protein surface in Figures 2.6C and D. The UBL1 residues exhibiting pronounced frequency 
(chemical shift) changes are mainly located in loops I and II. The residues of UBL2 affected by 
ICP0 binding are located in two distinct regions. The first region includes a hydrophobic patch 
formed by residues in strands β1, β2, β3 and β5 of the UBL2 β-sheet. This face of the UBL2 
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domain makes extensive contacts with UBL1, which protect this patch from solvent exposure 
(Figure 2.6D). The second region is solvent exposed and includes residues from the two loops: 
the UBL2 loop connecting the β2-strand with the following -helix, and the loop connecting the 
β4- and β5-strands (Figures 2.6C and E). These loops form a negatively charged cluster on the 
UBL2 surface, which provides a binding interface for the positively charged ICP0 peptide. 
 
2.5. Discussion 
Owing to USP7 involvement in maintenance of several important tumor suppressors and key 
viral proteins, it has emerged as a potential therapeutic target for treatment of cancer and 
infections caused by DNA viruses (154). Therefore, the mechanisms of USP7 specificity toward 
its diverse substrates are of significant interest.  
While functions of the USP7 N-terminal TRAF and catalytic domains were previously 
characterized, the functions of its UBL domains remain largely unknown. Roughly, UBLs within 
the USP family of proteins can be divided into three groups: N-terminal,  C-terminal or 
embedded in the USP catalytic core (155). The USP7 UBL domains belong to the third group of 
the C-terminal UBLs. Previous studies revealed that UBLs of USP7 enhance its enzymatic 
activity, since even small truncations of the extreme C-terminus dramatically decrease USP7 
catalytic activity (71,83). Furthermore, it was recently shown that the UBL domains can function 
as a binding platform for several USP7 substrates. However, the precise location of the C-USP7 
substrate binding sites remained unknown (50,70,83). 
USP7 is unique within the USP family, since, unlike other family members, it contains a 
tandem array of five UBL domains. As a consequence of the large size of the USP7 C-terminus, 
it is challenging to study all five tandem UBL domains together. Here we show that this complex 
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system can be simplified by the isolation of stable individual UBL domains and/or constructs 
containing two consecutive UBL domains. Our NMR data reveal that these constructs can be 
studied in isolation in solution, providing new insights into the C-USP7 structure, dynamics and 
substrate specificity. Although there are two available X-ray crystal structures of C-USP7 (PDB 
IDs: 2YLM, 4PYZ), these structures provide little information about protein dynamics. In this 
study we focused on the UBL1 domain and UBL12 tandem. We have: (i) determined the three-
dimensional NMR structure of the UBL1 domain and characterized its dynamic properties, (ii) 
narrowed down the ICP0-binding region of the USP7 to the UBL12 domains, and (iii) obtained 
high-resolution NMR mapping of the USP7 binding site for ICP0. 
Once inside the cell, HSV-1 encounters a hostile environment created by host proteins that 
are intrinsically antiviral. HSV-1 encodes proteins such as ICP0 intended to inactivate cellular 
antiviral mechanisms (54). The interaction between ICP0 and USP7 is essential to prevent ICP0 
degradation during the infection, and in this study, we have structurally and functionally 
characterized this interaction. As a first step, we have investigated the effect of USP7 ablation on 
the efficiency of HSV-1 lytic infection. We utilized shRNA to generate USP7 knockdown cells 
and demonstrated that in cells lacking USP7 virus growth is severely reduced. These results 
suggest that the USP7-ICP0 interaction is important for the establishment of effective lytic HSV-
1 infection in HFF-1 cells. 
Next, we used solution NMR to structurally characterize the ICP0 – USP7 interaction, and 
have shown that USP7 binds ICP0 via its first two C-terminal UBL domains, providing evidence 
that the USP7 UBL domains function as a substrate interacting platform. The ICP0 peptide used 
in this study was previously identified as a minimal USP7-binding region of ICP0 (152). This 
peptide is composed of eleven amino acid residues, six of which are positively charged and three 
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are polar (Figure 2.7B). Thus, of the two USP7 regions affected by ICP0 binding, the one located 
at the UBL2 β-sheet is unlikely to directly interact with ICP0 because it consists of mainly 
hydrophobic residues buried on the UBL1/UBL2 interface. On the other hand, the second region 
encompassing the UBL2 loops, one between the β2-strand and the following α-helix and the 
other between the β4- and β5-strands, has a negatively charged surface and is more likely to 
directly bind positively charged ICP0 peptide. The high enthalpy of complex formation (-24.5 ± 
0.7 kcal/mol) measured by ITC provides further evidence of the electrostatic nature of UBL12 – 
ICP0 interaction. 
NMR chemical shift mapping revealed that the binding of the two proteins is likely mediated 
by electrostatic interactions. This is in agreement with previous mutational analysis of ICP0, 
which identified Arg619, Lys620, Lys624 and Arg626 as residues critical for interaction with 
USP7 (152) (Figure 2.7A). Interestingly, although the UBL1 domain alone does not interact with 
ICP0 (Figure 2.5B), it exhibits extensive binding-induced chemical shift changes in the context 
of the UBL12 construct (Figure 2.6F). Notably, UBL1 residues involved in ICP0 binding belong 
to the two long flexible loops located in the close proximity of the UBL1 - UBL2 interface, 
supporting the notion that these two domains may function in tandem. The presence of UBL2 
may constrain conformation of the UBL1 flexible loops, as seen in crystal structures of the C-
USP7 UBL domains. Overall, our data suggests that UBL12 may undergo micro- to millisecond 
opening/closing events, resulting in the observed line broadening and/or disappearance of peaks 
on the interface of UBL1 and UBL2 domains. As evident from chemical shift mapping, most of 
the UBL12 biding site for ICP0 is located on the UBL2 surface with an additional participation 
of residues from loop II of the UBL1. We speculate that the substrate binding may lock the two 
domains in a closed conformation, thus limiting micro- to millisecond conformational sampling 
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and quenching exchange contributions to transverse relaxation. This model could explain the 
chemical shifts changes and line narrowing on the inter-domain interface observed upon ICP0 
binding. 
The HSV-1 ICP0 has never been structurally characterized, although it was shown to contain 
an N-terminal RING domain similar to one from an immediate-early protein of equine herpes 
virus. (156,157). The USP7-binding motif of ICP0 is located within the molecule’s C-terminus 
(residues 619-626). We used Jpred (158) to predict the secondary structure of the HSV-1 ICP0 
and found that its C-terminal region is predicted to contain a structured domain with an 
 arrangement (Figure 2.7A). Furthermore, we have compared the HSV-1 ICP0 
protein with its orthologues from other Alphaherpesvirinae subfamily viruses using SIB Blast 
followed by multiple sequence alignment in ClustalW (159) and conservation score calculation 
using ConSurf server (160,161) and found that the ICP0 sequence has two highly conserved 
regions. The first region includes the N-terminal RING domain characteristic of E3 ubiquitin 
ligases, while the second contains a yet uncharacterized C-terminal domain (CTD). Figure 2.7A 
shows a multiple sequence alignment of the ICP0 CTD. Remarkably, the USP7 binding motif 
(residues 619-626) is one of the best conserved regions within the ICP0 C-terminus and it is 
predicted to form an α-helix. According to a helix wheel projection, this helix is amphipathic 
(positively charged on one side and neutral on the other), which may facilitate its interaction with 
a negatively charged cluster on the UBL2 surface (Figure 2.7B). Other predicted secondary 
structure elements of the ICP0 CTD are also conserved, supporting the notion that ICP0-like 
proteins harbor a structured CTD in addition to the N-terminal RING domain. High amino acid 
conservation in the ICP0 region involved in USP7 binding implies that ICP0 interaction with the 
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USP7 is not unique to HSV-1 but may represent a common feature shared by other members of 
the Herpesvirus family. 
The fact that the five non-homologous USP7 UBL domains can interact with multiple USP7 
targets suggests that the UBL domains serve as a versatile binding platform and endow the 
enzyme with specificity to its diverse substrates. However, until now, none of the C-USP7 
substrate binding sites has been characterized at high resolution. In this work, for the first time, 
we have structurally and functionally characterized the interaction of the C-USP7 with its first 
identified target – HSV-1 ICP0 protein. Our results, along with future studies of other C-USP7 
substrate-binding sites, may unravel determinants of the USP7 specificity towards its substrates 
and provide a structural basis for the future development of new therapeutic strategies to prevent 
livelong HSV-1 infection and virus expansion among human population.  
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Table 2.1. NMR structural statistics of USP7 UBL1 domain. 
Summary of restraints 
NOE distance restraints 
Short range (|i-j|<=1) 1358 
Medium range (1<|i-j|<5) 576 
Long range (|i-j|>=5) 1107 
Total 3041 
Dihedral angles (φ and ψ) 187 
Hydrogen bonds 32 
Deviation from experimental restraints 
NOE (Å) 0.022±0.0
03 
Dihedral restraints 
(degrees) 
1.757±0.1
23 
Deviation from idealized geometry 
Bonds (Å) 0.019 
Angles (degrees) 1.3 
Ramachandran plot statistics 
Most favored regions 77.2%  
Additionally allowed regions 21.8% 
Generously allowed regions 0.8% 
Disallowed regions 0.2% 
RMSD from mean structure (Å) 
All residues 
Backbone atoms 1.96±0.44 
Heavy atoms 2.70±0.38 
Residues in ordered regions1 
Backbone atoms 0.62±0.09 
Heavy atoms 1.25±0.14 
 
 
1The following secondary structure elements were included as ordered regions in the RMSD 
calculation: 539-548, 551-554, 556-570, 592-595, 602-613, 617-619, 621-624, 649-652, 658-
663. 
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Figure 2.1. Isolated USP7 UBL domains can be studied independently in solution. A. 
Schematic representation of the domain arrangement of the human USP7 protein. B. 2D 
1
H-
15
N 
HSQC spectra of the UBL1 (blue), UBL12 (green), UBL3 (black) and UBL45 (red) domains. 
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Figure 2.2. Solution NMR structure of the USP7 UBL1 (residues 537-664). A. The top panel 
shows TALOS+ derived probabilities of α-helix and β-sheet formation, marked as P(α) and P(β), 
respectively. The bottom panel shows RCI-based backbone amide order parameters, S
2
. B. The 
backbone representation of the ensemble of 20 NMR lowest-energy structures of the USP7 
UBL1. C. Amino acid sequence of the USP7 UBL1 domain with cartoon representation of its 
secondary structure elements shown at the top. Helices are colored in red, β-strands are shown in 
green. D. Ribbon representation of the UBL1 structure with secondary structure elements and 
loops I and II labeled. E. Superposition of solution (red) and crystal (blue; (PDB ID: 2YLM) 
structures of the UBL1. F. NOE connectivity plot of UBL1. Flexible loops I and II are labeled 
and shown in grey. 
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Figure 2.3. The backbone dynamics of UBL1 from 
15
N relaxation. A. 
15N R1, R2 relaxation 
rates and 15N{1H} heteronuclear NOE values shown as a function of the UBL1 residue number. 
Secondary structure elements are shown at the bottom. B. Mapping of heteronuclear 1-NOE 
values onto the UBL1 structure. 1-NOE values are mapped as a color gradient (blue to magenta) 
and ribbon radius. Dynamic regions correspond to intense magenta color and thicker ribbon. All 
experimental relaxation data were acquired at 500 MHz (1H) and 25 °C. 
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Figure 2.4. USP7 is required for successful establishment of HSV-1 lytic infection. HFF-1 
cells were infected with lentiviruses expressing shRNA against USP7 (shUSP7) in order to 
downregulate cellular USP7. shRNA against GFP (shGFP) was used as a control. A-B. After 
selection, knockdown cells were infected with HSV-1 at an MOI of 0.1 PFU/cell. Progeny virus 
was collected at 24 hours post infection and titers were determined on Vero cells by staining with 
either crystal violet (A) or X-gal for β-galactosidase-positive plaques (B). In B, values 
correspond to the average of three independent experiments and error bars correspond to one 
standard deviation. C. Efficiency of USP7 knockdown and ICP0 stability were tested by Western 
blot analysis. USP7 knockdown cells were infected with HSV-1 at an MOI of 2 PFU/cell and 
cell lysates were prepared at 4 hours post infection and subjected to Western blot analysis for 
ICP0 and USP7. Ku70 serves as a loading control. 
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Figure 2.5. NMR and ITC analysis of the USP7 UBL domain interactions with the ICP0617-
627 peptide. Overlay of 
1
H-
15
N HSQC spectra of the  UBL12 (A), UBL1 (B), and UBL3 (C) 
domains before (red) and after addition of the unlabeled ICP0 peptide (residues 617-627) to a 
final protein:peptide ratio of 1:10 (blue). In A, the signals of UBL12 with chemical shift 
perturbations over 100 Hz are labeled. Among these, the peaks corresponding to residues located 
on the ICP0-binding interface are labeled with asterisks. The bottom panel shows changes in line 
shapes for selected UBL12 peaks upon ICP0 binding. D. ITC profiles for UBL12 binding to 
ICP0. The left panel shows heat change upon ligand addition; the right panel shows an integrated 
ITC isotherm and its best fit to an independent site model. 
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Figure 2.6. Analysis of ICP0 binding to the USP7 UBL12 tandem. A. Completeness of the 
backbone assignment for the free and ICP0-bound UBL12. Here and later UBL1 and UBL2 
domains are colored in shades of blue and green, respectively. Circles below the protein 
sequence represent amino acid residues with assigned NMR resonances in 
1
H-
15
N HSQC spectra 
of the free (light circles) and ICP0-bound UBL12 (dark circles). Open spaces indicate residues 
with unassigned amide peaks. Asterisks indicate UBL12 residues with assigned amide peaks in 
the bound state only, while arrows indicate residues with assigned amide peaks in the free state 
only. B. Ribbon representation of the UBL12 (pdb ID: 2YLM) (71). C. Mapping of the 
frequency differences between the free and ICP0-bound UBL12 i=(N
2
+H
2 
)
1/2
 on the 
UBL12 surface. The color gradient corresponds to values, with larger changes shown by 
more intense color. D. Mapping of the UBL2 residues located on the UBL1/UBL2 interface and 
affected by ICP0 binding. As in C (top view) but rotated about the z-axis by 90°, for clarity, 
UBL1 is shown as orange ribbon. E. Close-up view of the UBL12 ICP0-binding interface. F. 
Per-residue amide frequency differences between the free and ICP0-bound states of the UBL12 
(Hz as a function of residue number. Residues with peaks missing in one of the two spectra 
(free or bound) are shown as bars with the maximum  of 650 Hz to indicate that these 
residues are sensitive to ICP0 binding. Prolines and residues with missing amide group 
assignment in both spectra are shown as empty spaces. Secondary structure elements are shown 
at the top. 
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Figure 7. The C-terminal region of ICP0 may contain a structured domain. A. Sequence 
alignment of the HSV-1 ICP0 (residues 604-775) and a number of its viral orthologues 
performed in ClustalW (159). Viruses are Human Herpesvirus 1 (HSV1), Chimpanzee alpha-1 
herpesvirus (ChHV), Human Herpesvirus 2 (HSV2), Cercopithecine Herpesvirus 1 (CeHV1), 
Cercopithecine Herpesvirus 16 (CeHSV16), Macropodid Herpesvirus 1 (MaHV1) and Saimiriine 
Herpesvirus 1 (SHV1). Residues are colored according to conservation scores calculated using 
the ConSurf server (160,161). Secondary structure elements predicted in Jpred (158) for the 
HSV-1 ICP0 are shown at the top. Arrows above the alignment indicate residues critical for 
USP7 binding identified in previous mutagenesis analysis (152). B. HSV-1 ICP0 peptide 
(residues 617-627) shown in a helical wheel projection created using the EMBOSS Pepwheel 
program. Hydrophobic residues are shown as grey spheres, polar residues as diamonds and basic 
residues as blue spheres. 
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3.1. Abstract 
USP7 is a deubiquitinating enzyme that plays a pivotal role in multiple oncogenic pathways 
and therefore is a desirable target for new anti-cancer therapies. However, the lack of structural 
information about the USP7 – inhibitor interactions has been a critical gap in the development of 
potent inhibitors. Using a multidisciplinary approach, we obtained new and unexpected insights 
into the mechanisms of USP7 activation and inhibition by small-molecule compounds that can 
aid this development. USP7 is unique among other USPs in that its active site is catalytically 
incompetent and is postulated to rearrange into a productive conformation only upon binding to 
ubiquitin. Here we show that, contrary to previous reports, ubiquitin binding alone is not 
sufficient to induce active site rearrangement and leaves the enzyme in an unproductive 
conformation. Using a combination of NMR spectroscopy, mass spectrometry and computational 
modeling we found that inhibitors P22077 and P50429 covalently modify the catalytic cysteine 
of USP7 via distinct chemical mechanisms and induce a conformational switch in the catalytic 
domain associated with active site rearrangement. Cell-based enzymatic activity assays 
confirmed that the inhibitors inactivate the full-length protein in cells. This work represents the 
first experimental insights into USP7 activation and inhibition and provides a structural basis 
needed for rational development of highly potent anti-cancer therapeutics. 
 
3.2. Introduction 
The Ubiquitin-proteasome system (UPS) is required for the tightly controlled degradation 
and turnover of a majority of the proteins in eukaryotic cells. An enzymatic cascade of three 
classes of enzymes: E1 activating enzyme, E2 conjugating enzyme and E3 ligase work together 
to ubiquitinate a substrate and target it to the proteasome, where it is cleaved into short peptides. 
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The targeting of a protein to degradation in turn can be reversed by deubiquitinating enzymes 
(DUBs) that remove ubiquitin chains from their substrates (2). Inhibition of UPS components 
represents a promising therapeutic strategy to control cellular levels of proteins that lack 
enzymatic activity and thus cannot be inhibited (90). E3 ligases and DUBs directly interact with 
proteins targeted for (de)ubiquitination and determine substrate specificity of UPS. Therefore, 
their inhibition has emerged as a new approach to modulate stability of distinct proteins, such as 
oncoproteins and tumor suppressors (22,162,163). Ubiquitin-specific protease 7 (USP7), also 
known as Herpes virus-associated ubiquitin-specific protease (HAUSP), is a cysteine protease 
that belongs to the USP family of DUBs in humans (53). It is widely known for its central role in 
the DNA damage response in which it regulates protein levels of the tumor suppressor p53 in 
response to genotoxic stress (24). In unstressed cells, USP7 preferably interacts with and 
stabilizes HDM2, an E3 ligase responsible for poly-ubiquitination of p53 and targeting it for 
degradation. During DNA damage, however, ATM-dependent phosphorylation of HDM2 
reduces its affinity for USP7. As a consequence, p53 is available to interact with USP7, resulting 
in stabilization of p53 and initiation of the p53-dependent DNA damage response (25-27). In 
addition to p53, USP7 has been shown stabilize proteins involved in DNA replication, epigenetic 
DNA alterations, apoptosis and cell cycle control (30,34,37,39,47,63,125,164,165). 
Microdeletions and mutations in the USP7 gene lead to neurodevelopmental disorders in humans 
characterized by intellectual disability, autism spectrum disorder, epilepsy and hypogonadism 
(132). 
Dysregulation of USP7 expression has been reported in number of human malignancies, 
including human prostate cancer (51), ovarian cancer (87) and non-small cell lung cancer 
(NSCLC) (86,136). The role of USP7 in oncogenesis and tumor suppression makes it an 
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attractive pharmaceutical target for inhibition by small-molecule compounds (154). Early studies 
in human colon cancer xenograft models showed that downregulation of USP7 suppresses cell 
proliferation and delays tumor growth due to p53 stabilization in the absence of cellular stress 
(166). High-throughput screening (HTS) efforts led to the discovery of the first semi-specific, 
uncompetitive and reversible inhibitor of USP7 (HBX 41,108) that stabilizes p53 and inhibits 
cell growth in HCT116 colon cancer cells (91). Later, more specific USP7 compounds were 
reported (92) along with a family of dual USP7/USP47 inhibitors (compounds 1 - 14) (93). 
Inhibition of USP7 by P5091 (compound 1) was shown to cause apoptosis of multiple myeloma 
cells and prolonged survival in animal xenograft models (94). Optimization of P5091 led to the 
discovery of P22077 (compound 4) that inhibited neuroblastoma growth (96) and P50429 
(compound 14) that inhibited the proliferation of HCT-116 cells (93). Although all of the above 
compounds show antitumor properties in various cancer cell lines and animal models, none is 
very potent and all require further optimization. 
USP7 consists of an N-terminal substrate-binding TRAF-like domain, five C-terminal 
regulatory ubiquitin-like (UBLs) domains, and a central catalytic core that binds ubiquitin and 
removes it from the substrate (70,71,138). The catalytic domain of USP7 adopts a papain 
protease-like fold that binds ubiquitin. This fold contains Thumb, Palm and extended Fingers 
regions similar to those of other USPs (72,75). Importantly, because all previously reported 
USP7 inhibitors were discovered using HTS, it is not clear whether the inhibitors bind to the 
active site of the enzyme or whether they bind to a region distinct from the active site, acting 
allosterically to induce a conformational change that leads to enzyme inactivation. Furthermore, 
given the structural conservation of the catalytic domains within the family of 58 USP enzymes, 
it is not clear how specificity for USP7 can be achieved (11). 
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In this study we uncover the mechanism of USP7 inhibition by small-molecule compounds 
as well as provide new insights into the mechanism of the enzyme’s activation. We have taken 
advantage of NMR spectroscopy, a powerful tool for studying protein-ligand interactions, and 
developed a robust assay to test binding of USP7 inhibitors to its catalytic domain in solution. 
We performed a backbone NMR resonance assignment of the catalytic domain and mapped 
surface binding sites for two USP7 inhibitors P22077 and P50429, the derivatives of a lead 
compound that previously showed antitumor potential (93). Interestingly, our NMR and mass 
spectrometry data reveal that both compounds occupy the active site of the enzyme and 
covalently modify the catalytic Cys223 residue. We suggest that these small molecules directly 
inhibit the catalytic activity of USP7 by preventing the cleavage of the isopeptide bond between 
the substrate and ubiquitin. The efficacy of these irreversible inhibitors was also confirmed using 
full-length USP7 in Jurkat cells. Our study, the first elucidation of the mechanism of action for 
any USP7 inhibitor, provides the foundation for rational design of more potent and selective 
USP7 inhibitor-based therapeutic agents. 
 
3.3. Experimental procedures 
Protein expression and purification. cDNA encoding the catalytic domain of the human 
USP7 (residues 208-560) was sub-cloned into pET28a-LIC Vector (Structural Genomics 
Consortium) downstream from an N-terminal His6-Tag and a thrombin cleavage site. A 
2
H/
13
C/
15
N – labeled catalytic domain was expressed in Escherichia coli BL21 (DE3) grown at 
37°C in 100% D2O-based M9 minimal medium supplemented with 
15
NH4Cl and 
13
C/
2
H -glucose 
as the sole source for nitrogen and carbon respectively. Protein expression was induced at an 
OD600 ~ 0.8 by adding 1mM IPTG. Cells were harvested after 16 hours of incubation at 20°C 
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and lysed by sonication in extraction buffer containing 20 mM NaH2PO4, 250 mM NaCl, 10 mM 
imidazole, pH 7.4. Cell lysates were clarified by centrifugation at 15000 rpm for 45 min and 
applied to a Ni-NTA resin (Thermo Scintific). Recombinant protein was eluted with extraction 
buffer containing 250 mM imidazole. Following thrombin digestion to remove the His6-tag, the 
catalytic domain was additionally purified by size exclusion chromatography using HiLoad 
Superdex 200 column (GE Healthcare) in sample buffer containing 20mM Tris-HCl, 100mM 
NaCl, 2mM DTT, pH 7.5. For NMR experiments the protein sample additionally contained 10% 
D2O. 
NMR spectroscopy. All NMR data including spectra for backbone resonance assignment and 
chemical shift perturbation experiments were collected on an 800 MHz (1H) Agilent VNMRS 
spectrometer equipped with a cryoprobe at 30°C. The data were processed with NMRPipe (140) 
and analyzed with CcpNmr Analysis (146). NMR experiments collected for backbone resonance 
assignment of USP7 catalytic domain included standard 2D 
1
H-
15
N TROSY-HSQC, TROSY-
based 3D HNCA, HNCOCA, HNCO, HNCACO, HNCACB and 
15
N-edited NOESY-HSQC 
(101,102). To assess ubiquitin binding, unlabeled ubiquitin was gradually added to 0.3 mM 
2
H/
13
C/
15
N – labeled catalytic domain of USP7 at ratios of up to 1:3 (protein to substrate). To 
monitor interactions of USP7 with its inhibitors, compounds P22077 or P50429 were dissolved 
in 100% DMSO and gradually added to 0.42 mM 
2
H/
13
C/
15
N – labeled catalytic domain up to a 
1:5 protein-to-inhibitor ratio and a final DMSO concentration of 5%. In all experiments changes 
in chemical shifts were monitored by acquiring 2D 
1
H-
15
N TROSY spectra. During inhibitor 
binding experiments a spectrum of the free catalytic domain in sample buffer additionally 
containing 5% DMSO was used as a reference spectrum. 
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For the USP7 catalytic core – ubiquitin complex, observed frequency perturbations for each 
amino acid residue were calculated using combined shift change of the amide nitrogen and 
proton obs=(N
2
+H
2 
)
1/2
, where N and H are 
15
N and 
1
H frequency differences 
between free and bound states in Hz. The dissociation constant for the complex of the catalytic 
domain with ubiquitin KD=[P][L]/[PL] (where [P], [L] and [PL] are concentrations of the free 
protein, free substrate and the complex respectively) was extracted by nonlinear least-square 
fitting of global chemical shift change plotted versus ligand concentration using the following 
equation: 
∆ωobs = ∆ωmax
(𝐾D + [L]t + [P]t) − √([𝑃]t + [L]t + 𝐾D)2 − 4[P]t[L]t
2[P]t
 
where [P]t and [L]t are the total protein and ligand concentrations and ∆max is the chemical shift 
difference at saturation. A total of 199 assigned, well resolved non-overlapped peaks were used 
for the analysis. The titration data analysis was performed using SciDAVis. 
Protein – ligand docking. Induced fit (flexible) and covalent docking of the complexes of the 
USP7 catalytic domain with DUB inhibitors P22077 and P50429 was performed using ICM-Pro 
(Molsoft). ICM method uses Monte-Carlo simulations based global optimization of flexible 
ligand positions in the space of grid potential energy maps calculated for a protein receptor 
(167). During induced fit docking, pockets were first automatically identified on the X-Ray 
structure of the USP7 catalytic core (PDB ID: 4M5W) (75). The inhibitor binding pocket for 
calculation of grid potential maps was chosen and further adjusted based on experimental NMR 
results. Full side-chains of residues within the search box were allowed to be flexible including 
residues 218-219, 222-224, 226, 291-292, 461-465 and 482 of P22077 and residues 218-227, 
291-296, 351, 405-411, 416-418, 456, 460-466, 481-482 and 514-515 – during docking of 
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P50429. The thoroughness level was set to 5. For covalent docking, chemical reactions for both 
of the compounds were sketched manually. Covalent adducts were identified based on MS 
results and represented products of the chemical reactions. Cys223 was chosen as the modified 
residue. Structures with the lowest predicted ICM scoring function accounting for ligand size, 
protein – ligand van der Waals interactions, conformational changes, changes in solvation 
electrostatic energy and hydrophobic free energy gain were chosen for analysis. 
Mass Spectrometry. Samples used for intact mass determination and LC-MS/MS were 
prepared by incubating 300 μg of the purified catalytic domain with either a 5-fold molar excess 
of P22077 or P50429 in the sample buffer containing 5% DMSO, or with vehicle (5% DMSO) 
overnight at room temperature. Following incubation, the protein samples were dialyzed in water 
to remove salts and excess of the small molecules. To determine the intact mass of the USP7 
catalytic core and its complexes with inhibitors, samples (~100 µg, 30 µl) were mixed with 200 
µl of 50% methanol containing 0.1% formic acid and analyzed by direct infusion on a Thermo 
Scientific Orbitrap Fusion Tribrid mass spectrometer. The instrument was operated in Intact 
Protein mode with an ion routing multipole pressure of 1mTorr. Spectra were acquired at 120K 
and 240K resolution. The isotopically resolved data were processed using Thermo Scientific 
Protein Deconvolution 4.0 software. 
For LC-MS/MS, the intact protein samples (~10ug) were dried using SpeedVac prior to 
dissolving and denaturing in 8M urea, 0.4M ammonium bicarbonate. The urea concentration was 
adjusted to 2M by the addition of water, and the proteins were digested with trypsin (Promega) at 
37ºC for 16 hours.  Samples were desalted using a C18 Ultra microspin column (The Nest 
Group) and peptides were eluted with 80% acetonitrile containing 0.1% trifluoroacetic acid 
(TFA), dried and reconstituted in 7% formic acid/0.1% TFA and then diluted with additional 
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0.1% TFA to a final protein concentration of 0.01µg/µl. LC-MS/MS analysis was performed on 
a Thermo Scientific Q Exactive Plus equipped with a Waters nanoAcquity UPLC system using a 
Waters Symmetry® C18 180µm x 20mm trap column and a ACQUITY UPLC PST (BEH) C18 
nanoACQUITY Column (1.7 µm, 75 µm x 250 mm) for peptide separation. Trapping was done 
at flow rate of 5µl/min in 97% Buffer A (100% water, 0.1% formic acid) for 3 min. Peptide 
separation was performed at 330 nl/min with the following gradient of Buffer B (100% 
acetonitrile, 0.1% formic acid) in Buffer A for 90 minutes: 3% B at initial conditions; 5% B at 1 
minute; 35% B at 50 minutes; 50% B at 60 minutes; 90% B at 65-70; and back to initial 
conditions at 71 minutes. MS was acquired in profile mode over the 300-1,700 m/z range using 1 
microscan; 70,000 resolution; AGC target of 3E6; and a full max ion time of 45 ms. MS/MS was 
acquired in centroid mode using 1 microscan; 17,500 resolution; AGC target of 1E5; full max 
ion time of 100 ms; 1.7 m/z isolation window; normalized collision energy of 28; and 200-2,000 
m/z scan range. Up to 20 MS/MS were collected per MS scan on species with an intensity 
threshold of 2E4, charge states 2-6, peptide match preferred, and dynamic exclusion set to 20 
seconds. MASCOT Distiller software was used to generate peak lists which were searched 
against the UBP7_HUMAN sequence as well as the Swiss-Protein database with taxonomy 
restricted to E. coli using the MASCOT algorithm (Matrix Science). Search parameters used 
were peptide mass tolerance of 10 ppm; MS/MS fragment tolerance of +0.25 Da; allow up to two 
missed cleavages; variable modification of methionine oxidation and custom modifications 
configured for the moieties added by the compounds. 
Cell Culture. Human T lymphocyte cell line Jurkat (p53MUT) was maintained in Roswell 
Park Memorial Institute (RPMI) 1640 Medium, supplemented with 10% FBS and 2mM L-
glutamine, and 50 units/mL penicillin/streptomycin. 
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Western Blotting. Jurkat cells were treated with USP7 inhibitors for 24 hours with indicated 
doses, harvested and washed once with ice-cold PBS. Cell pellets were lysed using modified 
RIPA lysis buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 1% NP40, 1% sodium deoxycholate, 
2mM EDTA, 10% glycerol, Protease inhibitor cocktail (Sigma, 1:500), 50µM PR-619 (Pan DUB 
inhibitor, LifeSensors). Protein estimation was carried out using the Bradford method (Bio-Rad). 
Twenty five µg of cell lysates were separated on 10% SDS-PAGE gel, transferred to PVDF 
membrane and probed with primary antibodies against DNMT1 (Cell Signaling) HDM2 (Santa 
Cruz), UHRF1 (Santa Cruz) and Actin (Sigma). Blots were developed using Millipore ECL or 
Pierce ECL depending on the sensitivity requirements and images were captured and quantified 
using the LI-COR Odyssey Fc imaging system. For repeated analysis of Western blots, 
membranes were stripped using Restore Western Blot Stripping buffer (ThermoFisher). 
Immunoprecipitation. Immunoprecipitation and measurement of USP7 activity were 
performed as reported previously (94) with slight modifications. Jurkat cells treated with DMSO 
or USP7 inhibitors were washed with ice cold PBS and lysed using NP40 lysis buffer (50mM 
Tris-HCl, pH 7.5, 150mM NaCl, 1%(v/v) NP40, 10%(v/v) glycerol, 1mM PMSF) and pre-
cleared using 30µl of protein G-sepharose (Invitrogen) for 1 hour at 4
o
C. 500µg of pre-cleared 
cell lysates were incubated with Protein G sepharose beads pre-loaded with 0.5µg of anti-USP7 
antibody (Progenra) for 1 hour. Beads were washed twice with lysis buffer containing 2mM β-
mercaptoethanol and USP7 activity was determined using Ub-CHOP2 reporter assays 
(LifeSensors). DMSO treated cell lysates were incubated with beads alone as a control. 5µl of 
beads from the immunoprecipitation was analyzed by Western blotting with anti-USP7 antibody 
to determine relative levels of USP7. 
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3.4. Results 
3.4.1. NMR studies of the 41kDa catalytic core of USP7 in solution 
Structural information about a protein target and its interaction with lead compounds is the 
key for successful rational drug design and optimization. Although several crystal structures are 
available for the catalytic core of USP7 and USP7-ubiquitin complexes (PDB IDs: 1NB8, 1NBF, 
4M5W) (72,75), structures of the enzyme with any known inhibitors have not been obtained. The 
relatively large size of the catalytic domain (41kDa) has also hindered its investigation in 
solution. We have overcome this hurdle by using full protein deuteration in combination with 
TROSY-based NMR experiments designed for large biological systems (101). A 2D 
1
H-
15
N 
TROSY-HSQC spectrum displayed good signal dispersion indicative of well-structured domains 
(Figure 3.1). The quality of the NMR data facilitated backbone resonance assignment, a 
prerequisite for mapping of inhibitor binding sites. 
Sequential assignment using a standard triple-resonance NMR spectroscopy approach was 
achieved for a total of 83% of the backbone atoms (NH, CO, Cα and Cβ), with 81 % of amides 
assigned (Figure 3.2A). The absence of several peaks and the presence of weak peaks prevented 
a higher percentage of resonance assignments. In particular, 61 of the 343 non-proline residues 
resonances could not be identified in the 
1
H-
15
N TROSY-HSQC spectrum. Approximately one-
half of the missing signals correspond to residues located in β-strands β8, β10 and β11 that are a 
part of an anti-parallel β-sheet buried in the interior of the protein. The absence of these signals is 
likely explained by the difficulty of deuterium – proton exchange in the hydrophobic core of the 
protein. Another cluster of missing resonances belongs to residues Lys217 – Ser227 from the 
non-structured and likely flexible N-terminus. Overall, the stability and behavior of the USP7 
catalytic domain in solution indicate that this domain is well suited for NMR spectroscopy. 
81 
 
Furthermore, the nearly complete backbone assignment provides confidence that NMR 
spectroscopy is a powerful tool for probing USP7 – substrate/ligand interactions. 
3.4.2. Interaction of the USP7 catalytic core with ubiquitin 
USP7 is postulated to recognize the ubiquitin moiety conjugated to its substrates via a direct 
interaction between the catalytic domain of the enzyme and ubiquitin. According to previous 
structural studies, this interaction causes a dramatic structural rearrangement of the USP7 active 
site, resulting in activation of the enzyme (72). However, despite the report of a structure for the 
USP7 catalytic core covalently modified with ubiquitin aldehyde, an interaction with free 
ubiquitin could not be confirmed using SPR experiments, suggesting that the interaction is very 
weak (71). Compared to other biophysical approaches, NMR spectroscopy  has the advantage of 
being sensitive to weak and transient interactions (168). Consequently, we used this method to 
detect USP7/ubiquitin binding in solution and follow the anticipated structural changes. Our 
chemical shift perturbation experiments showed that the direct interaction between USP7 
catalytic domain and ubiquitin occurs on a fast-to-intermediate exchange timescale, resulting in 
gradual changes in the NMR spectra of the 
2
H/
15
N/
13
C-labeled catalytic core upon titration with 
unlabeled ubiquitin (Figure 3.2B). These gradual chemical shift changes in the 
1
H-
15
N TROSY-
HSQC spectrum simplified the assignment of resonances of the catalytic domain complexed with 
ubiquitin and allowed quantification of binding affinity and mapping of the binding site. Overall, 
addition of ubiquitin caused prominent peak perturbations for a number of USP7 residues with 
peaks for Tyr331, Lys378, Arg343, Asp346, Glu371, Gln372, Ala381, Gln387 and Val 393 
exhibiting shifts over 100 Hz (Figure 3.2C). The NMR titration curve fit a two-state binding 
model (Figure 3.2E), confirming that the USP7 catalytic domain can bind to ubiquitin with low 
affinity (KD of 105.7 ± 15.9 μM). NMR chemical shift mapping revealed that the residues most 
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sensitive to ubiquitin binding are located in β-strands β1, β2, β4, β5, β6 and β7 that form the 
ubiquitin-binding Fingers of the USP7 catalytic domain (Figure 3.2D), consistent with the crystal 
structure of the domain complexed with ubiquitin aldehyde (PDB ID: 1NBF) (72). Surprisingly, 
the active site of the enzyme was not perturbed by ubiquitin, suggesting that ubiquitin binding 
alone does not cause the active site rearrangement necessary for catalysis (Figure 3.2C). 
3.4.3. Mapping of the small-molecule binding site 
The USP7/USP47 inhibitors P22077 and P50429 are analogs of P5091, a lead compound that 
showed antitumor potential in cancer cell lines and mice xenograft models (93,94). Both 
inhibitors are trisubstituted thiophenes with 5-(2,4-difluorophenyl)thio, 4-nitro, and 2-acetyl 
substituents in P22077 and 5-(3,5-dichloropyridyl)thio, 4-cyano and 2-(4-
(methylsulfonyl)phenyl)-NH substituents in P50429 (insets in Figures 3.3A and B, respectively). 
P50429 exhibits ten-fold more potent inhibition of USP7 compared to P22077 (IC50 = 0.42 μM 
versus 8.0 μM) (93). In order to understand the reason for the increased potency of P50429 and 
to develop compounds with even greater potency and target specificity, one must know how 
these compounds bind to USP7. We, therefore, set out to structurally characterize the binding of 
P22077 and P50429 to the enzyme’s catalytic core by performing NMR titrations in which 
increasing amounts of each compound were gradually added to the 
2
H/
15
N/
12
C-labeled catalytic 
domain up to a final protein-to-inhibitor molar ratio of 1:5. Upon addition of P22077, residues 
Gly215, Leu229, Glu248, Gly284, Thr287, Leu304, Asp305, Asp349 and Gly458 exhibited the 
most significant chemical shift changes (Figure 3.3A). Compound P50429 caused large chemical 
shift changes for residues Thr280, Leu304, Met407, Phe409, Met410, Gly458, Gly462 and 
Asp483 (Figure 3.3B). Notably, the intensity of a few peaks significantly decreased (>60%) upon 
addition of either of the compounds indicating that the corresponding amino acid residues are 
83 
 
also sensitive to inhibitor binding. These residues included Lys281, Ser282, Phe283, Trp285, 
Asn306, Asn460, Gly462, Gly463 and Tyr465 sensitive to P22077 and Lys281, Ser282, Phe283, 
Gly284, Trp285, Asn306, Asn460, His464 and Tyr465 sensitive to P50429. Although these 
residues could not be unambiguously assigned in the bound state, they are shown on histograms 
in Figure 3.3 as having negative chemical shift values of -10 Hz to emphasize their role in 
binding. Overall, addition of either compound caused chemical shift perturbations and decreases 
in intensity only for a few peaks in the spectra (18 and 17 peaks for P22077 and P50429 
respectively) indicating a small binding footprint on the surface of USP7 and suggesting that no 
major global conformational changes occur upon binding. Moreover, a very similar set of 
residues was affected by addition of both compounds with the exception of residues Met407, 
Phe409 and Met410 that lie within a loop connecting β8- and β9-strands and are sensitive to 
P50429 only. 
Chemical shift perturbations of more than 40 Hz for P22077 and more than 30 Hz for P50429 
were considered significant and were mapped onto the structure of USP7 catalytic domain (PDB 
ID: 1NBF). Chemical shift mapping revealed that residues sensitive to addition of either of the 
two DUB inhibitors cluster in two small regions on the surface of the protein (Figures 3.3C and 
D). The first set of residues affected by binding surrounds the catalytic cleft (Figure 3.3E). These 
include Gly458, Asn460, Gly462, Gly463 and Tyr465 located in β10- and β11-strands as well as 
the loop connecting them, and Asp349 from the loop between strands β2 and β3. Additionally, 
this region contains two residues from the flexible N-terminus, Gly215 and Leu216, as well as 
Leu229 from the first helix α1, indicating that the mostly unassigned N-terminus is also sensitive 
to inhibitor binding (Figure 3.3E). Importantly, the catalytic cleft is mostly formed by 
hydrophobic residues with the catalytic Cys223 situated at its bottom. Consistent with this 
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finding, both compounds are hydrophobic in nature. Furthermore, the pocket is large enough 
(~1075 Å3) to easily accommodate either of these small molecules. The second region consists of 
residues 281 – 285 and Thr287 located in the loop connecting helices α4- and α5 (referred to as a 
“switching loop”) and residues 304 – 306 located in helix α5, which is involved in active site 
rearrangement into the catalytically productive conformation (72). Although this region is 
sensitive to the presence of the inhibitors, only the catalytic cleft is involved in a direct 
interaction, as was confirmed by MS (see below). 
To elucidate the position of the inhibitors in the active site of USP7, we utilized an induced 
fit docking approach (ICM-Pro) that allows flexibility of side-chains of residues located in the 
binding site. The resulting structural models of the complexes of the catalytic core with P22077 
and P50429 are shown in Figures 3.3F and G, respectively. Overall, the compounds are similarly 
positioned in both models. The 2,4-difluorobiphenyl group in P22077 (3,5-dichloropyridyl group 
in P50429) inserts deeply into a cavity formed by residues Asn218, Gly220, Ala221, Thr222, 
Cys223, Asn226, His464, Tyr465 and Asp482. Thiophene is perpendicular to the aromatic rings 
and turned such that the sulfur is located in the bottom of the pocket and the electron-
withdrawing groups, -nitro in P22077 and -cyano in P50429, are exposed to solvent. The second 
aromatic, methylsulfonyl phenyl group in P50429 further penetrates the catalytic cleft and 
interacts with residues from the loop connecting strands β8 and β9. This is consistent with the 
data obtained from the NMR titration experiments in which chemical shift perturbations for 
residues Met407, Phe409 and Met410 located in the loop connecting β8- and β9-strands were 
observed only upon binding to P50429. These additional contacts might contribute to tighter 
binding of P50429 compared to P22077, suggesting new strategies for improvement of potency. 
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3.4.4. Mechanism of USP7 inhibition by DUB inhibitors P22077 and P50429 
The presence of a doubly deactivated, highly electron-deficient thiophene ring in both of the 
USP7 inhibitors used in this study suggested that the molecules might react directly with 
nucleophilic residues, such as cysteine, thus leading to covalently modified adducts. The USP7 
catalytic domain has seven cysteine residues that could potentially be modified. Addition of an 
excess of DTT to the catalytic core incubated with either P22077 or P50429 compounds did not 
cause any changes in the NMR spectra (data not shown) excluding the possibility of disulfide 
bond formation between a cysteine thiol group in the protein and the thioether linker in the 
small-molecule inhibitors. To investigate whether these compounds bind USP7 reversibly or 
covalently modify the protein we performed intact protein MS analysis of the free and inhibitor-
treated catalytic domain (Figure 3.4A). The deconvoluted spectrum of the free catalytic domain 
showed a major peak with an average mass of 41062.25 Da (calculated mass is 41088.4 Da). The 
intact masses of both complexes with the inhibitors were greater relative to the free protein. 
These results indicate that both compounds covalently modify USP7, since the measurements 
were taken in 50% methanol, where the protein would be expected to be largely denatured. 
Moreover, mass shifts of 169 Da and 146 Da for P22077 and P50429, respectively, were smaller 
than the corresponding molecular weights of the compounds (315.322 Da for P22077, 484.411 
Da for P50429), suggesting that significant parts of the small molecules are lost during final 
modification of the enzyme. 
To investigate whether these compounds covalently modify the catalytic and/or other 
cysteine residues within USP7 we performed LC-MS/MS experiments on tryptically digested 
samples. The fragment ions in the MS/MS scans were compared to theoretical fragments via a 
database search to identify peptides. A variable modification of cysteine was configured for each 
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inhibitor based on the added net mass determined by the intact mass study. Over 90% of the 
protein sequence coverage was achieved for the free and inhibitor-treated protein samples, 
including all seven cysteine residues. Virtually all identified tryptic peptides 218-
NQGATCYMNSLLQTLFFTNQLR-239 from samples treated with either P22077 or P50429 
exhibited a mass shift of 169 Da and 146 Da, respectively, compared to the same peptide from 
the unmodified protein. Importantly, the residue harboring the modification was almost 
exclusively assigned to catalytic Cys223 (Figures 3.4B and C). The data for P50429 was 
remarkably clear cut, with every peptide encompassing Cys223 identified as containing the 
inhibitor-based modification, while peptides containing other cysteine residues were rarely 
identified as modified. The putative 169 Da adduct for P22077 was more promiscuous, with 
Cys223 modified in all but one instance and other cysteines occasionally modified as well. 
Altogether, the MS results in combination with NMR-based mapping of the binding site 
strongly suggest that both of the compounds occupy the active site of USP7 catalytic domain and 
further selectively covalently modify the catalytic Cys223 residue, irreversibly blocking its 
enzymatic activity. Figure 3.5 shows the proposed mechanisms of USP7 active site modification. 
The observed mass shift of 169 Da for P22077-modified protein is consistent with an average 
molecular weight of 1-(4-nitro-thiophen-2-yl)-ethanone group (3 in Figure 3.5). The mass shift 
of 146 Da in the case of P50429 corresponds to an average molecular weight of 3,5-
dichloropyridyl group of the molecule (7 in Figure 3.5). Element composition of the proposed 
modifications was supported by analysis of MS/MS isotope patterns. Therefore, despite the 
overall scaffold structural similarity of the compounds (93), each compound modified the USP7 
catalytic core in a specific manner. P22077 (1) transfers the central thiophene onto the catalytic 
cysteine though a postulated mechanism involving initial nucleophilic attack on the thiophene to 
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give an intermediate thio-orthoester (2) which collapses though expulsion of difluorothiophenol 
(4) to form the re-aromatized adduct (3). Although P50429 (5) is also poised for a similar 
substitution reaction, the reaction follows a different course as a result of the substitution of the 
phenyl ring in (1) for the pyridyl ring in (5), which renders the ring prone to nucleophilic attack. 
A similar addition/elimination process occurs through the intermediacy of (6) to transfer the 
pyridyl ring to the enzyme as in (7), with the thiophenyl moiety (8) serving as the leaving group. 
3.4.5. Inhibition of endogenous full-length USP7 by DUB inhibitors P2077 and P50429 in 
Jurkat cells 
To determine if irreversible inhibition is also achieved against full-length USP7 in the 
context of live cells, we pre-treated Jurkat cells with either DMSO or graded concentrations of 
the compounds for 4 hours and monitored the activity of immunoprecipitated USP7 using Ub-
EKL reporter assay. As seen in Figure 3.6A, the inhibitors showed dose dependent inhibition of 
USP7 catalytic activity, with strong inhibition at a dose of 10 μM. Notably, total DUB activity 
measured in cell lysates was not significantly affected by these treatments (Figure 3.6B), 
indicating their cellular selectivity, in agreement with previously published results (93,169). 
The cellular effect of USP7 inhibition can be assessed by monitoring levels of its known 
protein targets. We used Western blotting of Jurkat cells to evaluate the effect of P22077 and 
P50429 on the stability of DNA methyltransferase DNMT1 and E3 ligase UHRF1 (39), both 
essential for maintenance of genomic DNA methylation, as well as HDM2. Compared to cells 
treated with DMSO, treatment with either compound resulted in dose-dependent decreases for all 
three substrates (Figure 3.6C). Thus, these compounds not only inhibit the isolated catalytic 
domain in vitro but also effectively inhibit full-length USP7 in cells, as evidenced by the 
destabilization of USP7 substrates. 
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3.5. Discussion 
Dysregulation of the ubiquitin-proteasome system has been reported in multiple human 
pathologies. Thus, targeting the UPS is considered a promising therapeutic strategy to treat 
cancer, cardiovascular, neurodegenerative and immunological disorders. Two FDA approved 
proteasome inhibitors, Bortezamib and Carfilzomib, are currently used for treatment of multiple 
myeloma (170,171). More recently, other components of the UPS, such as E2 conjugating 
enzymes, E3 ligases and DUBs have been exploited as potential targets for drug discovery. 
Inhibition of USP7 is of special interest because of its role in turnover of multiple proteins 
involved in DNA replication and repair, epigenetic regulation of gene transcription, immune 
responses and cell cycle control. Here we report the first structural characterization of the 
molecular mechanism of USP7 inhibition by small-molecule compounds. 
Ubiquitin binding alone is not sufficient for rearrangement of the catalytic core of USP7. By 
assigning NMR resonances of the catalytic domain of USP7, we developed a powerful tool for 
studying this challenging dynamic system in solution. We have shown that even transient and 
short lived interactions of USP7 can now be detected, along with evidence of conformational 
dynamics. Specifically, our NMR studies of the binding between the isolated catalytic domain 
and its only known substrate, ubiquitin, revealed that, contrary to previous reports, this 
interaction alone is not sufficient for active site rearrangement. According to the crystal 
structures, binding of ubiquitin to Fingers causes conformational changes in the catalytic domain 
that result in realigning of the catalytic triad into a competent conformation (72). In contrast, our 
results show that residues involved in such rearrangement are not sensitive to ubiquitin binding 
in solution. Specifically, no significant chemical shift changes were detected for residues located 
in helix α5, which moves by ~3Å during active site reorganization, as well as for the loops 
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connecting helices α4- and α5, and strands β10 and β11. Furthermore, upon ubiquitin binding the 
chemical shifts of residues surrounding the catalytic cleft are not perturbed. This indicates that 
the C-terminal tail of ubiquitin alone does not enter the catalytic cavity of the enzyme in 
solution. The active conformation of the catalytic domain in complex with ubiquitin aldehyde 
captured in the crystal structure (72) is likely induced by the covalent attachment of ubiquitin to 
the catalytic cysteine of USP7, which irreversibly traps the C-terminal tail of ubiquitin inside the 
catalytic cleft. There might be several reasons why free ubiquitin does not rearrange the active 
site of the isolated catalytic domain. Perhaps, presence of other USP7 domains or a ubiquitinated 
substrate, or both are required. Indeed, there is mounting evidence that the C-terminal UBL 
domains of USP7 may play an important role in activation of the enzyme (71,83,84). 
Furthermore, binding of a ubiquitinated substrate rather than isolated ubiquitin might be needed 
for efficient activation of the enzyme. In the absence of a protein substrate, ubiquitin binds to the 
Fingers of the catalytic core of USP7 but does not insert its flexible tail into the catalytic cleft 
and, therefore, does not cause the rearrangement of the active site required for catalytic activity. 
The presence of a substrate may ensure proper positioning of the isopeptide bond between 
ubiquitin and the substrate inside the catalytic cleft. The importance of the ubiquitinated 
substrate for the enzyme’s activation suggests that targeting the USP7 substrate binding sites 
may provide an effective and highly specific approach to inhibiting USP7 in the future. 
USP7 inhibitors selectively target and modify its active site. To investigate the molecular 
mechanism of USP7 inhibition we used NMR spectroscopy to map a binding site for two 
USP7/USP47-specific DUB inhibitors P22077 and P50429 on the structure of its catalytic 
domain. The results of chemical shift perturbation experiments showed that both compounds 
share the binding site located in the USP7 catalytic cleft. Surprisingly, residues from helix α5 
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and the “switching loop” were also affected by addition of the inhibitors. As mentioned above, 
these residues are involved in the active site realignment observed in the crystal structure of the 
USP7 catalytic core in complex with ubiquitin aldehyde. Remarkably, NMR frequency changes 
in this region of the protein were unique for the complexes with the inhibitors and were not 
detected in titrations with ubiquitin. The fact that the inhibitors bind to the cavity that 
accommodates the C-terminus of ubiquitin in the crystal structure together with the observed 
chemical shift changes in helix α5 and the “switching loop” suggest that binding of the 
compounds to USP7 causes a conformational rearrangement of the active site similar to that 
caused by ubiquitin aldehyde (72). These findings additionally highlight the significance of the 
interaction between the ubiquitin flexible tail and the active site for realignment of the latter. The 
inhibitors appear to mimic this interaction, causing conformational changes in the active site. 
The chemical structure of DUB inhibitors P22077 and P50429 suggest that these compounds 
can covalently modify cysteine residues. Our LC-MS/MS and intact mass determination 
experiments have confirmed this suggestion. The catalytic domain of USP7 contains seven 
cysteines, four of them surface exposed and, therefore, have a chance of being modified by 
reactive small-molecule compounds. Strikingly, we have shown that both compounds 
specifically modify only the catalytic Cys223. This result is consistent with NMR experiments 
showing that the compounds cause chemical shift perturbations for residues in the catalytic 
cavity. The molecular scaffold of the compounds allows the specific binding and presence of 
doubly deactivated thiophene, leading to modification of Cys223 situated at the bottom of the 
catalytic cleft. The reaction is possible due to the realignment of the active site upon inhibitor 
binding, which results in deprotonation of the cysteine thiol group by catalytic His464. Structural 
models of the complexes obtained with an induced fit docking algorithm provide strong 
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complimentary evidence of the inhibitors position in the catalytic cleft favorable for nucleophilic 
attack of deprotonated Cys223 on the thiophene ring. Notably, although both compounds are 
chemically similar and possess the basic structure of a trisubstituted thiophene, MS experiments 
revealed that specific substructures of each inhibitor had been transferred to the protein and 
indicated an intriguing divergence in the reactivity profile of the two inhibitors (Figure 3.5). The 
preference for attack on the pyridine in P50429 may relate to either reduced electrophilicity of its 
thiophene relative to the thiophene in P22077 (nitro/acetyl versus cyano/carboxamido) or a more 
optimal trajectory for attack in the bound state. Figures 3.7A and B depict Cys223 modified by 
compounds P22077 and P50429 and surrounding residues. In general, the docked poses of 
thiophene and pyridyl rings are similar. The rings have hydrophobic interactions with 
surrounding residues Tyr224, Met292 and Phe409 and an electrostatic interaction with His456. 
The only hydrogen bond is between the oxygen atom within the acetyl group and the alpha-
hydrogen atom of Gly462 (Figure 3.7A). Notably, as both reactions proceed through a 
nucleophilic aromatic substitution reaction to deliver an S-arylated cysteine, the adducts are 
likely much more stable than those formed from more reversible Michael-type reactions on 
deactivated alkenes and, therefore, are expected to produce a longer duration of inhibition.  
DUB inhibitors P22077 and P50429 selectively inhibit full-length USP7 in cells. MS data 
revealed that P22077 and P50429 form covalent adducts to the active site cysteine in in vitro 
reactions using the isolated catalytic domain of USP7. Full-length USP7 is a large (1102 amino 
acid residues) protein consisting of seven domains proposed to adopt a compact conformation 
during the enzyme activation (71) that may possibly interfere with the inhibitor binding. Our 
experiments in Jurkat cells showed that both compounds inhibit the catalytic activity of 
endogenous full-length USP7. Furthermore, P50429 proved to have more potency against USP7, 
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in agreement with previous studies (93). In particular, at 10 μM, P50429 inhibited USP7 by 
~70% compared to ~55% for P22077. 
Stabilization of p53, along with growth arrest of tumor cells, are well-known effects of USP7 
inhibition (91,92,94). However, it was suggested that p53-independent pathways might also be 
involved in the cytotoxic effects of the USP7 inhibitors (94). UHRF1 and DNMT1, recently 
discovered substrates of USP7, are critical for maintenance of genomic DNA methylation during 
replication (39). Therefore, we explored the effect of P22077 and P50429 on the stability of 
UHRF1, DNMT1, and HDM2 in Jurkat cells. The dose dependent decreases in the levels of all 
three substrates suggests that, their stability is compromised by deubiquitination. While 
degradation of HDM2 leads to stabilization of p53, the degradation of UHRF1 and DNMT1 
might cause methylation defects in newly synthetized DNA. These downstream effects may 
contribute to the overall cytotoxic activity of these compounds. 
Unique catalytic site environment may explain USP7/USP47 inhibitor selectivity. USP7 belongs 
to a superfamily of USP cysteine proteases consisting of 58 proteins with structurally conserved 
catalytic cores, which makes development of USP7-specific inhibitors challenging. Indeed, the 
two compounds tested in this work are the most specific among the currently available USP7 
inhibitors; however, they both can inhibit USP7 and its close homolog USP47 (172). The fact 
that inhibitors P22077 and P50429 bind to the conserved catalytic cleft of USP7 is intriguing and 
raises the question of how this specificity is achieved. In an effort to address this question, we 
performed protein sequence alignment using PROMAL (173), followed by calculation of 
conservation score (ConSurf) (161) for a set of USP enzymes that are selectively inhibited by 
P22077 (USP7 and USP47), as well as enzymes USP2, USP4, USP5, USP8, USP9X, USP15, 
USP20 and USP28, not susceptible to inhibition by P22077 (169). As expected, the majority of 
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the residues in the catalytic cavity are highly conserved with calculated ConSurf scores of 8 and 
9 out of 9 (Figure 3.7C). Interestingly, the alignment also revealed a few residues that are 
conserved between USP7 and USP47 but varied in other USPs. Specifically, Gln219 of USP7 is 
present only in USP47, while other proteins contain a hydrophobic amino acid residue at the 
equivalent position. Acidic amino acid residues equivalent to Asp289 in USP7 are also found in 
USP47 (Glu246) but replaced by residues with a neutral sidechain in USP2, USP4, USP5, USP8, 
USP9X, USP15 and USP28, and by basic arginine in USP20. Additionally, the positively 
charged His294 in USP7 has a ConSurf score of 8 and is conserved in USP47 and USP9X, in 
contrast to glutamine at the equivalent position in all other analyzed USPs. The hydrophobic side 
chain of USP7 Ala221 that is near the catalytic Cys223 is preserved in USP47 (Met175) and 
USP9X (Ala1564) but changed to polar asparagine in others. Finally, Gln405 in USP7 is 
conserved among USP47, USP9X and USP5. Other proteins have histidine at the equivalent 
positions, with the exception of USP28, which has aspartate. Overall, although some of these 
residues are not unique for USP7 and USP47, only these two enzymes contain all five. This 
distinct residue combination creates a network of hydrophobic and electrostatic interactions 
unique to the active sites of USP7 and USP47, which may provide the basis for the observed 
specificity of inhibitors. 
It is also possible that USP7-specific inhibitors preferentially target its unique, misaligned 
active site for initial binding. Indeed, catalytic triads in all existing structures of the USP catalytic 
domains, with the exception of USP7, are found in the catalytically competent conformation 
even in the absence of ubiquitin (76-79). In this light, the structure of the catalytic core of USP47 
also inhibited by P22077 and P50429 is a subject of great interest. 
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Altogether, our results reveal the molecular mechanisms of USP7 inhibition by DUB 
inhibitors P22077 and P50429. We showed that inhibitors specifically bind to the catalytic cleft 
of the enzyme and subsequently modify the catalytic cysteine residue. The modification of the 
cysteine thiol group irreversibly inhibits the enzymatic activity of USP7 by preventing formation 
of anionic sulfur and its following nucleophilic attack on the C-terminal carbonyl carbon of 
ubiquitin. 
Previously, only X-ray crystallography was used to structurally characterize the catalytic 
domains of USP proteins. We have shown that these large enzymes can be successfully studied 
in solution. Such studies may provide a unique insight into dynamic conformational changes and 
transient interactions within the molecule. More importantly, these studies will facilitate 
compound optimization and the discovery of more potent and specific inhibitors of USP7 and 
other pharmacologically important USPs. 
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Figure 3.1. Backbone resonance assignment of USP7 catalytic domain. 2D 
1
H-
15
N TROSY-
HSQC spectrum of the USP7 catalytic domain with sequence specific assignments indicated. A 
central region of the spectrum indicated by a box is expanded in the inset for clarity. 
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Figure 3.2. The isolated USP7 catalytic domain binds ubiquitin. A. Completeness of the 
backbone assignment of the catalytic domain. Circles below the protein sequence represent 
amino acid residues with assigned amide NMR resonances. Secondary structure elements are 
shown and labeled above the protein sequence. B. NMR chemical shift perturbations, in1H-
15
N TROSY-HSQC spectra of the catalytic domain caused by addition of increasing amounts of 
ubiquitin. C. A plot of per-residue NMR chemical shift differences between free and ubiquitin-
bound states of USP7. The Palm, Fingers and Thumb regions of the catalytic domain are 
indicated above the plot. D. Solvent accessible surface of the Fingers region of the catalytic 
domain colored according to NMR chemical shift perturbations from C. The shade of violet 
represents the degree of chemical shift changes in response to ubiquitin binding. Ubiquitin is 
shown in cyan. E. Normalized global chemical shift change corresponding to the fraction of 
bound catalytic domain plotted as a function of catalytic domain to ubiquitin ratio. KD of the 
binding was estimated from least-square fit of cumulative chemical shift change. 
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Figure 3.3. DUB inhibitors P22077 and P502429 occupy the active site of USP7. A and B. 
Per-residue NMR chemical shift perturbations,, caused by addition of inhibitors P22077 (A) 
and P50429 (B) to the USP7 catalytic core. Amino acid residues exhibiting chemical shift 
changes greater than 40 Hz for P22077 and 30 Hz for P50429 are labeled. Residues unassigned 
in the bound state, for which NMR peaks gradually disappear upon binding to P22077 and 
P50429, are shown with a negative value of -10 Hz and colored in red and blue, 
respectively. Chemical structures of the compounds are shown as insets. C. Mapping of chemical 
shift differences from A on the surface of the catalytic domain. The color gradient from grey to 
magenta corresponds to  values observed upon P22077 addition. The residues with negative 
values are shown in red D. Mapping of  from B on the surface of the catalytic domain. 
Chemical shift differences are colored with a gradient from gray to cyan according to the  
value. The residues with negative are shown in blue. E. Close-up view of the USP7 region 
affected by P22077 addition. Residues sensitive to binding are labeled and their side-chains are 
shown as spheres. The color code is the same as in C, ubiquitin is shown in beige. F and G. The 
structural models of the USP7 catalytic core in complex with P22077 (F) and P50429 (G). The 
binding pocket is shown as a surface and colored by electrostatic charge distribution (red is 
negative, blue is positive and green is hydrophobic). The compounds are colored by element: C – 
gray, S – yellow, N – blue, O – red, F – orange, Cl – green. 
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Figure 3.4. Inhibitors P22077 and P50429 covalently modify catalytic Cys223 residue in the 
USP7 active site. A. Centroid mode deconvoluted mass spectra of intact free (top), P22077-
bound (middle) and P50429-bound (bottom) catalytic domain. Average intact masses of the 
significant peaks are shown. The mass difference between unmodified and the inhibitor – 
modified protein is labeled. B. MS/MS spectrum of peptide corresponding to residues 218 – 239 
modified by P22077 (m/z = 1366.6, [M+2H]
2+
). C. MS/MS spectrum of the same peptide 
modified by P50429, (m/z = 903.4, [M+3H]
3+
). The b-ions denote N-terminal fragment ions and 
y-ions represent C-terminal fragment ions. Ions matched to the peptide sequence are shown in 
red. 
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Figure 3.5. Proposed mechanisms of chemical reaction between Cys223 of USP7 and 
inhibitors P22077 (1-4) and P50429 (5-8). See text for details. 
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Figure 3.6. P22077 and P50429 inhibit USP7 activity in cells. A. Jurkat cells were pretreated 
with either DMSO or the compounds at indicated concentrations for 2 hours and cell lysates 
were subjected to USP7 immunoprecipitation followed by western blotting (top panel) and USP7 
activity measurement using the Ub-CHOP2 reporter assay (bottom panel). B. Total DUB activity 
in cell lysates from A measured in a similar manner. C. Endogenous levels of USP7 substrates 
DNMT1, UHRF1, HDM2 monitored in Jurkat cells pretreated with either DMSO or the 
compounds at indicated concentrations for 24 hours. Western blotting with antibodies against 
Actin serves as a loading control. 
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Figure 3.7. Specificity determinants of dual USP7/USP47 inhibitors. A and B. Structural 
models of the USP7 active site with Cys223 covalently modified by P22077 (A) and P50429 (B) 
obtained by covalent docking (ICM-Pro). The surrounding residues are labeled and their side-
chains are shown in green. The small molecules are colored by element as in Figures 2F and G. 
C. Surface representation of the USP7 catalytic domain with residues conserved among USPs 
shown in maroon and residues unique for USP7 and USP47 shown in blue. Conservation scores 
were calculated using ConSurf server (161) and only highly conserved residues (with scores 9 
and 8) are shown. The USP proteins used for the score calculation included USP2, USP4, USP5, 
USP7, USP8, USP9X, USP15, USP20, USP28, and USP47. 
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4.1. Abstract 
Rev1 is a translesion synthesis (TLS) DNA polymerase essential for DNA damage tolerance 
in eukaryotes. In the process of TLS, stalled high-fidelity replicative DNA polymerases are 
temporarily replaced by specialized TLS enzymes that can bypass sites of DNA damage 
(lesions), thus allowing replication to continue or postreplicational gaps to be filled. Despite its 
limited catalytic activity, human Rev1 plays a key role in TLS by serving as a scaffold that 
provides access of Y-family TLS polymerases pol, , and  to their cognate DNA lesions and 
facilitates their subsequent exchange to pol that extends the distorted DNA primer-template. 
Rev1 interaction with the other major human TLS polymerases, pol, ,  and the regulatory 
subunit Rev7 of pol, is mediated by the Rev1 C-terminal domain (Rev1-CT). We used NMR 
spectroscopy to determine the spatial structure of the Rev1-CT domain (residues 1157-1251) and 
its complex with Rev1 interacting region (RIR) from pol (residues 524-539). The domain forms 
a four-helix bundle with a well-structured N-terminal -hairpin docking against helices 1 and 2, 
creating a binding pocket for the two conserved Phe residues of the RIR motif that upon binding 
folds into an -helix. NMR spin-relaxation and NMR relaxation dispersion measurements 
suggest that free Rev1-CT and Rev1-CT/pol-RIR complex exhibit s-ms conformational 
dynamics encompassing the RIR binding site, which might facilitate selection of the molecular 
configuration optimal for binding. These results offer new insights into the control of TLS in 
human cells by providing a structural basis for understanding the recognition of the Rev1-CT by 
Y-family DNA polymerases. 
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4.2. Introduction 
Reactive products of cellular metabolism and external genotoxic agents such as ultraviolet 
(UV) irradiation cause persistent damage to the genomic DNA, which is constantly removed 
through various DNA repair mechanisms (174). Unavoidably, however, some DNA 
modifications (lesions) are present during S-phase, creating blocks for progression of the DNA 
replication machinery since spatially constrained active sites of high-fidelity replicative DNA 
polymerases cannot accommodate most types of DNA damage. To circumvent this problem, 
organisms in all kingdoms of life have evolved DNA damage tolerance pathways employing 
specialized translesion synthesis (TLS) DNA polymerases that can insert nucleotides across 
DNA lesions, thereby allowing replication to proceed while temporarily leaving DNA damage 
unrepaired (35,175-179). Growing evidence suggests that an additional important component of 
TLS DNA polymerase action is to fill postreplicational gaps opposite lesions at the end of the 
cell cycle so that double strand breaks are not generated during the next round of DNA 
replication (180-184). 
The most intensively studied TLS polymerases are the Y-family enzymes Rev1, pol, pol, 
pol and the B-family polymerase pol (a complex of the catalytic Rev3 subunit with Rev7) 
(35,175-179). TLS polymerases lack 3'5' proofreading exonuclease activity, possess more 
accommodating active sites than replicative DNA polymerases, and make a relatively limited 
number of contacts with the template base and incoming nucleotide (185). These features allow 
them to insert nucleotides across from a wide variety of DNA lesions that would stall a 
replicative DNA polymerase. However, the ability to replicate through altered bases comes at an 
expense of fidelity. The nucleotide misincorporation rates of TLS polymerases copying 
undamaged DNA are ca.10
-1
-10
-4
, much higher than the misincorporation rates of 10
-6
-10
-8
 
105 
 
observed for pol and pol, the main replicative DNA polymerases (175,176,186). Consequently, 
the access of these error-prone TLS enzymes to primer termini is carefully regulated. 
Certain TLS polymerases are specialized for the efficient and relatively accurate insertion of 
nucleotides opposite particular lesions (35,178,179), termed cognate lesions. Examples of 
cognate lesions include thymine-thymine cyclobutane pyrimidine dimers (T-T CPDs) for 
pol(187,188) and N2-dG adducts, such as N2-benzo[a]pyrene-dG (BaP-dG) adducts, for 
pol(189,190) Although these TLS polymerases can also replicate over certain non cognate 
lesions as well, they do so in a more error-prone manner. Furthermore, the bypass of many DNA 
lesions, including bulky BaP-dG adducts, cisplatin (cisPt) adducts, and [6-4] photoproducts ([6-
4]PP), is accomplished via the coordinated consecutive action of two different TLS DNA 
polymerases (191-193). An inserter TLS polymerase (e.g. pol,  or ) incorporates a nucleotide 
across the site of DNA damage. This inserter polymerase is then replaced by another TLS 
enzyme that extends from the distorted primer terminus positioned across from the lesion. This 
extender role is frequently carried out by pol, which is recruited to the primer terminus in a 
process mediated by Rev1 (176,194,195). Rev1/pol-dependent TLS is responsible for most of 
the DNA damage-induced mutagenesis in eukaryotic cells and contributes to spontaneous 
mutagenesis as well (194,195). On the other hand, certain DNA lesions such as cyclobutane 
pyrimidine dimers (CPDs) or abasic sites can be effectively bypassed by a single TLS enzyme. 
For example, pol alone can efficiently replicate through T-T CPD, one of the common types of 
UV induced lesions, in an essentially error-free manner (187,188). Xeroderma pigmentosum 
variant (XPV) individuals, who lack pol function are highly UV-sensitive and cancer-prone 
(188). They exhibit increased UV-induced mutagenesis due to more error-prone polymerases 
carrying out TLS in the absence of the more accurate pol (196). 
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Protein-protein interactions play critical roles in controlling the access of TLS polymerases to 
their cognate DNA lesions and facilitating polymerase switching during bypass replication 
(35,177-179). Beyond their catalytic cores, Y-family TLS enzymes possess auxiliary domains 
and motifs that are important for their efficient interactions with one another and with the DNA 
(35,178,179). TLS polymerases possess ubiquitin-binding motif (UBM) or ubiquitin-binding 
zinc finger (UBZ) domains in addition to the proliferating cell nuclear antigen (PCNA) 
interacting motifs (197). These ubiquitin-binding domains play a role in the recruitment of TLS 
DNA polymerases to PCNA processivity clamps that have been mono-ubiquitinated at Lys164 in 
a Rad6/Rad18-dependent fashion in response to DNA damage (198). The PCNA-interacting 
protein (PIP) box motifs of pol, , and  additionally contribute to the interaction with mono-
ubiquitinated PCNA, while Rev1, which lacks a consensus PIP-box motif, instead utilizes its N-
terminal BRCT (BRCA1 C-terminus), its polymerase associated (PAD) or UBM domains for 
PCNA binding (199-201). In addition, as discussed in the detail in this paper, the C-terminal 
parts of vertebrate pol, ,  contain Rev1-interacting regions (RIRs), consisting of short peptide 
motifs containing two consecutive phenylalanines that bind to the Rev1 C-terminal domain 
(Rev1-CT) (202). 
The human Y-family Rev1 polymerase is a 1251 amino acid (aa) protein that is notable for 
its role, along with pol, in most DNA damage induced mutagenesis (203-205). The Rev1 
catalytic activity, however, is limited to inserting dCMP opposite a G template or certain types of 
DNA lesions, and thus is insufficient to explain its role in introducing mutations (205-207). 
Subsequent studies revealed that Rev1 possesses a “second function” besides its catalytic ability 
that is important for TLS and mutagenesis (208). This second, and more important, function of 
Rev1 proved to be the recruitment and coordination of other DNA polymerases during the 
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process of TLS via specific protein-protein interactions (35,178,179). Thus, Rev1 serves as a 
scaffold that provides access for the Y-family polymerases , , and to their cognate DNA 
lesions, and can also facilitate the subsequent exchange to pol, which then extends the distorted 
DNA primer terminus opposite the lesion. Remarkably, previous studies of intermolecular 
interactions of Rev1 fragments using yeast two-hybrid assays, co-immunoprecipitation and 
cellular co-localization revealed that Rev1’s interaction with the other three Y-family TLS 
polymerases, pol, , and  and with pol as well is mediated by a relatively small 100 aa Rev1-
CT domain (202,209-211). The human Y-family polymerases ,  and  bind the Rev1-CT with 
RIR peptide motifs that contain two consecutive Phe residues (202). Such motifs are absent in 
the Rev3 and Rev7 subunits of pol also known to interact with the Rev1-CT in vertebrates (209-
212), suggesting that their mode of Rev1-CT binding is different from that of polymerases ,  
and . Previous reports suggest that the loss of S. cerevisiae Rev1-CT has a detrimental effect on 
cell survival and results in a decrease of mutagenesis after DNA damage (213). Although the 
crystal structure of the central polymerase domain of both human and yeast Rev1 have been 
solved, the critically important protein-protein interaction Rev1-CT domain was removed to 
facilitate crystallization (214,215). 
The versatility of Rev1-CT interactions renders characterization of this module critical for 
understanding the underlying mechanisms of TLS. Here we report high-resolution spatial 
structures of the human Rev1-CT domain (residues 1157-1251) and its complex with Rev1 
interacting region (RIR) from pol (residues 524-539) determined by solution NMR 
spectroscopy, as well as a detailed characterization of conformational flexibility of the free 
Rev1-CT domain and the complex on various time-scales using 
15
N NMR spin-relaxation (216) 
and 
15
N NMR relaxation dispersion measurements (217). The functional importance of particular 
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amino acids to this interaction is demonstrated through the use of yeast two-hybrid analysis. 
Taken together, these data provide a rigorous structural basis for understanding Rev1 interactions 
with human Y-family TLS polymerases. 
 
4.3. Experimental Procedures 
Protein sample preparation for NMR spectroscopy. The gene encoding human Rev1-CT 
domain (residues 1158-1251 of Rev1 inserted after the cleavage site for TEV protease - 
ENLYFQG), codon optimized for expression in E. coli, was custom synthesized (GenScript) and 
sub-cloned into pET-28b(+) vector (Novagen) using NdeI - BamHI restriction sites.  
The recombinant human Rev1-CT was over-expressed in E. coli BL21(DE3) cells. 
15
N/
13
C 
labeled protein for NMR spectroscopy was produced by growing cells transformed with Rev1-
CT plasmid in minimal M9 medium using 
15
NH4Cl and 
13
C-glucose as sole nitrogen and carbon 
sources, respectively. Cells were grown at 37 
o
C to OD600 of 0.6-0.8 followed by induction of 
protein expression by 1 mM IPTG overnight at 20 
o
C. After harvesting, the bacterial pellets were 
re-suspended in loading buffer containing 50 mM NaH2PO4, 250 mM NaCl, 10 mM imidazole, 1 
mM PMSF, pH 7.4. After the cells were lysed by sonication, the soluble fraction was loaded onto 
a Ni
2+
 affinity column and incubated for 1 h at 4
o
C. After an extensive wash with the loading 
buffer, the protein was eluted with the buffer of the same composition, but containing 250 mM 
imidazole. The His-tag was removed by TEV cleavage for 4 h at 20
o
C or overnight at 4
o
C in the 
presence of 2 mM DTT and 0.5 mM EDTA, followed by protein purification on a HiLoad 
Superdex 75 column (GE Healthcare). After concentration, the final sample of free Rev1-CT 
domain contained 0.9 mM 
15
N/
13
C labeled protein, 50 mM NaH2PO4, 100 mM NaCl, 0.25 mM 
EDTA, 5 mM DTT, 0.05% NaN3, 10% D2O, pH 7.0. Protein cleavage with TEV protease leaves 
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an N-terminal Gly residue, so that the resulting Rev1-CT domain included residues 1157-1251 of 
human Rev1 with Pro1157 mutated to Gly. The consistency of the protein sample was confirmed 
by MALDI-TOF mass spectroscopy.  
The complex of 
15
N/
13
C labeled Rev1-CT domain with a custom synthesized (GenScript) 16 
aa unlabeled peptide that encompasses one of the two RIR regions of pol (residues 524-539; 
QSTGTEPFFKQKSLLL) (202) was prepared by gradually titrating 25 mM peptide solution into 
0.9 mM protein sample. The binding was monitored by recording 
1
H-
15
N HSQC spectra at each 
step of the titration. The final sample of the complex contained 0.9 mM 
15
N/
13
C Rev1-CT - 
unlabeled pol-RIR mixed in 1:1 molar ratio, 50 mM NaH2PO4, 100 mM NaCl, 0.25 mM 
EDTA, 5 mM DTT, 0.05% NaN3, 10% D2O, pH 7.0. At this protein concentration, about 89% of 
the protein and the peptide are in the bound state, estimated assuming dissociation constant KD = 
13 M for the complex reported in previous studies (202). 
NMR resonance assignment and protein structure calculation. NMR spectra for the free 
15
N/
13
C Rev1-CT domain and its complex with the unlabeled pol-RIR peptide were collected at 
15 
o
C on Agilent VNMRS spectrometers equipped with cold probes operating at 11.7 and 18.8 T 
magnetic fields (500 and 800 MHz 
1
H frequencies). The backbone and side-chain 
15
N, 
13
C and 
1
H resonances of Rev1-CT domain were assigned from 2D 
1
H-
15
N HSQC, 
1
H-
13
C HSQC and 3D 
HNCA, HNCACB, HNCO, HBHA(CO)NH, HC(C)H-TOCSY, (H)CCH-TOCSY, 
15
N-edited 
NOESY-HSQC and 
13
C-edited NOESY-HSQC (150 ms mixing time) spectra (102). Two sets of 
experiments were performed (i) for the free 
15
N/
13
C Rev1-CT domain and (ii) for 
15
N/
13
C Rev1-
CT - unlabeled pol-RIR complex. The assignments of 1H NMR resonances for pol-RIR 
peptide in complex with 
15
N/
13
C Rev1-CT domain were obtained from 2D 
15
N,
13
C-filtered 
TOCSY, COSY and NOESY (250 ms mixing time) spectra (218), containing intra-molecular 
1
H-
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1
H correlations from the unlabeled peptide, collected in both 90% H2O/10% D2O and in 100% 
D2O buffers (COSY spectrum was recorded in D2O buffer only). In addition, we have recorded 
3D 
13
C-edited 
15
N,
13
C-filtered NOESY-HSQC spectrum, containing inter-molecular NOE 
correlations between 
15
N/
13
C Rev1-CT domain and the unlabeled pol-RIR peptide used for 
structure determination of the complex (218). NMR spectra were processed with NMRPipe (140) 
and analyzed with CARA software (219). Nearly complete backbone 95% (94%) and side-chain 
90% (90%) resonance assignments were obtained for the free Rev1-CT domain (the complex). 
Structure calculations for the Rev1-CT domain and Rev1-CT/pol-RIR complex were 
performed in CYANA software (107). The restraints for the backbone dihedral  and  angles 
were derived from the backbone 
1
H, 
15
N and 
13
C chemical shifts using TALOS+ program (106). 
Intra-molecular 
1
H-
1
H distance restraints for the free and bound forms of Rev1-CT were 
obtained from 3D 
15
N- and 
13
C-edited NOESY-HSQC spectra, while inter-molecular distance 
restraints and restraints within the pol-RIR peptide were derived from 3D 13C-edited 15N,13C-
filtered NOESY-HSQC and 2D 
15
N,
13
C-filtered NOESY experiments, respectively. Intra-
molecular NOE correlations for Rev1-CT domain in free and bound states were assigned 
automatically in CYANA, while protein-peptide and inter-peptide NOEs were assigned 
manually. Hydrogen bond restraints were added on the basis of NOE analysis. A total of 200 
structures of the free Rev1-CT domain and the complex were generated, followed by refinement 
of 20 final lowest-energy structures by short constrained molecular dynamic simulations in 
explicit solvent using CNS software (145). Table 4.1 summarizes NMR based restraints used for 
structure calculation of Rev1-CT domain and the complex along with structure refinement 
statistics. 
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NMR characterization of protein dynamics. The backbone 
15
N R1, R2 (CPMG) and 
15
N{
1
H} 
NOE NMR relaxation measurements for the Rev1-CT domain and its complex with pol-RIR 
peptide were performed on a 11.7 T Agilent VNMRS spectrometer at 15 
o
C using the pulse-
sequences of Farrow et al. (117). The delay between 180
o
 refocusing pulses of CPMG sequence 
in 
15
N R2 experiment was set to  = 1 ms, corresponding to CPMG frequency CPMG = 1/(2) of 
500 Hz. 
15
N R1 and R2 rates and their uncertainties were obtained from exponential fits of peak 
intensities in a series of 8 2D 
1
H-
15
N correlation spectra recorded at different relaxation delays. 
15
N R2 rates were numerically corrected to take into account small systematic contributions due 
to off-resonance effects of CPMG refocusing pulses (220). 
15
N{
1
H} NOE values were calculated 
as ratios of peak intensities in corresponding 2D 
1
H-
15
N correlation spectra recorded with and 
without 
1
H saturation using 8 s delay between scans to ensure full recovery of 
15
N longitudinal 
magnetization. To account for possible systematic uncertainties in measured NMR relaxation 
data the minimal errors of 2% for 
15
N R1, R2 rates and 0.05 for 
15
N{
1
H} NOE values were 
assumed. 
Overall rotation diffusion tensors for the free Rev1-CT domain and Rev1-CT/pol-RIR 
complex and overall rotation correlation time R = 1/(2(Dx + Dy + Dz)) (Di, i = x,y,z are 
eigenvalues of rotation diffusion tensor) were calculated from 
15
N R1 and R2 data using the 
program DASHA (221). Specifically, 
15
N R1 and R2 rates were globally fit to the models 
assuming an isotropic, axially symmetric and fully anisotropic rotational diffusion tensor (216). 
Included in these calculations were the residues with (i) non-overlapped cross-peaks in 
1
H-
15
N 
correlation spectra, (ii) 
15
N{
1
H} NOE > 0.6 and (iii) 
15
N R2/R1 ratios within mean  2 standard 
deviations. In both cases the model of axially symmetric anisotropic rotation diffusion was 
selected according to F-test at 10% significance level, resulting in R = 8.96  0.07 ns (10.45  
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0.06 ns) and Dx/Dz = Dy/Dz = 0.91  0.02 (0.84  0.01) for the free Rev1-CT domain (Rev1-
CT/pol-RIR complex). 
Pico- to nanosecond conformational dynamics of the Rev1-CT domain in free and bound 
forms were assessed from the analysis of 
15
N relaxation data using the Lipari-Szabo model-free 
approach (115,216) performed in DASHA software (221). At this stage of the data analysis the 
parameters of molecular overall rotation were fixed to previously determined values, and 
15
N R1, 
R2 and 
15
N{
1
H} NOE data were fit on a per-residue basis using the models of spectral density 
function including the following adjustable parameters: (i) {S
2
}, (ii) {S
2
, e}, (iii) {S
2
, Rex}, (iv) 
{Sf
2
, Ss
2
, s} and (v) {S
2
, e, Rex}, where S
2
, Sf
2
 and Ss
2
 (S2 = Sf
2
Ss
2
) are generalized order 
parameters describing angular amplitudes of internal motions of N-H vectors, e, s are 
correlation times for fast ps and slower ns time-scale internal motions, Rex (below referred to as 
Rex,mf) is the contribution to transverse relaxation rate R2 due to s-ms conformational exchange. 
Model selection was performed based on the values of 2 penalty function, describing goodness 
of relaxation data fit, according to the protocol of Mandel et al. (222) (significance levels of 5% 
and 20%, respectively, were assumed for 2 and F-test). 
The residues in free Rev1-CT domain and its complex with pol-RIR peptide exhibiting 
micro- to millisecond conformational exchange were identified based on Rex,mf values obtained 
in model-free analysis of 
15
N relaxation data (115,216). The CPMG sequence used in the 
15
N R2 
experiment suppresses exchange contribution to R2 provided that 2CPMG >> kex and 2CPMG 
>> , where kex and  are exchange rate constant and frequency difference between the 
exchanging states (223). Therefore, Rex,mf primarily reflect contributions to R2 due to fast s-ms 
conformational exchange with kex ≥ 2CPMG accompanied by changes in NMR chemical shifts. 
To quantify Rex contributions to 
15
N R2 due to slower ms time-scale exchange we have 
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performed 
15
N CPMG relaxation dispersion measurements (217,224), where the effective 
transverse relaxation rates R2,eff were obtained as a function of CPMG. 
15
N relaxation dispersion 
profiles for the free Rev1-CT and Rev1-CT/pol-RIR complex were recorded at 11.7 T (the free 
domain and the complex) and 18.8 T (the complex only) magnetic fields with the pulse-sequence 
of Hansen et al. (225), using a constant relaxation period T = 30 ms and CPMG ranging from 33 
to 1000 Hz. Relaxation dispersion data measured at 11.7 T were least-square fit to a model of 
two-state conformational exchange as described elsewhere (226). The best-fit dependencies of 
R2,eff
clc
(CPMG) were used to estimate exchange contributions Rex,rd = R2,eff
clc
(33Hz)-
R2,eff
clc
(533Hz) to 
15
N R2 that complement model-free derived Rex,mf measured at CPMG of 500 
Hz. 
Yeast two-hybrid analysis. Studies of protein-protein interactions in the yeast two-hybrid 
system were performed in the PJ69-4A strain of yeast (227). DNA fragments encoding the C-
terminal fragment of human Rev1 (amino acids from 1131-1249) and full-length human polη 
(amino acids from 1-713), were subcloned into the pGAD-C1 (GAL4 AD) and the pGBD-C1 
(GAL4 BD) plasmids marked with leucine and tryptophan auxotrophy, respectively. The assay 
was performed by growing strains harboring the two plasmids in 3 ml of  media lacking leucine 
and tryptophan for 2 days at 30°C and spotting 5µL of cells on selective media plates lacking 
leucine and tryptophan (-LW) and on medium also lacking adenine and histidine (-AHLW) to 
score positive interactions. Interactions were scored after 3 days of growth at 30 °C. 
Site-directed mutations for yeast two-hybrid analysis were generated according to the 
protocol of the Quikchange Mutagenesis kit (Stratagene), except that we used an annealing 
temperature of 50 °C and an extension time of 2min/kb. Mutations were verified by sequencing. 
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4.4. Results and Discussion 
4.4.1. The Rev1 C-terminus is a structured domain that binds human Y-family DNA 
polymerases 
Previous studies established that the C-terminal ~100 aa region of DNA polymerase Rev1 
(Rev1-CT) is critical for DNA damage tolerance in eukaryotes (209-211). However, removal of 
a fragment of Rev1 containing this region does not alter the dCMP transferase activity of yeast 
Rev1 in vitro (228), supporting the notion that Rev1 plays a non-catalytic, structural role in 
translesion synthesis (TLS) by coordinating the action of other TLS polymerases through 
protein-protein interactions (35,177-179,229). The binding of the human and mouse Rev1-CT 
domain with each of the other vertebrate Y-family polymerases, pol,  , and with Rev7, the 
regulatory subunit of pol has been demonstrated by multiple experimental techniques, including 
yeast two-hybrid assays, co-immunoprecipitation, and cellular co-localization (202,209-211). 
Although the Rev1-CT domain is highly conserved in eukaryotes, its ability to bind other Y-
family DNA polymerases has only evolved in higher organisms (230), in contrast to the Rev1-
CT/Rev7 interaction, which has been reported in eukaryotes from yeast to humans (35). 
Secondary structure prediction and sequence alignment of Rev1-CT from different species 
suggested that the domain likely consists of four amphipathic helices, which would have the 
potential for forming a four-helix bundle, and identified several conserved motifs that seemed 
likely to be involved in the hydrophobic core of the domain and whose mutation impairs the 
function of yeast REV1 gene in vivo (213). 
Despite the wealth of biochemical and mutational data, the detailed atomic-level picture of 
Rev1-CT interactions with other TLS polymerases has remained obscure due to the lack of a 
high-resolution spatial structure of this domain. In order to determine the solution NMR structure 
115 
 
of the human Rev1-CT domain (residues 1157-1251) we have expressed and purified 
15
N/
13
C 
labeled protein and performed its backbone and side-chain resonance assignment using a 
standard set of triple-resonance NMR experiments (102). Figure 4.1A shows the 
1
H-
15
N HSQC 
spectrum of the free Rev1-CT domain (red) recorded at 11.7 T field at 15 
o
C, revealing a single 
set of well dispersed NMR resonances indicative of a structured protein domain. NMR chemical 
shifts obtained at this stage of the data analysis provide a plentiful source of information on local 
protein structure and conformational dynamics. Thus, secondary structure prediction based on 
the backbone 
1
H, 
15
N and 
13
C chemical shifts using TALOS+ program (106) (Figure 4.1B, red) 
confirmed that the domain consists of four -helices, referred to below as H1 to H4. Order 
parameters S
2
 for the backbone amide groups of the free Rev1-CT (Figure 4.1C, red) that 
describe the main chain conformational flexibility (S
2
 = 1 for fully restricted, 0 for unconstrained 
motions) were empirically predicted from the backbone chemical shifts using Random Coil 
Index (RCI) approach (150,231). High S
2
 observed throughout the protein sequence suggest 
rather limited mobility of the domain on ps-ns to s time-scale (231). In contrast, the free Rev1-
CT domain seems to be dynamic on a time-scale from s to ms. At temperatures above 20-25 oC 
the quality of Rev1-CT spectra deteriorate significantly due to extensive line-broadening 
indicative of s-ms conformational exchange. Decreasing the temperature to 15 oC improves 
spectra quality, although the resonances from loops between helices H1-H2 and H3-H4 still 
remain broadened, some beyond the level of detection.  
The Rev1-CT domain has been previously shown to form medium to weak affinity 
complexes with short peptide motifs (Rev1 interacting regions, RIRs) from human Y-family 
DNA polymerases ,  and  containing two consecutive Phe residues (Figure 4.1D) with 
dissociation constants (KD) ranging from 8 to 69 M (202). One RIR motif was identified in 
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each of human pol and pol, while two motifs were found in human pol (Figure 4.1D). In 
order to elucidate the structural basis for Rev1-CT interactions with human Y-family DNA 
polymerases, we have performed NMR studies of the Rev1-CT complex with a 16 amino acid 
peptide containing one of the two RIR motifs of human pol (residues 524-539, line 1 in Figure 
4.1D). Figure 4.1A shows 
1
H-
15
N HSQC spectrum of the Rev1-CT/pol-RIR complex (blue) 
superimposed on the spectrum of the free domain (red). The backbone and side-chain NMR 
resonance assignments for 
15
N/
13
C labeled Rev1-CT in complex with the unlabeled pol peptide 
were obtained as described above for the free domain, while 
1
H resonances of the peptide were 
assigned from a set of filtered 2D 
1
H-
1
H experiments. The analysis of the backbone 
1
H, 
15
N and 
13
C chemical shifts of Rev1-CT domain bound to pol-RIR peptide suggests that neither 
secondary structure (Figure 4.1B, blue) nor backbone amide order parameters S
2
 that report on 
main chain dynamics (Figure 4.1C, blue) change significantly upon the complex formation. On 
the other hand, NMR resonances from H1-H2 and H3-H4 loops exhibit somewhat less 
broadening due to s-ms conformational exchange. Chemical shift changes upon complex 
formation are observed in the region of the Rev1-CT domain comprising helices H1 and H2, as 
well as in the N-terminal part preceding helix H1, suggesting that this part of the domain is 
involved in Y-family polymerase binding. 
Titrations of Rev1-CT domain with increasing amounts of pol-RIR peptide monitored by 
1
H-
15
N HSQC spectra suggest that the binding process is slow on the NMR time-scale. Namely, 
peaks corresponding to free Rev1-CT decrease in intensity and ultimately disappear, while peaks 
of the bound form show up in new places in spectra and increase in intensity with increasing 
peptide concentration (as illustrated in the inset to Figure 4.1A for Leu1171). In the case of two-
state chemical exchange between equally populated states, two peaks are observed in the NMR 
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spectrum of a nucleus if the forward and reverse rates k for the process are slower than /23/2 
(coalescence point), where  is frequency difference between the exchanging states (232). 
Separate peaks as close as 0.03 ppm (
1
H) corresponding to free and bound Rev1-CT are observed 
in 11.7 T 
1
H-
15
N HSQC spectra recorded at about 1:0.5 protein/peptide ratio, suggesting that 
association kon[L] ([L] is concentration of free peptide) and dissociation koff rates for Rev1-
CT/pol-RIR interaction are slower than ~33 s-1. Assuming the previously reported KD = 13 M 
(202) and total protein and peptide concentrations [P0] = 0.9 mM and [L0] = 0.45 mM, 
respectively, one can estimate the upper limit for kon of Rev1-CT/pol-RIR association as 
2.7∙106 M-1s-1, which is of the same order of ~106 M-1s-1 expected for diffusion controlled protein 
association (233). This observation suggests that the Rev1-CT/pol-RIR association is likely 
somewhat slower than diffusion controlled, potentially pointing to a barrier crossing event due to 
rearrangements of interaction partners. 
4.4.2. Structure of the free Rev1-CT domain 
Figure 4.2 shows the spatial structure of the human Rev1-CT domain (residues 1157-1251) 
as determined by solution NMR spectroscopy. The ensemble of 20 least-energy structures of the 
domain (Figure 4.2A) is in excellent agreement with the input experimental data, displaying 
mean pairwise RMSD for the backbone atoms of regular secondary structure elements of 0.53 Å, 
and exhibiting minimal violations of distance/torsion angle restraints and deviations from 
idealized molecular geometry (Table 4.1). As expected, the domain adopts a four-helix bundle 
fold with helices H1, H2, H3 and H4 spanning the residues 1165-1178, 1184-1199, 1203-1219 
and 1224-1243, respectively (Figure 4.2B). The N-terminal 8 residues (1157-1164) of the 
domain preceding -helix H1 form a rigid type I' -hairpin stabilized by two hydrogen bonds 
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between Leu1159 and Ala1162 (NH1159-CO1162, CO1159-NH1162). The -hairpin tightly packs 
against helices H1 and H2, resulting in multiple long-range NOE contacts between Leu1159 - 
Val1163 and Asn1166, Asp1167, Val1168, Leu1172 in -helix H1, and between Leu1159 and 
Gln1189 in -helix H2. Two hydrophobic residues in the -turn, Ala1160 and Gly1161, together 
with hydrophobic side chains of Leu1171, Trp1175 from helix H1 and negatively charged 
Asp1186 from helix H2 form a pocket on the surface of the domain (Figure 4.2C, left plot) 
capable of accommodating the FF residues of RIR motifs of Y-type DNA polymerases (see 
below). It is notable that this region comprised of residues from the N-terminal -hairpin and 
helices H1 and H2, exhibits the largest NMR chemical shift change upon pol-RIR peptide 
binding. Figure 4.2C shows electrostatic charge distribution color mapped onto the surface of 
Rev1-CT domain. In addition to hydrophobic/negatively charged pocket described above located 
between helices H1 and H2 there is a large positively charged patch on the opposite side of the 
molecule formed by side-chains of Lys1169 and Arg1173 from helix H1 and Lys1211, Lys1214 
and Arg1215 from helix H3. 
Side-chains of residues with solvent exposure less than 5% and an accessible surface area 
less than 10 Å
2
 that form the core of the Rev1-CT domain are shown in Figure 4.2B and are 
listed in the figure caption. Beyond side-chains buried in the hydrophobic core of the four-helix 
bundle, several residues form the interface between the N-terminal -hairpin and -helices H1 
and H2. Recently, extensive sequence alignment of Rev1-CT domains from multiple eukaryotic 
species identified five conserved 5-6 residue regions within Rev1 C-terminus, referred to as 
rev1-108 to rev-112 (213). Alanine-patch mutations of four of these regions (rev1-108 - rev1-
111) in yeast Rev1-CT completely abrogate the function of the REV1 gene in cell survival after 
DNA damage induced by UV or methanesulfonate (MMS) exposure (213). It is interesting to 
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note that each of the rev1-108, rev1-110 and rev1-111 regions in the human Rev1-CT contain 2 
to 4 residues from the core of the domain (see caption to Figure 4.2). Simultaneous mutations of 
multiple core residues, therefore may cause significant destabilization of the domain. Provided 
that the core of Rev1-CT is conserved among eukaryotic species, this observation explains why 
mutations of rev1-108, rev1-110 and rev1-111 in yeast are equivalent to loss of the whole 
domain, and, once again, underlines the importance of the Rev1-CT domain for DNA damage 
tolerance in eukaryotes. 
4.4.3. Structure of the Rev1-CT/pol-RIR complex 
The finding that vertebrate Rev1-CT directly interacts with the three Y-family DNA 
polymerases, pol,  and  sparked a search for Rev1 binding sequences (RIR motifs) in 
eukaryotic Y-family DNA polymerases (202,209-211). This search proved non-trivial. As shown 
in Figure 4.1D, there is limited sequence homology among the four RIR regions found in human 
Y-family polymerases. Based on mutational analysis and truncations of RIR containing peptides 
Ohashi et al. (202) described the minimal RIR region as yyyFFxxxx (underlined in Figure 4.1D), 
where F is a phenylalanine residue, y is any amino-acid, and x is any amino acid but a proline. 
The two consecutive Phe residues are conserved among RIR regions, and substitution of any of 
them to Ala results in complete abrogation of RIR - Rev1-CT binding. In 3 of 4 RIRs found in 
human Y-family enzymes (Figure 4.1D) the FF sequence is preceded by Ser whose mutation in 
pol decreases, but does not abolish Rev1-CT interaction (202). Intriguingly, while there is no 
obvious sequence conservation in the region C-terminal to the FF motif, studies of the truncated 
RIR peptides suggest that at least four residues must follow the FF sequence in order to 
efficiently bind Rev1-CT. Mutation of any of the four residues to Ala has no effect on Rev1 
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interaction, yet substitution of any of them to Pro results in a complete loss of Rev1 interaction, 
suggesting that main chain conformation of RIR peptides is important for binding rather than 
specific side-chain contacts (beyond those formed by FF residues) (202).  
To ascertain the mechanism of Rev1 recognition of Y-family DNA polymerases, we have 
determined the solution NMR structure of the Rev1-CT domain complex with an RIR containing 
peptide from human pol (residues 524-539) shown in Figure 4.3. The ensemble of 20 least-
energy structures (Figure 4.3A) agrees well with the input experimental restraints (Table 4.1), 
exhibiting mean pairwise RMSD for the backbone atoms of regular secondary structure elements 
of 0.62 Å (Rev1-CT)/0.27 Å (pol peptide). Structure comparison of the free and bound forms of 
Rev1-CT domain (Figure 4.3B) reveals no noticeable structural changes in the domain upon 
pol-RIR binding. Interestingly, in the complex with Rev1-CT, the pol-RIR peptide forms an 
-helix starting at Phe531 and continuing all the way to the C-terminal Leu539. The two 
phenylalanine residues, Phe531 and Phe532, are located in the first turn of the helix facing Rev1-
CT domain surface. As anticipated from the mutational analysis of Rev1-CT/pol-RIR 
interaction, the majority of contacts between Rev1-CT and pol-RIR peptide involve the two 
Phe residues, displaying extensive inter-molecular NOE connectivities in 
13
C-edited 
15
N,
13
C-
filtered NOESY-HSQC spectrum (218) (Figure 4.4). Both aromatic side-chains become buried 
upon Rev1-CT binding. The ring of Phe532 deeply penetrates into the binding pocket on Rev1-
CT surface formed by residues Ala1160, Gly1161 from the N-terminal -turn, Leu1171, 
Trp1175 from helix H1, and Asp1186, Gln1189 from helix H2, while the ring of Phe531 packs 
against Thr1178 and Ile1179 on the domain surface (Figures 4.3C and D). Notably, the pocket is 
already preformed in the free form of Rev1-CT domain (Figure 4.2C). As a result, Phe531 and 
Phe532 contribute 110 and 180 Å
2
, respectively, to the ~600 Å
2
 interaction surface between 
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Rev1-CT domain and pol-RIR peptide. The pol-RIR -helix is tilted towards helices H1 and 
H2 of Rev1-CT (Figures 4.3A and B), with the backbone amides of Phe531, Phe532 and Lys533 
in the first turn of the -helix facing the negatively charged surface of the Rev1-CT domain 
(Figure 4.2C). The key residue in Rev1-CT that interacts with the above amide groups of pol-
RIR peptide is a highly conserved Asp1186 from the helix H2, which is surface exposed in the 
free domain, but becomes completely buried upon complex formation. Strikingly, as also 
discussed more fully below, mutation of Asp1186 to alanine completely eliminates the binding 
of the full-length pol to the Rev1-CT in the yeast two-hybrid system (Figure 4.5). The carboxyl 
of the Asp1186 side-chain participates in charge-dipole interactions with the backbone amides of 
Phe531 (whose 
1
H
N
 resonance is shifted to 11.1 ppm) and Phe532 of pol-RIR peptide, and is 
also proximal to the side-chain N

H group of Trp1175 and the backbone amide of Met1183 from 
the H1-H2 loop of Rev1-CT domain (Figure 4.3D). It is not an unusual feature for a buried 
ionizable side-chain in a protein to be involved in interactions with the backbone / side-chain 
dipole or oppositely charged side-chain group (234). Residues Lys531, Ser532 and Leu539 from 
the two turns of the pol-RIR -helix following the FF sequence interact with Ala1160 and 
Gly1161 from the N-terminal -hairpin of Rev1-CT, while Thr528 and Glu529 preceding the FF 
pair pack against the side-chains of Pro1182 and Met1183 in the H1-H2 loop. 
The spatial structure of the Rev1-CT/pol-RIR complex (Figure 4.3) reveals that the two 
consecutive phenylalanine residues, Phe531 and Phe532, of the pol RIR motif are responsible 
for the majority of specific inter-molecular interactions and are crucial for the complex 
formation. Accordingly, mutation of these critical Phe531 and Phe532 residues to glycine within 
the pol RIR nearly completely eliminates interaction with the Rev1-CT via the yeast two-
hybrid system described below (Figure 4.5A). We also observe a relatively weaker binding when 
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the Phe483 and Phe484 residues within the first RIR of pol were mutated to glycine, consistent 
with an earlier report that all four phenylalanine residues within the two pol RIRs contribute to 
Rev1-binding (202). 
Another important interaction involves the backbone amide groups of Phe531 and Phe532 
from the N-terminal face of the pol-RIR -helix and negatively charged Asp1186 of Rev1-CT 
completely buried on the binding interface. The fact that the pol-RIR peptide adopts an -
helical conformation provides a rationale for the previously published mutational data (202). It is 
clear that the helix is needed to maintain proper orientation of the two aromatic rings of the FF 
sequence that fit into the binding pocket on the Rev1-CT surface, as well as to position the 
backbone amides of the first -helix turn towards the side-chain of Asp1186 in Rev1-CT. 
Mutational data suggest that at least four residues following the FF sequence are necessary to 
maintain the -helical conformation secured by hydrogen bonds between residues i and i+4. 
Alanine is highly favorable in -helices (235), so that substitution of residues C-terminal to the 
FF sequence with Ala maintains -helical conformation of RIR peptide and, therefore, has little 
effect on Rev1-CT binding. In contrast, mutation to a helix-breaking Pro (235) disrupts the -
helix of RIR motif and thereby abolishes Rev1-CT interaction. The -helix of RIR motifs found 
in Y-family DNA polymerases starts with the FF sequence following the N-cap Ser or Pro 
(Figure 4.1D). Pro is often found in N-cap positions of protein -helices (236), while Ser is 
known as one of the most favorable N-cap residues (along with Asn, Asp, Cys and Thr) (237). 
Therefore, it is not surprising that Ser to Ala substitution in the pol-RIR motif results in 
weakening of Rev1-CT binding (202). Although Thr528 and Glu529 preceding the FF sequence 
interact with the side-chain of Met1183 of Rev1-CT (Figure 4.3), these and other residues from 
the N-terminal part of pol-RIR peptide exhibit no well-defined conformation and are likely of 
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little importance for interaction with Rev1-CT. Therefore, based on our analysis of the Rev1-
CT/pol-RIR structure (Figure 4.3) Rev1 binding motif can be re-defined as nFF(4h), where n is 
an N-cap residue, F is phenylalanine and 4h are at least four residues that form an -helix. 
4.4.4. Corroboration of Rev1-CT/Pol-RIR interface by yeast two-hybrid assays 
Having elucidated the structure of the human Rev1 C-terminus in complex with the polη-
RIR, we employed a yeast two-hybrid system to monitor the interaction between the proteins. 
The region encoding the human Rev1-CT and full-length polη was fused to the Activation 
Domain (AD) and the Binding Domain (BD) of the GAL4 transcription factor, respectively. The 
presence of the constructs after transformation into the PJ69-4A strain of yeast was ensured by 
growth on selective media plates lacking leucine and tryptophan (-LW). Interactions between the 
two proteins activate the expression of the HIS3 and ADE2 reporter genes, both driven by 
promoters responsive to the Gal4 transcription factor. These interactions were scored by growth 
on selective media plates additionally lacking adenine and histidine (-AHLW). We determined 
that a longer Rev1-CT construct of ~120 amino acids, rather than the 95 amino acid Rev1-CT 
fragment that was used in structure determination, reproducibly recapitulated the interaction with 
polη. Consistent with earlier data, the interaction between the Rev1-CT and full-length polη 
resulted in robust growth of the strains in –AHLW selective media plates (Figure 4.5A). In 
contrast, no growth was observed in strains expressing the Rev1-CT and the BD alone, showing 
that the interaction is specific between the two proteins.  
Having established a strong interaction between the Rev1-CT and polη we asked if mutations 
of residues within the N-terminal β-hairpin and -helices H1, H2 of Rev1-CT affect the 
interaction with polη. To extend and validate our predictions from the Rev1-CT/polη-RIR 
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complex, we created a series of point mutations within the Rev1-CT and examined its interaction 
with polη via the yeast two-hybrid assay. As shown in Figure 4.5B, the Rev1-CT mutations 
L1159A, L1171A, L1172A, W1175A and D1186A completely abrogate the interaction, whereas 
the mutations E1174A, T1178A and M1183A severely diminish binding to polη. The mutant 
proteins containing A1160G, I1179A and Q1189A substitutions, however, show an interaction 
similar to wild-type Rev1-CT. Among the set of residues in Rev1-CT that show complete loss of 
binding, Leu1159 lies on the interface between the N-terminal β-hairpin and helices H1 and H2 
that create a binding pocket for the Phe531 and Phe532 residues of the pol-RIR, and likely is 
important for stabilization of the β-hairpin. The key residue Leu1171 interacts with Phe532 and 
is exposed in the free Rev1-CT but becomes buried upon binding the polη-RIR. Its mutation to 
alanine, therefore, completely eliminates the interaction with the polη-RIR. Leu1172, however, 
forms part of the hydrophobic core of the Rev1-CT so a change to alanine, while rendering it 
incompetent to bind polη, is likely due to a destabilization of the Rev1-CT itself. Similarly 
Trp1175, one of the key residues on the binding interface between the Rev1-CT and polη 
interacts with Phe532, but is partially buried in the free domain and, therefore, participates in 
stabilization of the hydrophobic core. Like L1172A, the W1175A mutation likely significantly 
destabilizes the Rev1-CT domain. Strikingly, Asp1186, a crucial residue for the Rev1-CT - pol-
RIR interaction is almost completely buried on the binding interface. It interacts with the 
backbone amide groups of Phe531 and Phe532 from the first turn of pol-RIR -helix and, 
consequently, mutation of this negatively charged amino acid to alanine abrogates interaction 
with the polη-RIR, as evidenced by a complete lack of growth of yeast strains harboring these 
plasmids on selective media plates lacking AHLW (Figure 4.5B). 
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The weaker polη-RIR interacting residues Glu1174 and Thr1178 in the Rev1-CT are located 
in the -helix H1 at the periphery of pol-RIR binding interface, while Met1183 is located in the 
loop between helices H1 and H2 and interacts with N-terminal residues of the pol-RIR 
preceding the conserved Phe531 and Phe532. Their mutation to alanine results in a significantly 
reduced growth of yeast strains carrying the plasmids on –AHLW plates. Surprisingly, mutation 
of Ala1160, which makes contacts with the two turns of the pol-RIR -helix following the FF 
motif, and Ile1179, Gln1189 located on the periphery of the interface and interacting directly 
with Phe531 and Phe532, had no effect on binding to the Rev1-CT in the yeast two-hybrid assay 
(Figure 4.5B). Taken together, these results show that residues Leu1171, Glu1174, Thr1178, 
Met1183 and Asp1186 of Rev1-CT make contacts with pol that contribute to stabilization of 
the complex between the two proteins. 
4.4.5. Conformational dynamics of Rev1-CT domain and Rev1-CT/pol-RIR complex 
Protein conformational flexibility plays an important role in molecular recognition, often 
conferring upon protein domains the ability to bind multiple targets (238,239). Pre-sampling of 
multiple interconverting conformers enables rapid selection of molecular configuration optimal 
for binding. On the other hand, loss of conformational mobility and/or ordering upon binding 
imposes an entropic penalty that weakens molecular interaction, thereby modulating specificity 
of recognition by allowing more selective binding. Not surprisingly, a number of molecular 
complexes have been described involving flexible and/or disordered interaction partner(s) that 
only fold into an ordered structure upon binding (239). The interaction between the Rev1-CT and 
the Y-family DNA polymerases pol, , and  seems to fall into this category. The Rev1 
interacting regions (RIRs) of pol, pol, pol are mapped outside structured domains of the 
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enzymes (35,178,179) and likely adopt -helical conformation only upon binding the Rev1-CT 
domain. Although the Rev1-CT is shown to be well structured, NMR line broadening in the H1-
H2 and H3-H4 loops, as well as in parts of helices H1 and H2 points to ms-s conformational 
rearrangements of RIR interaction interface. Therefore, to elucidate the role of Rev1-CT 
flexibility in Y-family DNA polymerase recognition we have examined ps-ns and ms-s time-
scale conformational dynamics of free and pol-RIR bound forms of the domain using 15N spin-
relaxation (216) and 
15
N CPMG relaxation dispersion (217) measurements. 
Figure 4.6A (top plots) shows 
15
N R1, R2 relaxation rates and 
15
N{
1
H} NOE values for the 
Rev1-CT domain (red) and Rev1-CT/pol-RIR complex (blue) measured at 11.7 T magnetic 
field, 15 
o
C. NMR spin-relaxation data were analyzed using the Lipari-Szabo model-free 
approach (115,216) to extract order parameters S
2
 (Figure 4.6A, bottom plot) and correlation 
times (data not shown), describing angular amplitudes and time-scales of fast ps-ns internal 
motions of the backbone NH vectors, respectively, along with parameters of overall rotational 
diffusion of the molecule. As expected, overall rotation correlation time R for the complex 
(10.45  0.06 ns) exceeds R for the free domain (8.96  0.07 ns) by 17%, closely matching the 
increase of molecular size upon Rev1-CT (95 aa) - pol-RIR (16 aa) complex formation. 
Uniformly high order parameters S
2
 > 0.8 are observed for the backbone amide groups of the 
free Rev1-CT domain and the complex (Figure 4.6A), stemming from fast (fs-ps) restricted 
thermal flexibility of the protein backbone (S
2
 = 1 for fully constrained, 0 for unrestricted 
motions). The exceptions are 5-6 residues in the C-terminal part of the domain and residues from 
the H3-H4 loop, exhibiting a lower S
2
 pointing to increased ps-ns mobility. The experimental S
2
 
values (Figure 4.6A) are in line with those predicted from the backbone chemical shifts using 
RCI approach (150,231) (Figure 4.1C), albeit the later are underestimated in loop regions. 
127 
 
Interestingly, the experimental S
2
 for the backbone amides in the N-terminal -hairpin are about 
as high as in the regular secondary structure elements (Figure 4.6A), confirming that the N-
terminal part adopts a rigid conformation in both free and bound forms of the Rev1-CT domain. 
Overall, 
15
N relaxation data analysis suggests that ps-ns time-scale internal motions of the Rev1-
CT domain are restricted and that ps-ns dynamics of the domain does not change upon pol-RIR 
binding.  
Along with order parameters S
2
 and correlation times of internal motions, model-free 
analysis of 
15
N relaxation data allows extraction of exchange contributions Rex,mf to transverse 
relaxation rates R2 that report on s-ms conformational dynamics accompanied by changes in 
15
N chemical shifts (216). The extracted Rex,mf primarily originate from faster s-ms processes, 
since the CPMG sequence in our 
15
N R2 experiment suppresses contributions to R2 due to ms 
exchange with kex << 2CPMG and  << 2CPMG (where kex is exchange rate constant,  is 
frequency difference between the exchanging states; CPMG frequency CPMG in our 
15
N R2 
experiment was set to 500 Hz) (223). To additionally quantify contributions to 
15
N R2 rates due 
to slower ms time-scale conformational exchange, we have performed 
15
N CPMG relaxation 
dispersion experiments (217,224,225) that measure effective transverse relaxation rates R2,eff as a 
function of CPMG, and quantified Rex,rd = R2,eff
clc
(33Hz) – R2,eff
clc
(533Hz) that complement Rex,mf 
obtained in model-free analysis of 
15
N relaxation data. The sum Rex,mf + Rex,rd provides an 
approximation for total exchange contribution Rex to 
15
N R2 in free-precession limit.  
15
N R2 rates plotted vs. residue number (Figure 4.6A) reveal that residues in (and adjacent to) 
H1-H2 and H3-H4 loops in the free Rev1-CT domain and in the complex exhibit enhanced 
15
N 
R2 caused by significant s-ms exchange contributions Rex,mf that were quantified using model-
free analysis of 
15
N spin-relaxation data (115,216). 
15
N CPMG relaxation dispersion 
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measurements (217,224,225) that were used to identify amide groups involved in slower ms 
time-scale exchange not captured in Rex,mf significantly extend the list of residues in free and 
bound forms of Rev1-CT undergoing s-ms conformational rearrangements. Figure 4.6B shows 
examples of 
15
N CPMG relaxation dispersion profiles for the backbone amide groups of 
Gly1161, Leu1171, Trp1175 and Asp1186 that form the pol binding site of Rev1-CT. In is 
clear that for these residues R2,eff (CPMG) profiles reach a plateau at CPMG~500 Hz where the 
exchange contribution to R2 is effectively suppressed by the CPMG sequence. Figure 4.6C 
shows total exchange contribution Rex = Rex,mf + Rex,rd to 
15
N R2 rates (at 11.7 T magnetic field) 
mapped onto structures of free Rev1-CT domain (top) and the complex (bottom), with residues 
involved in faster s-ms and slower ms dynamics marked, respectively, in cyan and magenta. 
Remarkably, the region exhibiting extensive s-ms conformational exchange in both free and 
bound states of Rev1-CT encompasses the binding site for the pol-RIR motif formed by 
residues from the N-terminal -hairpin, the two last turns of -helix H1, the H1-H2 loop, and 
two first turns of -helix H2. Although s-ms exchange contributions Rex generally decrease 
upon complex formation, the binding interface remains dynamic on s-ms time-scale in Rev1-
CT/pol-RIR complex. Interestingly, Rex contribution to 
15
N R2 increase upon complex 
formation for Gly1161 from the N-terminal -hairpin of Rev1-CT (Figure 4.6B), which directly 
interacts with pol-RIR -helix. 
Beyond intramolecular processes, ms time-scale exchange observed in the Rev1-CT/pol-
RIR complex may be caused by an on-off equilibrium between free and bound forms of the 
protein (240). From the upper limits of kon (2.7x10
6
 M
-1
s
-1
) and koff (33 s
-1
) obtained as described 
above one can derive the upper estimate for the exchange rate constant of the on-off equilibrium 
kex = kon[L] + koff ~ 300 s
-1
 at the condition of our 
15
N CPMG dispersion experiment (0.9 mM 
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total protein, 0.9 mM total peptide concentrations; free ligand concentration [L] ~ 11% of 0.9 
mM at KD = 13 M (202)). Even at a relatively slow kex of 100-300 s
-1
 the exchange between 
free and bound forms of Rev1-CT may cause noticeable exchange contributions to transverse 
relaxation rates. To elucidate whether the observed ms time-scale exchange in the complex can 
be solely explained by on-off equilibrium between free and bound forms of Rev1-CT we have 
additionally recorded 
15
N CPMG dispersion profiles at 18.8 T magnetic field, and globally fit 
11.7 and 18.8 T relaxation dispersion data to a model of two-state conformational exchange 
(Figure 4.7A), resulting in a population of the second (minor) state pB = 5.9 ± 0.4% and 
exchange rate constant kex = 585 ± 23 s
-1
. This is about two times faster than the estimated 300 s
-
1
 upper limit of the exchange rate constant for the Rev1-CT/pol-RIR binding equilibrium. 
Interestingly, 
15
N chemical shift differences obtained from CPMG relaxation dispersion data, 
disp, are in good agreement with 
15
N chemical shift differences between free and pol-RIR 
bound forms of Rev1-CT, spec (Figure 4.7B), with the exception of few residues on the 
binding interface (such as Trp1175). In addition, significant contributions Rex,mf to 
15
N transverse 
relaxation rates R2 due to faster s-ms dynamics have been obtained in 'model-free' analysis of 
15
N relaxation data for the binding site residues 1175-1179 (Figures 4.6A and C). Taken 
together, these data suggest that conformational exchange observed on the binding interface of 
the Rev1-CT - pol-RIR complex may include contributions from both on-off equilibrium 
between free and bound forms of Rev1-CT and intra-molecular dynamic process(es).  
The analysis of 
15
N spin-relaxation and 
15
N CPMG relaxation dispersion data established that 
free and pol-RIR bound forms of Rev1-CT domain are rigid on ps-ns time scale, but exhibit 
significant s-ms conformational dynamics encompassing the RIR binding site. Transitions to 
low-populated states occurring on s-ms time-scale observed on the intermolecular interface of 
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the complex may point to the existence of multiple modes of Rev1-CT/pol-RIR binding. Such a 
plasticity of interaction interface in the bound state might prove beneficial for minimizing the 
entropic penalty of the complex formation (239). On the other hand, s-ms sampling of multiple 
conformational states in the free Rev1-CT domain may facilitate selection of a molecular 
configuration(s) that enables efficient binding of RIR motifs (238,239), exhibiting surprisingly 
little sequence conservation among Y-family DNA polymerases (Figure 4.1D). 
 
4.5. Concluding Remarks 
In this study, we have made a significant contribution to our understanding of how Rev1 
regulates TLS in human cells through its interactions with the Y-family TLS polymerases pol, 
, and  by (i) solving the structure of Rev1’s important C-terminal domain, (ii) revealing the 
structural details of how the RIR of pol binds to Rev1’s C-terminal domain, and (iii) showing 
that the RIR binding site of the Rev1 C-terminal domain displays conformational dynamics on 
the s-ms time scale that may facilitate the selection of the molecular configuration optimal for 
binding. We have also been able to redefine the Rev1 binding motif, RIR, as nFF(4h), where n is 
an N-cap residue, F is phenylalanine and 4h are at least four residues that form an -helix. 
The interactions that Rev1 makes with the Y-family DNA polymerases pol, , and  enable 
a later acting form of TLS control that acts subsequent to the Rad6/Rad18-mediated 
monoubiquitination of PCNA that is triggered by a variety of types of DNA damage (184,241). 
The Rev1-CT is not important for the recognition of monoubiquitinated PCNA nor is it 
necessary for recruitment to nuclear foci after DNA damage (229,242). Reciprocally, the RIR 
sequences of pol are not necessary for recruitment to UV-induced nuclear foci, since its C-
terminal 120 amino acids which do not include either of the RIRs are sufficient for its 
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localization (243). Nor are the RIR sequences necessary for damage-induced foci formation by 
pol (202) or pol (244). Thus the interactions that the Y-family TLS DNA polymerases pol, , 
and  make with the Rev1-CT represent another level of regulation beyond that of PCNA 
monoubiquitination that helps to ensure that these inherently error-prone DNA polymerases do 
not introduce mutations by gaining access to primer termini in undamaged DNA. Subsequent 
polymerase exchanges that are mediated through the interactions that each of these TLS 
polymerases make with Rev1’s C-terminal domain could possibly also help with the process of 
matching each polymerase with its cognate lesion over which it can replicate relatively 
accurately. Example of cognate lesions include thymine-thymine cyclobutane pyrimidine dimers 
for pol, N2-BPDE-dG lesions for pol, and dA for pol (35,174). Polymerase exchange 
mediated by the Rev1 C-terminal domain could also help exchange a non functional TLS 
polymerase for an alternative TLS polymerase (245). Evidence has been reported indicating that, 
in higher eukaryotes, a component of TLS can also proceed in the absence of PCNA 
monoubiquitination (246). In these cases, the interactions that Rev1 makes with other TLS DNA 
polymerases might be particularly important in facilitating and regulating TLS (209,211,247). 
The exchanges that Rev1 likely facilitates between pol, , and  are apparently made possible 
by the s-ms conformational dynamics of the region of the Rev1-CT that interacts with their 
RIRs.  
In TLS events requiring the coordinated consecutive action of two DNA polymerases, the 
Rev1 C-terminal domain can also serve to facilitate the exchange from an inserter DNA 
polymerase to the extender DNA polymerase pol via its interaction with the accessory subunit 
Rev7. Recent evidence indicates that human Rev1 recruits pol through an interaction with Rev7 
as it does in yeast (248). Rev7 clearly interacts differently with the Rev1-CT than do pol, , and 
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 since it lacks an RIR and the Rev1-binding interface of Rev7 appears be a portion of the 
surface of a five-stranded -sheet of Rev7 rather than a disordered peptide (249). Although pol 
can accurately replicate UV-irradiated DNA independently of Rev1, pol-Rev1 interactions are 
involved in suppressing spontaneous mutations, probably by promoting accurate TLS past 
endogenous lesions (250).  
Although TLS DNA polymerases can act at the replication fork, there is a growing body of 
evidence in both yeast and mammalian cells that a substantial amount of TLS occurs at 
postreplicational gaps caused by lesions rather than at active replication forks (180-184,251). In 
fact, in yeast TLS occurs efficiently if it is constrained to occur during G2/M by manipulating 
the cell cycle dependence of Rad6/Rad18-dependent monoubiquitination (180,182). Of particular 
interest is the observation that in S. cerevisiae Rev1 is synthesized at extremely low levels during 
G1 and most of S phase, but then is expressed at fifty-fold higher levels during G2/M (251). 
Thus, most of the Rev1-pol interactions that occur in S. cerevisae via interactions of the Rev1 
C-terminal domain with Rev7 are naturally confined to postreplicational gaps during G2/M 
(183,252). Given the growing body of evidence that a significant amount of TLS takes place 
during G2/M in mammalian cells (181), it seems likely that a substantial fraction of the 
interactions between the Rev1 C-terminal domain and other TLS DNA polymerases similarly 
take place at postreplicational gaps.  
Knowledge of the structure of the Rev1-CT should also make it possible to clarify the 
molecular details of the interactions that Rev1 makes during interstrand crosslink repair and may 
make it possible to gain additional insights into the relationship between interstrand crosslink 
repair and Fanconi anemia (253). Since inhibition of TLS can help to improve chemotherapy 
(254,255), it is possible that searching for inhibitors that target specific protein-protein 
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interactions required for TLS might be an alternative to searching for inhibitors that selectively 
inhibit only one TLS DNA polymerase out of the 15 DNA polymerases found in human cells 
(256). 
 
Accession codes 
Atomic coordinates of the Rev1-CT domain and the Rev1-CT/polh-RIR complex were 
deposited to Protein Data Bank (PDB entries 2LSY, 2LSK). The backbone and side chain NMR 
resonance assignments were deposited to BioMagResBank (BMRB entries 18455, 18434). 
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Table 4.1. NMR-based restraints used for structure calculation of Rev1-CT domain and Rev1-
CT/pol-RIR complex, and structure refinement statistics.  
 Free Rev1-CT Rev1-CT/pol complex  
Summary of restraints   
Total NOE distance restraints 1853  1526  
Short range (|i-j|<=1) 1013  856/53a 
Medium range (1<|i-j|<5) 468  315/9a 
Long range (|i-j|>=5) 372  221/0a 
Intermolecular  -  51/21b 
Dihedral angles restrains (φ and ψ) 180 152 / 26a 
Hydrogen bonds  46 40/4a 
Structure refinement statistics   
Deviation from NMR-based restraints    
NOE (Å) 0.02 0.02 
Dihedral restraints (degrees) 1.1 1.3 
Deviation from idealized geometry   
Bonds (Å) 0.02 0.02 
Angles (degrees) 1.1 1.2 
Ramachandran plot favorable  90.1% 90.3% 
RMSD, pairwise (Å)   
All residues  Rev1-CT pol-RIR 
Backbone atoms 0.87±0.16 1.08±0.19 2.58±1.03 
Heavy atoms 1.35±0.14 1.83±0.23 3.40±1.00 
Residues in regular secondary structure 
elementsc  
   
Backbone atoms 0.53±0.11 0.62±0.12 0.27±0.08 
Heavy atoms 1.08±0.10 1.51±0.22 1.38±0.26 
 
 
a - intra-molecular restraints for Rev1-CT / pol peptide  
b - upper/low distance restraints  
c - residues 1165-1178, 1184-1199, 1203-1219, 1224-1243 in Rev1-CT, 532-539 in pol.  
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Figure 4.1. The Rev1-CT forms a structured domain that binds DNA polymerase η. A. 1H-
15
N HSQC spectra of free 
15
N/
13
C Rev1-CT domain (red) and the 
15
N/
13
C Rev1-CT complex 
with the unlabeled pol-RIR peptide (blue) recorded at 11.7 T magnetic field, 15 oC. The inset 
shows the peak of Leu1171 in 
1
H-
15
N HSQC spectra of a titration series recorded at different 
ratios of peptide to protein. B. Probability of -helix, P(helix), in the free (red) and pol-RIR 
bound (blue) Rev1-CT domain predicted from backbone chemical shifts using TALOS+ program 
(106) plotted vs. residue number. C. Order parameters S
2
 for the backbone amide groups of the 
free (red) and pol-RIR bound (blue) Rev1-CT domain predicted from the backbone chemical 
shifts using RCI approach (150,231). D. Alignment of 16 aa peptides comprising RIR regions of 
human pol, ,  used by Ohashi et al. (202) to identify the minimal motif required for Rev1-CT 
interaction (underlined). The two consecutive Phe residues shown in the box are the only 
residues conserved in all four RIR regions found in human Y-type DNA polymerases. 
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Figure 4.2. Three-dimensional structure of the human Rev1-CT domain (residues 1157-
1251) determined by solution NMR spectroscopy. A. Superposition of the backbone folds of 
20 final lowest-energy structures obtained in CYANA (107) followed by refinement in explicit 
solvent by CNS software (145). B. Ribbon representation of the Rev1-CT structure showing the 
positions of four -helixes of the domain. Side chains are shown for residues that form core of 
the domain with less than 10% surface exposure and 10 Å
2
 accessible surface area (averaged 
over 20 best structures), including Leu1159, Ala1162 from the N-terminal -hairpin, Val1168, 
Leu1172 (rev1-108), Ile1176 (rev1-108) from -helix H1, Val1190 (rev1-110), Tyr1193 (rev1-
110), Cys1194 (rev1-110), Leu1197, Ile1198 from -helix H2, Leu1206 (rev1-111), Val1209 
(rev1-111), Ile1210 (rev1-111), Met1213, Leu1216, Met1217 from -helix H3, Trp1225, 
Ala1228, Ile1232, Val1236, Leu1240 from -helix H4; underlined are residues from four 
conserved 5-6 aa residue regions, referred to as rev1-108 to -111, identified by extensive 
sequence alignment of Rev1-CT domains from different eukaryotic species (213). C. 
Electrostatic charge distribution on the surface of the Rev1-CT domain (blue is positive, red is 
negative). Encircled is a pocket on the surface of the domain that accommodates the FF residues 
of RIR motifs of Y-family polymerases. 
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Figure 4.3. Spatial structure of the complex of the human Rev1-CT domain (residues 1157-
1251) with the RIR containing peptide from DNA polymerase  (residues 524-539). A. 
Superposition of the backbone folds of 20 final least energy structures. Also shown are side-
chains of Phe531 and Phe532 of pol critical for interaction with Rev1-CT. B. Superposition of 
NMR structures of the free Rev1-CT domain (light colors) and the Rev1-CT/pol-RIR complex 
(saturated colors). C and D. Interaction interface of the Rev1-CT domain complex with the pol-
RIR peptide. Side chains of Rev1-CT residues that contribute 5 Å
2
 or more (averaged over 20 
best structures) to the intermolecular interaction interface are shown on plot D. 
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Figure 4.4. Inter-molecular NOEs observed for the Rev1-CT/polη-RIR complex. 1H-1H 
cross-sections from a 
13
C-edited 
15
N,
13
C-filtered NOESY-HSQC spectrum of the Rev1-CT/polη-
RIR complex, displaying intermolecular protein-peptide NOE cross-peaks between selected 
groups of the 
13
C/
15
N labeled Rev1-CT domain and 
1
H nuclei of the unlabeled polη-RIR peptide. 
Multiple NOE connectivities are observed between the protons from the polη-RIR binding site of 
the Rev1-CT domain and aromatic 
1
H of Phe residues of the polη-RIR motif. 
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Figure 4.5. Mapping of the Rev1-CT/pol-RIR interface by yeast two-hybrid assays. The 
region encoding the human Rev1 C-terminal 120 amino acid fragment (Rev1-CT) was fused to 
the GAL4 Activation Domain (AD). The full-length polη-encoding region was appended to the 
DNA-binding Domain (BD) of GAL4. A. Rev1 plasmids were transformed into strains harboring 
BD-fused wild-type (WT) polη and the indicated mutations or into strains harboring the empty 
expression plasmids (indicated by the – symbol in the figure). B. AD-appended WT Rev-CT and 
the indicated mutations were transformed into strains containing BD-WT polη or the empty 
expression plasmid (-). The plasmids were selected for by growth on media lacking leucine and 
tryptophan (-LW) and interactions were scored by growth on plates also lacking Adenine and 
Histidine (-AHLW). 
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Figure 4.6. Conformational dynamics of the Rev1-CT domain and the Rev1-CT/polη-RIR 
complex. A. 
15
N R1, R2 relaxation rates and 
15
N{
1
H} NOE values measured at 11.7 T magnetic 
field, 15 
o
C, along with order parameters S
2
 (or S
2
 = Sf
2
Ss
2
) for the backbone amide groups 
obtained in model-free analysis of 
15
N relaxation data for the free Rev1-CT domain (red) and the 
Rev1-CT/pol-RIR complex (blue). B. Examples of experimental 15N CPMG dispersion profiles 
R2,eff(CPMG) measured at 11.7 T magnetic field for selected residues of free (top plot) and pol-
RIR bound (bottom plot) forms of Rev1-CT. C. Exchange contributions Rex = Rex,mf + Rex,rd to 
15
N R2 rates measured at 11.7 T magnetic field mapped onto structures of the free Rev1-CT 
domain (top) and the complex (bottom). Labeled numbers are residues with Rex > 5 s
-1
. Residues 
exhibiting fast s-ms time scale exchange identified in model free-analysis of 15N relaxation data 
(115,216) with Rex,mf contributing over 60% to a total Rex are marked in cyan. Residues 
displaying slower ms time-scale exchange detected by 
15
N CPMG dispersion measurements 
(217,224,225) with Rex,rd contributing over 60% to a total Rex are marked in magenta. Shown in 
blue are residues with comparable Rex,mf and Rex,rd contributions. Phe1165, Ser1223 (free domain 
and the complex) and Val1224 (the complex only) whose resonances are not detected in NMR 
spectra presumably due to severe s-ms exchange line-broadening are assumed to have high Rex 
values and are marked in grey. 
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Figure 4.7. On-off equilibrium between free and bound forms of Rev1-CT contributes to 
ms time-scale conformational exchange observed for the Rev1-CT/polη-RIR complex. A. 
15
N CPMG relaxation dispersion data for the backbone amides of Trp1175 and Gln1189 of 
Rev1-CT domain bound to the polη-RIR peptide recorded at 11.7T (red circles) and 18.8T (blue 
circles) magnetic fields, and their best fits to a model of 2-state conformational exchange (solid 
lines). Relaxation dispersion data for 77 residues of a bound form of the Rev1-CT domain 
measured at two magnetic field strengths were globally fit to the model of 2-state exchange, 
resulting in a population of the second (minor) state pB = 5.9 ± 0.4% and exchange rate constant 
kex = 585 ± 23 s
-1
. B. 
15
N chemical shift differences obtained in the global fit of 
15
N CPMG 
relaxation dispersion data for the Rev1-CT/polη-RIR complex, Δϖdisp, (red circles), and 
15
N 
chemical shift differences between the free and polη-RIR bound forms of the Rev1-CT domain, 
Δϖspec (grey impulses), plotted vs. residue number. 
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CHAPTER 5 
 
 
 
 
 
Summary and future directions 
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5.1. Summary 
The overall goal of this thesis was to elucidate the molecular mechanisms of USP7 substrate 
specificity, its activation and inhibition. To address the specific aims, we explored the possibility 
of studying USP7 using NMR spectroscopy. We optimized expression and purification 
conditions for USP7 fragments including the catalytic core as well as the UBL1, UBL12, UBL3 
and UBL45 C-terminal domains, performed backbone resonance assignment of the catalytic core 
(Chapter 3), the UBL1 and the UBL12 domains (Chapter 2), and determined the solution 
structure of the UBL1 domain described in Chapter 2. Almost complete backbone NMR 
resonance assignment of the above USP7 fragments enabled structural characterization of the 
enzyme interactions with its substrates and small-molecule compounds. 
In Chapter 2, using NMR spectroscopy, we characterized a novel substrate-binding site 
within USP7. In particular, we showed that ICP0 from HSV-1 interacts with the first two UBL 
domains of USP7. The binding site is located on the surface of UBL2, which makes it the first 
substrate-recognizing site discovered outside the N-terminal TRAF-like domain. In addition, 
using cellular assays, we found that knockout of USP7 in HFF-1 cells negatively affects the 
efficiency of HSV-1 lytic infection. Together these results provide a rationale for designing 
small-molecule compounds for breaking the USP7 – ICP0 interaction that might be used for 
treatment of HSV-1 infection in humans. 
In Chapter 3, we described an unexpected insight into the mechanism of regulation of USP7 
catalytic activity. We, for the first time, detected a weak (KD = 105.7 ± 15.9 μM) but specific 
interaction between the isolated catalytic core of USP7 and free ubiquitin in solution. Consistent 
with previous reports (72), we showed that ubiquitin binds to Fingers region of the enzyme. 
However, strikingly, we discovered that this interaction does not induce conformational 
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rearrangement of the USP7 active site that is critical for the deubiquitinase activity of the 
enzyme. Therefore, contrary to previous findings (72), we revealed that ubiquitin binding alone 
is not sufficient for USP7 activation and a substrate binding is likely required. 
In Chapter 3, we presented the first structural analysis of USP7 inhibition by two small-
molecule compounds. We demonstrated that two USP7 inhibitors P22077 and P50429 (93) target 
the catalytic cleft of the enzyme in a similar manner. Further, we uncovered the mode of action 
for these inhibitors and, surprisingly, found that although P22077 and P50429 are structurally 
related, they act via distinct chemical mechanisms to covalently modify the catalytic Cys223 
residue. We complemented the obtained in vitro data with cellular studies showing that P22077 
and P50429 specifically inhibit endogenous full-length USP7 in cells. Overall, these results 
provide a structural basis for development of a new class of anti-cancer therapeutics. 
Altogether, the results presented in this work aided to our understanding of how USP7 
recognizes its substrates and how its catalytic activity is regulated in the cell and by available 
small-molecular compounds.  
Another goal of this work was to characterize the mechanism by which TLS DNA 
polymerase REV1 recognizes other Y-family polymerases. We determined the spatial structures 
of the free Rev1-CT domain and its complex with Polη-RIR. NMR characterization of the 
protein structures and conformational dynamics, along with yeast two-hybrid assays revealed 
that Polη binding to Rev1 is primarily mediated by the two conservative phenylalanine residues 
of the Polη-RIR motif and amino-acid residues from the N-terminal β-hairpin of Rev1-CT. The 
results allowed us to define the RIR motif as nFF(4h) where n is N-cap serine or proline residue, 
F is phenylalanine and 4h are at least four residues that form an α-helix.  
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5.2. Closing remarks and future directions 
5.2.1. NMR spectroscopy is a powerful tool for studies of USP7 
The work presented in this thesis differs from previous structural studies of USP7 in that it 
employs solution NMR spectroscopy to study the enzyme. Several crystal structures of the 
isolated USP7 domains were available in the literature (58,71,72) but we were the first to 
determine the solution structure of one of the domains, UBL1. Most importantly, we proved the 
feasibility of investigating USP7 interactions with its substrates and small-molecule compounds 
in solution using NMR spectroscopy. 
Here, we have developed a robust system for studies of USP7 in solution (Figure 5.1). In 
addition to the assignments of USP7 catalytic core and UBL1, and UBL12 domains described 
above, we also performed backbone resonance assignment of UBL3 (Figure 5.2) and UBL45 
(Figure 5.3) domains. The TRAF-like domain has been previously assigned by Saridakis at al. 
(58). Thus, our “divide and conquer” strategy provides nearly complete backbone resonance 
assignment of the entire enzyme, which creates a powerful tool for future studies of USP7. 
NMR sequence specific assignments accompanied by available crystal structures made it 
possible to map substrate/inhibitor binding interfaces on the structure of USP7. Moreover, 
solution NMR spectroscopy can now be used to investigate the molecular mechanisms of USP7 
regulation such as inter-domain rearrangements and interactions with proteins altering the 
activity of the enzyme. Furthermore, studies of the USP7 conformational dynamics are now 
possible. Revealing the structural changes that occur during USP7 binding to its substrates, 
regulatory factors or inhibitors will gain our understanding of how the enzyme functions and will 
provide new possibilities for modulating its activity. 
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5.2.2. Identification of novel substrate-binding sites within USP7 
In Chapter 2, we described a novel substrate-binding site within USP7 located in its C-
terminal region. Although it was previously known that C-USP7 is involved in protein-protein 
interactions, the precise location of the binding sites remained unknown. We showed that a 
negatively charged patch on the surface of UBL2 domain serves as an interaction site for a 
positively charged peptide from a viral protein ICP0. 
Our findings provided the first structural evidence that C-USP7 functions as a substrate-
binding platform along with the N-terminal TRAF-like domain. Two other research groups have 
reported crystal structures of UBL12 in complex with ICP0 that confirmed our findings (85,257). 
In addition, crystal structures of UBL1-3 complexes with UHRF1 and DNMT1 were recently 
published (258,259). Interestingly, these structures revealed that both UHRF1 and DNMT1 
recognize C-USP7 in a manner similar to ICP0. Specifically, these proteins have a positively 
charged motif in their sequence that binds to the same negatively charged surface of UBL2 as 
ICP0. Thus, our and others’ studies combined discovered the molecular mechanism of substrate 
recognition by UBL12 tandem. Moreover, provided the fact that these three proteins harbor 
short, ~10 amino residue sequence containing several lysines or/and arginines, the presence of 
such a sequence in a USP7 substrate can be now used to predict its interaction with UBL12 
tandem. Along with a search for P/AxxS motifs that bind to the USP7 TRAF-like domain, a 
search for this newly described substrate feature might simplify the future mapping of 
USP7/substrate binding interfaces. 
USP7 interacts with and deubiquitinates over cellular 30 proteins (Table 1.1). Although the 
majority of these interactions have been biochemically and functionally characterized, only five 
complexes have been characterized structurally. These include complexes with p53, HDM2, 
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DNMT1, UHRF1 and UbE2E1 (27,73,74,258,259). The lack of structural information about 
USP7/substrate binding interfaces is a critical gap in the development of highly targeted 
compounds modulating activity of USP7 towards a particular protein. Likely, several of known 
USP7 binding partners will be found to interact with either the TRAF-like domain or UBL12 
tandem via discovered mechanisms. However, it is already clear that structural studies of some 
interactions such as HDM2 binding to the C-terminal UBL3 domain or FOX(O)4 and p53 
binding to UBL45 tandem will reveal new determinants of USP7 substrate specificity. Among 
others, USP7 interaction with TRIM27 E3 ligase is of the special interest. According to a 
recently published study, the C-terminal region of TRIM27 directly binds to the USP7 catalytic 
domain that previously was known to recognize only ubiquitin (132). Interestingly, this E3 ligase 
is both the substrate of USP7 and the regulator of its catalytic activity (63,132). Therefore, 
structural characterization of the complex might not only identify a novel substrate-binding site 
within the USP7 catalytic domain but also uncover the molecular mechanism of USP7 regulation 
by co-factors. Finally, structural characterization of USP7 interactions with histone-associated 
proteins represents another interesting subject for future investigations. USP7 interacts with all 
PRC1 components in vitro (reviewed in subchapter 1.1.3) but it is not clear whether these 
multiple interactions occur simultaneously or competitively in the context of the intact complex 
in cells. Moreover, USP7 binds several other proteins involved in post-translational 
modifications of histones; however, it is not known how all these interactions are organized in 
space and time. Mapping of the binding interfaces between USP7 and its substrates located on 
chromatin will help to answer these questions and provide insight into not yet known functions 
of USP7. 
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5.2.3. Mechanism of USP7 activation 
In Chapter 3 of this thesis, we found that USP7 interaction with free ubiquitin does not cause 
the rearrangement of the catalytic residues into productive conformation contrary to what was 
previously postulated (72). These results suggest that binding to a ubiquitinated substrate might 
be needed for efficient activation of the enzyme. We hypothesize that the simultaneous 
interactions of the substrate with TRAF-like/UBL domains and ubiquitin with the catalytic core 
ensure the correct placement of the flexible ubiquitin tail in the catalytic cleft and promote 
conformational changes in the active site necessary for cleavage of the isopeptide bond. 
Furthermore, there is mounting evidence that C-terminal region of USP7 is critical for efficient 
ubiquitin binding and enzymatic activity (62,71). Interestingly, even in the absence of a 
substrate, a USP7 construct containing the catalytic core and C-terminal UBL domains is active 
on di-ubiquitin and ubiquitin-AMC (ubiquitin fused to 7-amido-4-methylcoumarin) while the 
isolated catalytic domain is not (71). These observations together with our results suggest that C-
USP7 might play a role in the active site rearrangement. In addition, there is a possibility that 
both, presence of the C-terminal domains and an interaction with a ubiquitinated substrate are 
required for efficient activation of USP7. Thus, to fully answer the question “How is USP7 
activated?” we need to determine the structure of the full-length protein and investigate the effect 
of a substrate binding on the overall conformation of the enzyme.  
The current model of the full-length USP7 suggests that UBL domains fold back in order to 
bring the extreme C-terminal peptide required for the deubiquitinase activity towards the 
catalytic domain (Figure 1.4C) (71,84). The large size of USP7 and inter-domain dynamics 
makes structure determination using X-Ray crystallography challenging. Figure 5.4A illustrates 
the alternative multi-disciplinary approach that might be used to overcome the challenge. We 
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propose to initially identify possible inter-domain interactions using methods such pull-downs, 
SPR, ITC and mutagenesis. NMR might be further used to map the inter-domain binding 
interfaces. To investigate whether USP7 adopts a compact or extended conformation, or samples 
both conformations, one can use small-angle X-Ray scattering (SAXS). Finally, a high-
resolution structure of full-length USP7 can be determined by fitting the structures of individual 
domains into density maps obtained with cryo-electron microscopy (cryo-EM). A structure of 
intact USP7 complexed with one of its ubiquitinated substrates might also be determined using 
cryo-EM. Together, the structures of free full-length USP7 and its complexes with substrates will 
provide a detailed picture of the enzyme’s action. 
As the first step towards determination of the structure of fill-length USP7, we used negative 
stain EM and collected microphotographs of the protein purified from insect cells. Our results 
indicate that USP7 adopts a compact structure as evidenced by observed doughnut shaped 
molecules (Figure 5.4B). These preliminary results provide further support for a model of the 
full-length enzyme where its C-terminal and N-terminal regions closely interact with each other. 
However, the high-resolution structure of intact USP7 is needed to elucidate the exact positions 
of its domains relative to each other and to explain how its C-terminal peptide affects the 
catalytic activity. 
5.2.4. Future of USP7 inhibition by small-molecule compounds 
In Chapter 3, we uncovered the mechanism of USP7 inhibition by two dual USP7/USP47 
inhibitors. Despite the success of high throughput screening, the lack of structural biophysical 
characterization hindered their further optimization. The work described in Chapter 3 is the first 
comprehensive study that characterizes binding of the inhibitors to the enzyme as well as their 
mechanism of action. Since we found that compounds P22077 and P50429 used in this study 
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covalently modify the catalytic Cys223 residue, our results raise the critical for drug 
development question “If the inhibitors target the highly conservative active site, how is the 
specificity towards USP7 and USP47 achieved?” Our findings do not answer this question but 
provide a few interesting clues. In particular, we show that the inhibitors’ binding induces 
conformational changes in the unique misaligned active site of USP7 similar to those seen in the 
enzyme modified by ubiquitin aldehyde (72). One possible explanation for P22077 and P50429 
specificity is that they target the catalytically unproductive conformation of the USP7 catalytic 
core. In this light, it would be interesting to see whether the USP47 active site is also misaligned. 
Furthermore, our structural models of USP7 – inhibitor complexes in combination with 
identification of conserved residues revealed a few residues in the proximity of the active site 
that are unique to USP7 and USP47. However, mutagenesis studies are required to check if these 
unique residues are significant for initial binding. In addition, at least one another inhibitor of 
USP7, HBX 19,818, was shown to target its active site (92). This compound is highly specific 
for USP7, thus its structural characterization in complex with the enzyme would significantly 
contribute to the understanding of the molecular mechanism of USP7 inhibition and might 
provide novel approaches to making compounds more specific. 
The mapping of USP7/substrate interfaces opens a new alternative strategy for manipulating 
the enzyme by targeting one of its substrate-binding sites instead of the catalytic domain. Such 
compounds can potentially control stability of a specific USP7 substrate or a group of substrates. 
Importantly, the success of designing compounds that break protein-protein interactions depends 
on the size and structural complexity of a binding interface. It is easier to design a small 
molecule resembling a linear short peptide rather than a molecule mimicking interaction with 
secondary or tertiary structure elements (97). The fact that both the TRAF-like domain and 
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UBL12 recognize short extended peptides  is encouraging for discovery of compounds that can 
interrupt USP7 binding to specific substrates. NMR spectroscopy can be a useful tool in the 
development such compounds. It is widely used in fragment based drug design (FBDD) that was 
proved to be a more effective approach to targeting protein-protein interactions than high-
throughput screening (260). FBDD identifies initial low-complexity molecules that weakly bind 
to protein/substrate interfaces; therefore, NMR backbone resonance assignment of the isolated 
USP7 domains presented in this work might simplify the identification of such small molecules 
in the future. 
 
Manipulation of the ubiquitin – proteasome system might be an effective strategy for 
treatment of human cancers (90); yet before targeting any of the E1, E2, E3 or DUB enzymes in 
humans, we need to fully comprehend how these enzymes function and how their activity is 
controlled. This thesis expands our knowledge of molecular mechanisms underlying substrate 
specificity and regulation of deubiquitinating enzyme USP7. Nevertheless, this work is only the 
beginning. There is still much to be learned about USP7 on the molecular level as well as in 
context of the cell and the whole organism. Furthermore, there are dozens of other DUBs and 
other components of UPS that are involved in vital cellular processes and need to be extensively 
studied in terms of their pharmaceutical potential. Once we have a complete picture of the 
interplay between various UPS participants, we will be able to take full advantage of this 
fascinating cellular system to treat life-threatening human diseases. 
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Figure 5.1. NMR resonance assignment of all USP7 domains provides new opportunities 
for studying the enzyme in solution. 2D 
1
H-
15
N HSQC spectra of USP7 fragments including 
the TRAF-like domain (pink), catalytic domain (purple), UBL1 (blue), UBL12 (green), UBL3 
(black) and UBL45 (red) domains, for which backbone resonance assignment is available. NMR 
resonances of TRAF-like domain have been assigned previously (58); resonance assignment of 
all other fragments has been performed during studies presented in this thesis. The schematic 
representation of USP7 domain organization is shown above the spectra. 
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Figure 5.2. Backbone resonance assignment of the USP7 UBL3 domain. The 
1
H-
15
N HSQC 
spectrum of USP7 C-terminal UBL3 domain with residue-specific assignments indicated. 
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Figure 5.3. Backbone resonance assignment of the USP7 UBL45 domain. The 
1
H-
15
N 
TROSY-HSQC spectrum of USP7 C-terminal UBL45 tandem with residue-specific assignments 
indicated. 
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Figure 5.4. Pathway towards the structure of full-length USP7. A. Multi-method approach 
for determining the structure of full-length USP7. B. Negative stain electron microscopy of full-
length USP7. Left panel shows an example photomicrograph with three selected particles boxed. 
The inset shows the same particles at larger magnification (100Å scale bar). Right panel shows 
class averages obtained using EMAN2 (261). 
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